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Abstract

Spreading depression (SD) is a severe depolarization of both neurons and
astrocytes that can propagate throughout CNS tissue. SD has long been
associated with migraine, and recent work has strongly suggested that closely
related events are likely to be involved in pathophysiological conditions where
they provide a large additional metabolic burden to injured tissues. The major
goal of this dissertation was to test the overall hypothesis that manipulation of
astrocyte metabolic capacity can modify the initiation and propagation of
deleterious spreading depression (SD)-like events. If this were the case, then it
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may support targeting these cells in a range of pathological conditions where SDlike events are known to occur.
Work in this dissertation utilized acutely prepared hippocampal brain slice
preparations from adult mice to study mechanisms regulating SD initiation and
propagation. For the majority of studies, slices were prepared from naïve mice to
study functions of normal astrocytes. One set of studies utilized preparations in
which astrocytes were activated by bilateral lenti-viral injections of ciliary
neurotrophic factor (CNTF) into the hippocampus.

SD was generated under

either normoxic conditions (using localized microinjections of KCl or block of
Na+/K+-ATPase activity) or in a model of ischemia (using deprivation of oxygen
and glucose). Initiation and propagation of SD and related events was monitored
using a combination of extracellular voltage recordings and optical imaging
methods. Simultaneous recordings of NAD(P)H autofluorescence and evoked
excitatory potentials (fEPSPs) were also used to assess changes in
mitochondrial redox potential and neuronal viability.
Initial studies sought to determine the contribution of astrocyte metabolism
on the initiation and propagation of SD and related events. Previous work had
shown that selective inhibition of astrocyte oxidative metabolism increased SD
propagation rate, but little was known about roles of astrocyte glycogen.
Pharmacologically preventing glycogen availability significantly increased SD
propagation rate and increasing astrocyte glycogen stores resulted in either
compete block of SD initiation or, in preparations where SD still occurred, a
significant decrease in propagation rate (Chapter 2). Other studies confirmed the
vi

effectiveness of inhibition of astrocyte oxidative metabolism, but showed that
targeting glycogen stores may prove more efficacious therapeutically.
Previous work has shown that localized astrocyte activation can be
achieved in vivo by lenti-viral injections of ciliary neurotrophic factor (CNTF) in rat
striatum and lead to neuroprotection. My studies sought to establish a similar
model of astrocyte activation suitable for subsequent electrophysiological studies
in the well-characterized hippocampal slice preparation. I then used this model
to assess the effects of astrocyte activation on SD propagation and initiation.
CNTF-infection resulted in sustained astrocyte activation and preparations from
these tissues showed profound resistance to SD initiation and propagation under
both normoxic and ischemic conditions (Chapter 3). This model may be suitable
for many studies of astrocyte activation and these results suggest that targeting
astrocyte activation may be useful therapeutically to limit SD.
A final set of studies was conducted to test the hypothesis that an
additional metabolic burden in the context of SD, even under normoxic
conditions, can lead to irrecoverable neuronal damage. Nitric oxide (NO) has
been proposed as a possible treatment to reduce the number of SD-like events
following subarachnoid hemorrhage.

My studies investigated the effects of

manipulation of NO concentrations on the progression and consequences of SD
under normoxic conditions.

Exogenous NO led to inhibition of mitochondrial

respiration, which has been well described previously, and converted recoverable
SD events into irreversible depolarizations leading to neuronal damage. These
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studies suggest that if NO is to be used therapeutically to limit SD, care must be
taken to ensure concentrations do not inhibit oxidative metabolism (Chapter 4).
Overall the studies in this dissertation suggest that strategies which target
the maintenance of brain metabolism and normal astrocyte function, including the
clearance of extracellular glutamate and K+, may reduce the incidence of SD and
may also limit neuronal injury in pathologic conditions where SD-like events still
occur.

This work may provide a useful starting point for future studies to

determine specific therapeutic interventions including in tissue where astrocyte
phenotype may be modified by pathologic processes.
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1. Introduction
1.1 Spreading Depression
1.1.1 The phenomenon of spreading depression
Spreading depression (SD) was first described in 1944 by Aristides Leao
in a series of studies originally intended to observe electrical cortical activity
occurring during experimental epilepsy. Electrocorticogram (EcOG) responses
were recorded from the exposed rabbit cortical surface using a series of
differential electrodes. He found that following brief, repetitive electrical
stimulation to a region of the cortex, there was a complete abolition of
spontaneous electrical activity, which spread slowly in all directions, and involved
the whole cortex within 3-6 minutes (Leao, 1944). These events were completely
reversible and recovery generally began 5-10 minutes after the depression was
initiated, beginning at the point of stimulation (Leao, 1944). In later studies, Leao
used direct current (DC)-coupled amplification to record a slow negative voltage
shift, which accompanies the depression of spontaneous activity (Leao, 1947).
These propagating extracellular voltage changes triggered by SD were large
(maximum of 8-15mV). Similar events were also generated by global forebrain
ischemia (Leao, 1947). Some key findings from these initial studies were that SD
not only affected spontaneous cortical activity, but also inhibited responses to
touch, electrical stimulation, and illumination of the retina (Leao, 1944).
Importantly, while the mechanisms underlying the spread were initially unclear,
Leao suggested that it was likely neuronal and that related events may also be
involved in ischemic injury (Leao, 1947).
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Figure 1.1

The ionic shifts underlying DC potential changes during SD have been
extensively characterized using ion-selective microelectrodes and include a very
large and rapid increase in extracellular K+, from normal levels of ~3mM up to 5060mM (Vyskocil et al., 1972; Mares et al., 1976). It is well established that SD is
initiated once [K+]e reaches 10-12mM (Vyskocil et al., 1972; Hansen and
Zeuthen, 1981; Muller and Somjen, 2000), and the subsequent rapid increase in
extracellular K+ is accompanied by decreases in extracellular Ca2+ (from 1.3 to
0.07mM), Na+ (from 155 to 60mM), and Cl- (from 130 to 74mM) (Hansen and
Zeuthen, 1981) (Figure 1.1) as ions move intracellularly.
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1.1.2 Methods for studying SD
1.1.2.1

Induction of SD and related events

Inducing SD in vivo
In his initial studies, Leao used a variety of methods to trigger SD in rabbit
cortex, and showed not only that high frequency electrical stimulation was
effective, but that SD events could be induced with mechanical stimulation, by
touching a blunt rod to the cortical surface. Although initial studies were done in
rabbit, SD could also be induced in other species as well, including pigeon and
cats (Leao, 1944). Since that initial report, many other investigators have used a
wide range of stimuli to induce spreading depression-like events including
mechanical stimulation such as pressure or puncture, low osmolarity challenges,
and a variety of stimulant chemicals (Roitbak and Bobrov, 1975; Lauritzen et al.,
1988; Chebabo et al., 1995; Balestrino et al., 1999). Many of these methods are
also used to induce seizure discharge, and it is still unclear why one
phenomenon may appear instead of the other. A commonly used method today
for inducing SD has become the elevation of extracellular K+ concentrations by
either microdialysis, localized microinjections or topical application of KCl
(Nedergaard and Hansen, 1988; Herreras et al., 1994; Busch et al., 1996;
Takano et al., 2007).
As noted above, events similar to SD have also been shown to occur
during global ischemia (Leao, 1947), and many subsequent studies have
characterized SD-like events with focal and global ischemia in rodent and nonhuman primate models (Mies et al., 1993; Nedergaard and Hansen, 1993;
3

Hossmann, 1996; Strong et al., 1996). These events will be discussed further
below (Section 1.3.3).
Studies of SD in vitro
The mechanisms underlying SD and related events triggered by ischemia
have been studied in detail using cortical and hippocampal brain slice
preparations. Using these preparations, stimuli, which induce SD under normoxic
conditions (usually using K+), do not result in observable damage to cells and
repetitive SDs may be induced. However, SD-like events induced in in vitro
ischemia models are irrecoverable and result in neuronal damage if metabolic
substrates are not supplied immediately following the depolarization (discussed
below, Section 5.4). For the purposes of this dissertation, SD events generated in
brain slice by microinjections of K+, which are recoverable and are induced under
normoxic conditions, will be termed “high K+-SD.” Propagating SD-like waves
induced to model responses in ischemic conditions can be generated by
metabolic substrate removal (oxygen and glucose deprivation; OGD) or
pharmacological block of Na+/K+-ATPase activity (ouabain). These events will be
termed “OGD-SD” and “ouabain-SD,” respectively.
1.1.2.2

Recording SD (electrically and optically)

A common method used for recording SD is through the amplification of
extracellular direct current (DC) potential changes (Leao, 1947; Herreras and
Somjen, 1993). Intracellular recordings have repeatedly shown that, at the onset
of SD, neuronal membrane potential transiently approaches zero, and is followed
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by a longer-lasting plateau or slowly declining phase (Collewijn and Harreveld,
1966; Czeh et al., 1993; Muller and Somjen, 2000). Because single electrode
recordings lack spatiotemporal information, SD propagation rate may be
monitored by using electrodes placed at several sites along the exposed cortical
surface or brain slice (Leao, 1944; Largo et al., 1997b; Hashimoto et al., 2000).
However, imaging is a powerful adjunct method and many in vivo studies have
utilized techniques associated either with changes in cell volume, tissue
autofluorescence, or blood flow to visualize the spread across the brain surface.
For example, laser speckle flowmetry (LSF) has recently been applied to in vivo
studies as a semiquantitative measure of real-time changes in cerebral blood
flow associated with SD under both normoxic and ischemic conditions (Dunn et
al., 2001; Ayata et al., 2004; Shin et al., 2006; Strong et al., 2007). The studies in
this dissertation exploit brain slice preparations to study SD mechanisms
regulated by neurons and astrocytes without the additional complexity of blood
flow changes. Therefore, the discussion below concentrates on imaging methods
applicable for in vitro brain slice alone.
A widely used method of imaging used in in vitro slice preparations has
been recording intrinsic optical signals (IOS). IOS signals are due to changes in
light absorption or scattering (by either reflection of refraction) in living tissue, and
changes during SD are due mainly to changes in cell volume (Andrew et al.,
1999). It is assumed that both neurons and astrocytes contribute to these
signals, and IOS imaging has been utilized in brain slice studies where SD was
induced by either increasing extracellular K+ or with models of ischemia (OGD
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and ouabain) (Basarsky et al., 1998; Obeidat and Andrew, 1998; Obeidat et al.,
2000; Anderson and Andrew, 2002). Cellular swelling leads to increases in light
transmittance (LT) while decreased LT may be due to either cell shrinkage or, in
the context of injury, decreases in LT may be due to dendritic beading, which will
lead to an increase in light scattering (Andrew et al., 1999).
Autofluorescence imaging of NADH has been used to monitor the
propagation of SD in both in vivo (Strong et al., 1996; Hashimoto et al., 2000;
Strong et al., 2000) and in vitro slice preparations (Foster et al., 2005; Galeffi et
al., 2010). This approach has an important advantage over IOS signals because
it provides a measure of mitochondrial redox potential. This is based on the fact
that the reduced form NADH fluoresces at 460nm when excited at 360nm (UV
range), but the oxidized form (NAD+) is non-fluorescent. It is assumed that
autofluorescence excited at 360nm is due primarily to mitochondrial NADH
dynamics and that cytosolic accumulation of NADH is negligible (Chance and
Baltscheffsky, 1958; Chance et al., 1962; Blinova et al., 2008). Therefore,
changes in autofluorescence can indirectly assess regional oxygen consumption
(Takano et al., 2007; Galeffi et al., 2010) in addition to providing visual
confirmation of an SD event. During SD induced by topical KCl application (high
K+-SD), bulk NADH changes had a biphasic waveform (Hashimoto et al., 2000;
Takano et al., 2007). In vivo NADH transients due to SD are more complex in the
ischemic brain, due to effects of ischemia on mitochondria alone (Strong et al.,
1996; Strong et al., 2000). Under both ischemic and normoxic conditions,
autofluorescence signals are likely to be contaminated by some cellular swelling,
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and blood flow changes (see Section 5.3). It is currently unknown how
significantly cellular swelling may affect NADH autofluorescence measurements
in brain slice, and how well these signals can be used to deduce changes in
metabolic

status.

Simultaneous

measurements

with

flavoprotein

autofluorescence, which should mirror NADH signals if they are indeed
mitochondrial (Shuttleworth, 2010), could help address this issue, and may
provide important information about the metabolic competence of tissues
following either high K+ or OGD-SD.

1.1.3 SD initiation and propagation
It is well established that elevations in extracellular K+ and/or glutamate
are key factors responsible for the initiation and propagation of SD. The role of K+
was first proposed by Bernice Grafstein (1956), who suggested that K+ released
by neurons during intense firing accumulates extracellularly, which, in turn,
results in the complete depolarization of these neurons and then adjacent cells;
initiating a feed-forward cycle of depolarization (Grafstein, 1956). This hypothesis
was based in part on findings that there was a brief period of intense single unit
activity prior to the negative DC shift indicative of SD, which may liberate
intracellular K+, and that if this intense spontaneous activity could be inhibited,
SD could be prevented (Grafstein, 1956). Since those initial experiments, many
studies have verified extracellular K+ ([K+] e) elevations associated with the
spread of SD, and there is remarkable consistency in threshold concentrations
(10-12mM) required for SD initiation and propagation recorded in different
laboratories (Vyskocil et al., 1972; Hansen and Zeuthen, 1981; Muller and

7

Somjen, 2000). Therefore, factors that regulate [K+]e are likely to be critical for SD
initiation and propagation.
An important role for glutamate was first proposed in 1959 by Anthonie
Van Harreveld (Van Harreveld, 1959). In his initial studies, the effects of cortical
extracts on crustacean muscle contraction were used to investigate factors
underlying SD initiation. The active compound was found to be heat resistant, not
oxidized by exposure to air at room temperature for >24hrs, not destroyed by
bringing pH to 3 or 12, and was completely absorbed by ion exchange resins
(Van Harreveld, 1959). These findings suggested that the compound was likely
an amino acid, and indeed, when applied to the rabbit cortex, L-glutamic acid
could trigger SD (Van Harreveld, 1959). Many studies have since shown that
extracellular glutamate levels increase during SD due to release from both
neurons and glia (Szatkowski et al., 1990; Szerb, 1991; Iijima et al., 1992;
Fabricius et al., 1993; Davies et al., 1995). Inhibition of NMDA receptors with
selective antagonists, such as AP-5 and MK-801, has been shown to block high
K+-SD both in vivo and in vitro slice preparations (Lauritzen and Hansen, 1992;
Busch et al., 1996; Anderson and Andrew, 2002), but it is less effective at
blocking SD in the context of ischemia (Lauritzen and Hansen, 1992). However,
more recent work has shown that the use of NMDA receptor antagonists, during
long-term recordings following focal ischemia in vivo, reduced the number of SDlike events (Hartings et al., 2003).
Taken together, these data suggest that glutamate and K+ are likely to
contribute to the spread of SD-like events in both physiological and
8

pathophysiological conditions. Since astrocytes are major regulators of these two
mediators, one goal of the dissertation is to consider the roles of astrocytes in
limiting the initiation and progression SD.

1.2 Spreading Depression and Migraine
1.2.1 Medical Impact
Migraine, a primary headache disorder, is a common, recurrent and
extremely disabling phenomenon, which affects nearly 30 million people in the
United States (Lipton et al., 2001; Steiner, 2005; Ramadan and Olesen, 2006).
Migraine is ranked in the top 20 causes of disability worldwide by the World
Health Organization and it can be extremely costly; with direct costs ranging from
$200-800 per migraine patient and far greater indirect costs ($4,000-5,000) due
to patients’ inabilities to carry out normal day-to-day functions (Fishman and
Black, 1999; Organization, 2001). The most prominent theory for the primary
underlying cause of migraine has been inappropriate dilation of cranial vessels;
making vasoconstriction the most obvious treatment (Goadsby, 1999). However,
recent work suggests that the trigeminal system (TS) is involved; raising the
important possibility that migraine is primarily a neuronal disease (Moskowitz,
2008; Tajti et al., 2010).

1.2.2 SD and migraine
The symptoms most frequently reported by migraine patients are pulsatile
pain, light and sound sensitivity, nausea, blurred vision or aura, unilateral pain
and vomiting (Lipton et al., 2001). Prior to the onset of migraine, one-fifth of
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patients suffer from transient neurological symptoms, which are commonly
known as aura (Tajti et al., 2010). While migraine auras are generally visual, they
may also be manifested as other sensory alterations, including motor and speech
deficits (Kelman, 2004). In 1941, Karl Lashley first described the occipital cortex
as the origin of a migrating visual aura (Lashly, 1941), and in 1945, Aristides
Leao observed a similar rate of spread between his cortical spreading depression
measurements and Lashley’s aura (Leao and Morrison, 1945). It is generally
accepted today that SD is an underlying phenomenon of migraine aura (Milner,
1958; Lauritzen, 1985; Ayata, 2010).
There can be a genetic component to migraine susceptibility, and there
are a wide range of identified mutations in familial hemiplegic migraine (FHM)
accounting for an increased susceptibility to headaches, particularly those
associated with aura (Ophoff et al., 1996; De Fusco et al., 2003; Moskowitz et al.,
2004; Vanmolkot et al., 2006). FHM-1 is caused by a mutation in the α1 subunit
of the presynaptic P/Q voltage-gated Ca2+ channels (VGCCs) that result in
changes in glutamate release (Ophoff et al., 1996). FHM-2 results from a
mutation on the α2 subunit of the Na+/K+-ATPase and may lead to impaired
extracellular glutamate and K+ clearance (De Fusco et al., 2003). Lastly, FHM-3
is associated with a missense mutation of the voltage-gated Na+ channels that
will disrupt the inactivation of excitatory synapses (Dichgans et al., 2005).
Excitingly, some FHM mutations have been expressed in transgenic mice, and
lead to significant increases in SD susceptibility (van den Maagdenberg et al.,
2004; Eikermann-Haerter et al., 2009). Furthermore, SD is also generally
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associated with a rapid increase in blood flow (hyperemia) followed by a
persistent mild reduction in blood supply (oligemia) (Ayata, 2010). Consistent
with a role for SD in migraine, these changes in blood flow that are associated
with SD can appear similar to those observed during migraine attacks
(Hadjikhani et al., 2001). Together, these studies provide several lines of
evidence to support for the hypothesis that SD underlies migraine aura, and for
the idea that SD may in fact trigger the onset of migraine headaches (Ayata,
2010).

1.2.3 Current therapeutic strategies
Drug development for the treatment of migraine has proved much more
promising that for other pain disorders, and has focused on both acute treatment
as well as long-term preventative care. One of the most widely used acute
treatments

is

sumatriptan,

a

5-HT

receptor

agonist,

which

leads

to

vasoconstriction and reduces inflammation in the dura matter (Buzzi and
Moskowitz, 1990; Goadsby, 1999). Selectivity for 5-HT1B/1D receptors appears to
underlie the selectivity of sumatriptan and related drugs for cranial circulation, but
the potential deleterious vasoconstrictive side effects on coronary circulation
makes the discovery of new therapeutics important (MaassenVanDenBrink et al.,
1998). In addition, the relatively short half life (2 hours) of sumatriptan may
explain the large percentage of patients who suffer headache recurrence (Fowler
et al., 1991; Goadsby, 1999), and sumatriptan is not effective in the treatment of
migraine aura (Bates et al., 1994).
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For patients who suffer several migraine attacks a month, chronic
prophylactic treatment is recommended in an attempt to reduce the frequency
and intensity of the headaches, and while this strategy has proved to be
moderately effective, new treatments are still required (Ayata et al., 2006). There
is a growing body of evidence suggesting SD as a promising target for migraine
treatment. Many drugs already utilized for migraine treatment, but with no
obvious common mechanism underlying their protective effects, have all been
shown to reduce SD events in a dose-dependent manner when administered
chronically (Ayata et al., 2006). While these drugs effectively reduce SD
incidence, the mechanism(s) underlying this effect are not well understood and
finding more selective ways of targeting SD-like events associated with migraine
are required.
SD in the context of migraine aura is believed to occur under normoxic
conditions, and therefore, the mechanisms underlying these events may be
studied using high K+ to induce the depolarization. Previous work has
concentrated on modifying neuronal excitability to treat these disorders, but
targeting other cell types may also be useful. Astrocytes may play an important
role in preventing the initiation or propagation of SD by clearing extracellular K+
and/or glutamate. In addition, repetitive SDs are known to induce astrocyte
activation (Kraig et al., 1991), which may occur in chronic migraine patients who
suffer from recurrent headaches. However, it is currently unknown what
functional role these phenotypic changes induced by SD might have.
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1.3 Spreading Depression and Stroke Injury
1.3.1 Medical Impact
Stroke is generally defined as events that follow a sudden loss of blood
flow to the brain as a result of vascular hemorrhage or occlusion. Each year in
the United States, about 795,000 people suffer from a new or recurrent stroke
(Lloyd-Jones et al., 2010). In addition, stroke is the third leading cause of death,
and it is also recognized as the leading cause of severe, long-term disability
(Rosamond et al., 2007; 2009). As many as 30% of all stroke survivors are
permanently disabled and 20% of these patients still require institutional care
months after the initial insult (Lloyd-Jones et al., 2010). Thus, the average
lifetime cost for an individual having suffered an ischemic stroke is $140,048,
which includes inpatient care and subsequent rehabilitation necessary for any
lasting deficits. When considered with the prevalence in our population, different
forms of stroke lead to annual national cost of ~63 billion dollars (Rosamond et
al., 2007).

1.3.2 Current therapeutic strategies
Ischemic strokes, due to transient or permanent obstruction of blood
supply, are most frequent (~87% of all stroke cases), while intracerebral and
subarachnoid hemorrhage strokes account for the remainder (2006; Rosamond
et al., 2007; Lloyd-Jones et al., 2010). Thrombolysis became the primary clinical
treatment for acute ischemic stroke when tissue plasminogen activator (tPA) was
approved by the US Food and Drug Administration in 1996, and over a decade
later, it remains the sole pharmacologically approved treatment for ischemic
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stroke (Lee et al., 1999; Goldstein, 2007). While in theory tPA could be used as a
therapeutic agent for the majority of ischemic stroke cases, due to safety
concerns, it is only used rarely in clinical settings. tPA significantly increases the
risk of hemorrhage, and can only be used within a short time window (<3 hours)
after stroke onset (Alberts, 1998; Alberts et al., 2000), and most patients do not
receive intravenous tPA treatment due to arrival to the hospital beyond the
approved treatment window (Katzan et al., 2004). An alternative to tPA would be
neuroprotective therapies, which aim to preserve brain tissue by reducing the
intrinsic vulnerability to ischemia until blood flow returns to the region (Lee et al.,
1999; Goldstein, 2007). Such therapies would have the benefit of being
potentially useful for both ischemic and hemorrhagic strokes and may have
potentially larger windows of time for intervention. The majority of such
approaches have focused on limiting the excitotoxic effects of glutamate and
calcium overload (O'Collins et al., 2006). However, despite an ever-growing
number of clinical trials for neuroprotective agents, which reduce neuronal
damage in animal models, none has proved effective in human studies (Dirnagl
et al., 1999; O'Collins et al., 2006). This is likely due to a number of unwanted
side-effects, which alter normal physiology, including respiratory depression and
cardiovascular dysregulation, and may become equally detrimental to patients as
the initial stroke injury itself (Dirnagl et al., 1999). Exciting new work suggests
that focusing on events similar to SD, which propagate from the infarct core, may
be more useful than traditional targets of excitotoxicity mechanism (Hossmann,
1996; Lauritzen et al., 2011) (see below).
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As mentioned above, hemorrhagic strokes may be intracerebral (blood
accumulates within brain tissue) or subarachnoid (blood accumulates between
the skull and brain). Subarachnoid hemorrhages (SAH) make up ~3% of all
strokes cases, and the majority arise due to the rupture of a saccular aneurysm,
which has developed over the patient’s lifespan at the base of the brain (van Gijn
and Rinkel, 2001). Patient outcome is generally determined by the initial damage
induced by the hemorrhage itself in addition to the commonly occurring
complication known as delayed ischemic neurologic deficit (DIND). DIND
features narrowing of large cerebral blood vessels known as radiological
vasospasm and occurs in 20-40% of patients with a delayed peak onset roughly
7 days after the initial injury (Al-Tamimi et al., 2010; Lauritzen et al., 2011).
Vasospasm was initially defined in patients by Arthur Ecker and Paul
Riemenschneider in 1951, and although vasospasm appears to be a marker of
poor outcome following SAH, there is increasing controversy over whether this
phenomenon is correlative rather than causative of DIND (Ecker and
Riemenschneider, 1951; Stornelli and French, 1964; Al-Tamimi et al., 2010). As
with ischemic stroke injuries, there is currently a lack of effective treatment for
DIND following SAH, but (as discussed below) the occurrence of SD-like events
following these injuries have been recorded and may be a very useful target for
reducing the expansion of SAH injury .
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1.3.3 SD and stroke injury
1.3.3.1

Time course of anoxic depolarizations and repetitive SD

During an ischemic stroke, local restriction of blood supply results in the
rapid depletion of energy substrates, primarily oxygen and glucose, which are
required for the maintenance of ionic and glutamate homeostasis (Martin et al.,
1994). This leads to loss of membrane potential and depolarization of both
neurons and glia within the region a phenomenon termed “anoxic depolarization”
(Somjen, 2001). If there is no vascular re-supply in a region subjected to anoxic
depolarization, no substrates are available for repolarization, and little can be
done to prevent the rapid necrotic cell death that follows and establishes the
infarct core.
The

primary

mechanism

underlying

ischemic

injury

occurring

in

conjunction with anoxic depolarization was thought to be the excitotoxic
accumulation of extracellular glutamate, which is released when neurons
depolarize and remains elevated since the energy-dependent process of
glutamate clearance by glia is compromised (Dirnagl et al., 1999). In this
schema, the mechanisms underlying neuronal damage change over time, but
excessive extracellular glutamate leading to neuronal depolarization and
intracellular Ca2+ overload is likely to initiate the cascade of pathological
conditions that follow (Figure 1.2). Increases in intracellular Ca2+ then were
proposed to lead to the activation of a wide range of signaling molecules that led
to the production of free radicals and nitric oxide, which may ultimately contribute
to inflammation and glial activation as well as induction of DNA and mitochondrial
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damage leading to apoptosis (Dirnagl et al., 1999; Lee et al., 1999; Lipton, 1999).
As noted above, efforts have been made to target some of these downstream
signaling pathways, but they have not yet led to new viable therapeutic
interventions suggesting that excitotoxicity may not be the best target.
Figure 1.2

An important shift in understanding of the progression of stroke injury has
come from the realization that excitotoxicity alone may not be a primary
contributor to progression of injury. It is recognized that the initial anoxic
depolarization described above spreads across the brain surface in much the
same way as the phenomenon of SD. Transient increases in extracellular K+,
indicative of SD-like events, have been described following middle cerebral artery
occlusion (MCAO) in both the cat and baboon cortex (Branston et al., 1977;
Strong et al., 1983). Subsequent work observed repetitive waves of severe
depolarization that originate at the edge of infracted regions following in vivo

17

ischemia that spread outwards and these events propagated at a rate of
approximately 3mm/min (Nedergaard and Astrup, 1986). As a result, SDs, which
occur under the context of ischemia and originate from the ischemic core, have
been termed peri-infarct depolarizations (PIDs) (Hossmann, 1996).
PIDs have been studied in a wide range of species including rodent, cat,
and non-human primate (Iijima et al., 1992; Strong et al., 2000; Hartings et al.,
2003). There is evidence supporting a correlation between the number of PIDs
and final infarct volume in in vivo MCAO studies (Iijima et al., 1992; Mies et al.,
1993; Mies et al., 1994). Glutamate receptor antagonists (MK-801 or NBQX)
reduced the number of PIDs and infarct volume, suggesting that these
depolarizing events contribute to the expansion of injury in acute studies (Iijima et
al., 1992; Mies et al., 1994; Busch et al., 1996). Furthermore, early studies
suggested that hypothermia was protective against PIDs and also reduced infarct
volume following transient MCAO (Chen et al., 1993). However, historically, there
had been little enthusiasm for trying to prevent these depolarizations clinically
since they were initially thought to occur only at the very onset of stroke and their
relevance in human stroke patients was unknown (Figure 1.2).
In early studies with continuously anesthized animals, the incidence of
PIDs may have been significantly underestimated. Inhalational anesthetic drugs,
particularly halothane, have been shown to be neuroprotective, slow brain
metabolism, and reduce SD frequency (Saito et al., 1997; Kitahara et al., 2001).
A recent study has implied that during MCAO, PID incidence may be suppressed
by anesthesia, since the SD incidence in the absence of anesthesia was much
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higher than in previous results with anesthesia (Hartings et al., 2003).
Furthermore, in freely-moving unanesthetized rats monitored for 72 hours after
reperfusion, a large number of additional depolarizing events were recorded
(Hartings et al., 2003). The number of PIDs correlated with final infarct volumes,
particularly those that occurred during a secondary phase (8-18 hours after the
insult), and early onset of this secondary phase of PIDs was also predictive of a
larger infarct volume (Hartings et al., 2003). These initial long-term recording
studies in animals provided an additional motivation for the formation of a
collaborative clinical study, whose aim was to measure SD-like events in patients
suffering from various acute brain injuries. A primary goal of this multi-center
consortium, known as the Cooperative Study on Brain Injury Depolarization
(COSBID), has been to determine the relevance of these depolarizations on
patient final outcome.
Since its formation in around 2003, COSBID has concentrated on
recording SD-like events in human pathologies including traumatic brain injury
(TBI) (Strong et al., 2002; Hartings et al., 2009), subarachnoid hemorrhage
(SAH) (Dreier et al., 2006; Dreier et al., 2009), intracerebral hemorrhage
(Fabricius et al., 2006), and large ischemic strokes (malignant hemispheric
stroke) (Dohmen et al., 2008). For these studies, the use of implanted electrode
strips in patients who required a craniotomy for lesion evacuation or
decompression allowed for long-term (>100hrs) electrocorticographic (ECoG)
recordings. Where possible, electrode strips have been placed across the border
of infarcts, so that recordings can include signals from irrecoverably damaged
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areas, as well as from penumbral and normally perfused regions. To date, these
types of measurements have been made in over 200 patients from at least nine
centers (Dohmen et al., 2008; Fabricius et al., 2008; Hartings et al., 2008), and
there is now compelling evidence to support a role for these SD-like events in the
expansion of injury (Lauritzen et al., 2011).
In these COSBID studies, depression of ECoG activity across electrodes
was shown to be time-locked with the large negative voltage shift indicative of SD
that spreads from one electrode to the next, and limited ECoG recovery has been
shown to be associated with prolonged DC shifts (Oliveira-Ferreira et al., 2010).
Furthermore, these spreading depolarizations have been shown to cause
spreading ischemia in SAH patients causing limited O2 availability to tissues
(Dreier et al., 2009). Consistent with a causative, rather than simply correlative
role for SDs in progression of brain injury, interim analysis of collective COSBID
data suggests that the occurrence of SD-like events following TBI is a stronger
predictor of 6-month patient outcome than any previously established covariate
(Lauritzen et al., 2011). Furthermore, similar to what was observed in animal
ischemia studies (Hartings et al., 2003), following both TBI and SAH in humans,
a recurrent secondary phase of many clustered PID events has been observed in
some patients 5-10 days post-injury (Dreier et al., 2006; Hartings et al., 2009).
These new findings raise the exciting possibility that targeting PIDs following
ischemic injury may be very useful, as this prolonged time course may provide a
much larger window of opportunity for therapeutic intervention than the current 3
hr window for tPA treatment.
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To date, there are no known blockers of these depolarizing events, but
there is evidence that their initiation is dependent on energy availability in both
neurons and astrocytes. Therefore, these depolarizations may be an important
target with a wide time window for therapeutic intervention (Figure 1.3), and
knowing the mechanisms that contribute to energy consumption should be
important in the overall assessment of how to prevent continuous depolarizing
events.
1.3.3.2

SD and Subarachnoid hemorrhage

Treatments for DIND following SAH, including hemodynamic therapy and
nimodipine, have often targeted vasospasm in an attempted to reduce secondary
brain injury. Previous studies preformed meta-analysis on results from all
randomized trials of prophylactic nimodipine treatment following SAH and found
almost a 50% reduction in the risk of DIND, but the mechanism underlying these
protective effects has remained unclear (Barker and Ogilvy, 1996). It has recently
become well established that SD occurs following SAH in human patients (Dreier
et al., 2006; Dreier et al., 2009), and nimodipine can inhibit SD induced by the
Na+/K+-ATPase inhibitor, ouabain, in hippocampal slice preparations (Dietz et al.,
2008) raising the possibility that inhibition of SD can underlie part of the
protective effects observed with nimodipine treatments.

21

Figure 1.3

1.3.4 Potential targets for SD intervention
1.3.4.1

Glutamate receptors

From the mechanisms described above, one would predict that
approaches to limit glutamate action would be effective for inhibiting SD. There
is a relationship between SD, glutamate excitotoxicity, and brain damage that is
not fully understood. NMDA or non-NMDA glutamate antagonists, serotonin
agonist sumatriptan, as well as the non-selective cation blocker LOE-908 are all
drugs that act mainly on preventing the growth of the lesion size in animal
models of ischemic injury (Hossmann, 1996; Hartings et al., 2003). As mentioned
above, blocking glutamate receptors has been shown to inhibit PIDs and reduce
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infarct volume in animal studies (Iijima et al., 1992; Mies et al., 1993; Mies et al.,
1994; Busch et al., 1996), and in a recent clinical case study, the use of the
NMDA receptor antagonist, ketamine, reduced the incidence of PIDs in two
patients

following

traumatic

and

spontaneous

intracerebral

hemorrhage

(Sakowitz et al., 2009). However, they were unable to provide clear evidence for
a reduction in final infarct volume in this preliminary clinical study. While NMDA
antagonists may reduce the number of SD-like events following ischemia, there
are a number of undesirable effects that are known to be associated with drugs
that target glutamate receptors, including their psychomimetic properties as well
as their potential to disrupt normal physiological function (see section 1.3.2);
making these receptors a difficult therapeutic target.
There is accumulating evidence that glutamate receptor antagonists
provide protection following injury not by preventing excitotoxicity per se
(Obrenovitch, 1999), but rather by reducing the number of PIDs (Hossmann,
1996). PIDs will result in the release of glutamate for feed-forward propagation of
depolarizations across tissues, but it is likely that the large metabolic burden
generated by repetitive PIDs is responsible for death of already compromised
tissue (Hossmann, 1996). As reviewed above, complete depolarization of
neurons induced by SD requires substantial ATP consumption to restore ionic
gradients.

In the context of penumbral tissue, where metabolic substrate

availability is compromised (Lipton, 1999), massive ionic shifts associated with
each PID may not be successfully resolved, and lead to irrecoverable membrane
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depolarization. These studies, suggest that selectively targeting metabolic
consequences of PIDs may be more effective than targeting NMDA receptors.
1.3.4.2

Nitric oxide

NO has been suggested as a potential therapeutic target for treatment of
subarachnoid hemorrhage (SAH). This is due to the vasodilatory effects of NO to
alleviate vasospasm, which has been thought to be the major contributor to
delayed ischemic neurologic deficits (DIND) (Thomas et al., 1999; Al-Tamimi et
al., 2010). The release of hemoglobin by erythrocytes following hemolysis of the
subarachnoid clot is thought to induce the vasospasm (Pluta et al., 1998).
Hemoglobin binds NO with high affinity (Gibson and Roughton, 1957), and in
patients who develop DIND-related vasospasm, significant decreases in NO
concentrations were observed over time post-SAH (Sakowitz et al., 2001)
suggesting NO scavenging by hemoglobin. Thus adding back exogenous NO
has been suggested to compensate for this loss and reverse vasospasm.
Several days following SAH, patients also show significant increases in
[K+]e that are well-matched with the onset of hemolysis (Ohta et al., 1983) and
this raises a possible role for SD-like events in the observed DIND. Indeed,
recent studies have shown that SD-like events occur in human patients following
SAH and are also associated with DIND (Dreier et al., 2006). Nitric oxide (NO)
production is known to increase following SD and inhibition of NO synthesis both
in vitro and in vivo reduces SD threshold (Read et al., 1997; Petzold et al., 2008).
Consistent with this idea, replacing endogenous NO with an exogenous donor
recovered SD threshold to baseline levels, and led to the suggestion that NO
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may be therapeutically protective against SD events in this condition (Petzold et
al., 2008). However, NO is also known to inhibit cytochrome oxidase in the
electron transport chain, which can result in inhibition of mitochondrial respiration
(Brown and Cooper, 1994). Therefore, the addition of exogenous NO may
actually be deleterious to the tissue following SAH by further compromising the
metabolic capacity of tissue in the presence of repetitive PIDs. This theoretical
possibility has not yet been investigated in SD models.
1.3.4.3

Astrocytes

SD and related events affect not only neurons but astrocytes as well. The
role of astrocytes in the propagation of SD has been unclear and will be
discussed in detail below (Section 1.4.2). Early work suggested that astrocytes
might underlie SD initiation, while more recent studies support the idea that glial
cells are not responsible for inducing SD and may actually be important for
preventing the propagation of the depolarization through tissues. This may be of
particular relevance in post-ischemic brain, as astrocytes are more resistant than
neurons to ischemic challenges, and furthermore, may change functional
phenotype in response to injury (Chen and Swanson, 2003). Therefore, a greater
understanding of how astrocytes actually contribute to SD both in normoxic and
ischemic conditions is needed; as well as how they might be targeted to mitigate
SD and/or its consequences.
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1.4 Astrocytes and Spreading Depression
1.4.1 Normal astrocyte physiology
Studies over the past decade have provided substantial new insight into
the role of astrocytes within the nervous system. The ratio of glial cells to
neurons in the human nervous system is at least 10 to 1 (Kimelberg and
Nedergaard, 2010), consistent with crucial roles in signal transduction as well as
ionic and metabolic homeostasis (Haydon, 2001). What were once thought of as
mere scaffolding for neurons, are now being recognized as dynamic organizers
that play significant roles in modifying neuronal activity (Nedergaard et al., 2003;
Kimelberg and Nedergaard, 2010). Indeed, it has been suggested that to
understand synaptic transmission fully, the synapse must be thought of as a
tripartite system rather than simply the interaction between pre and postsynaptic
neurons (Newman, 2003). Astrocytes organize into nonoverlapping spatial
domains, and each astrocyte may cover more than 100,000 synapses on many
different neurons (Bushong et al., 2002). In addition, astrocytes establish large
cellular networks by joining hemichannels to form gap junctions, which allow for
the transport of metabolites, ions, and potentially other information over large
distances (Theis et al., 2005).
Astrocytes are established to be critical for the maintenance of appropriate
extracellular K+, H+, and glutamate concentrations, and also have emerging roles
in providing metabolic support to neurons (by control of cerebral blood flow and
additional metabolic substrates), and may even provide antioxidant support to
neurons (Chen and Swanson, 2003; Kimelberg and Nedergaard, 2010). When
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glutamate is released from presynaptic terminals, it can bind to ionotropic and/or
metabotropic receptors on astrocytes, as well as on the better studied
postsynaptic neurons. One of the best characterized responses within astrocytes
is an increase in intracellular calcium concentration ([Ca2+]i) (Haydon, 2001;
Nedergaard et al., 2003; Newman, 2003). This increase in [Ca2+]i can initiate the
release of “gliotransmitters” that may include glutamate, ATP, and D-serine,
which can all influence normal neuronal activity (Newman, 2003; Halassa et al.,
2007; Hamilton and Attwell, 2010). Glutamate release due to astrocyte
stimulation has shown that glial-derived glutamate can potentially modulate
synaptic transmission between surrounding neurons (Newman, 2003). There is
some debate within the field as to whether astrocytes can actively modify
synaptic transmission as a result of Ca2+-dependent gliotransmission (Fiacco et
al., 2007; Agulhon et al., 2008). However, astrocytes express all the proteins
required for vesicular fusion, and some studies have shown compelling evidence
to support vesicular release of glutamate from astrocytes (Parpura et al., 1994;
Parpura and Haydon, 2000). Along with releasing glutamate, astrocytes are
solely responsible for both the production and release of D-serine in the central
nervous system (CNS), a chemical cofactor that must bind along with glutamate
in order to allow activation of NMDA receptors (Ouyang et al., 2007).
1.4.1.1

Potassium clearance

Astrocytes are highly permeable to K+ and their resting membrane
potential (Vm) closely follows the K+ equilibrium potential; suggesting that
changes in glial Vm will mimic changes in extracellular K+ (Orkand et al., 1966;
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Amedee et al., 1997). There are large populations of K+ channels in the plasma
membrane of astrocytes, which are generally thought to be active at resting
membrane potentials. The inward rectifying K+ channel, Kir4.1, appears to be
most important for maintaining the high K+ permeability of glia (Duffy et al., 1996;
Djukic et al., 2007; Chever et al., 2010). Loss of these channels in in vivo studies
resulted in decreased K+ permeability and a depolarization of Vm by >20mV
(Chever et al., 2010). Astrocytes accumulate K+ at a much faster rate than do
neurons (Walz and Hertz, 1982), and clearance from the extracellular space is
achieved by both active and passive uptake (Figure 1.4).
Both intracellular Na+ and K+ concentrations are regulated by Na+/K+ATPase activity (Walz and Wuttke, 1999). When extracellular K+ concentrations
rise, some transport of K+ is ATP-dependent and mediated by the Na+/K+ATPase and Na+/K+/Cl- cotransporter (Kofuji and Newman, 2004). The activity of
these pumps and carriers is believed to be linked, since the influx of Na+ by the
Na+/K+/Cl- cotransporter provides the increase in intracellular Na+ required to
drive ATPase activity (Newman, 1995; Walz, 2000). Thus, application of the
nonselective Na+/K+-ATPase inhibitor, ouabain, in astrocyte culture results in
decreased K+ uptake (Walz and Hinks, 1985), but does not completely eliminate
clearance of K+ by astrocytes because of remaining passive uptake.
Passive uptake, also known as K+ spatial buffering, is ATP-independent
and believed to occur primarily by coupled influx with Cl- through channels driven
by Donnan forces as a result of the uneven distribution of ions across the plasma
membrane (Boyle and Conway, 1941; Walz and Hinks, 1985). As mentioned
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above, Kir channels are the primary potassium channel on astrocytes and allow
K+ ions to flow more readily in the inward direction (Stanfield et al., 2002). In
addition, the large glial network established by gap junctions is necessary to
allow the diffusion of K+ between cells to prevent accumulation of intracellular K+
to concentrations that would no longer allow uptake (Kofuji and Newman, 2004).
Under conditions of SD, the relative contributions of these different transport
mechanisms to clear [K+]e are not well differentiated. It is possible that during SD,
with large [K+]e accumulations, ATP-dependent mechanisms may have a
significantly larger contribution.
Figure 1.4

1.4.1.2

Glutamate clearance

Astrocytes are critical for the clearance of glutamate from the extracellular
space; a process essential for regulating normal synaptic transmission as well as
preventing irreversible excitotoxic injury in the CNS (Swanson et al., 2004). In the
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brain, there are three primary glutamate transporters; EAAC1 is primarily
neuronal and does not appear to play a large role in the clearance of extracellular
glutamate. GLT-1 (also termed EAAT2) and GLAST (also termed EAAT1) are
located on astrocytes and are responsible for the majority of glutamate clearance
(Schousboe, 1981; Rothstein et al., 1996; Danbolt, 2001). There is a relatively
large energetic cost for glutamate co-transport with Na+ requiring about 1 ATP
per glutamate molecule. This is because co-transport with Na+ requires the
maintenance of a large Na+ gradient across the plasma membrane, which, in
turn, requires Na+/K+-ATPase pump activity (Figure 1.5). Therefore, either a loss
of ionic gradients or ATP depletion results in significantly reduced glutamate
uptake by astrocytes (Swanson et al., 1997; Rose et al., 2009).
Within astrocytes, glutamate is converted to glutamine by the astrocytespecific enzyme glutamine synthetase (GS). Following release into the
extracellular space, glutamine can then be taken up by neurons (MartinezHernandez et al., 1977), and phosphate-activated glutaminase (PAG) converts
glutamine to glutamate for neuronal vesicular repackaging (Kvamme et al., 2001;
Bak et al., 2006). Recent studies focusing on the properties of glutamate
transporters in both healthy and metabolically compromised astrocytes are
providing new insights into glial function during ischemia. Indeed, loss of
glutamate uptake by astrocytes can result in elevated extracellular glutamate
levels and neurodegeneration (Ouyang et al., 2007; Kimelberg and Nedergaard,
2010).
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Figure 1.5

1.4.1.3

Astrocyte metabolism

It is often assumed that anaerobic metabolism is a primary source of ATP
production in astrocytes under normal conditions. Consistent with this
assumption, the primary source of glycogen, an excellent anaerobic substrate, in
the brain is found within astrocytes (Wender et al., 2000; Dugan and Kim-Han,
2004). However, astrocytes have been shown to be abundant in mitochondria, so
they are likely also to be capable of aerobic metabolism (Boitier E, 1999; Lovatt
et al., 2007). Furthermore, astrocytes have been shown to express similar levels
to neurons of enzymes required for a functional TCA cycle, and TCA cycle
pathways are active within these cells under normal conditions (Lovatt et al.,
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2007). As mentioned above, one primary astrocyte function is clearance of both
extracellular glutamate and K+; both of which can require ATP. Therefore,
targeting either glycolytic or oxidative metabolism in astrocytes may reduce
extracellular accumulation of these two important mediators and limit SD-like
events.
Figure 1.6

1.4.2 Role of Astrocytes in Spreading Depression
Early studies speculated that waves of calcium within astrocytes were
responsible for the induction of SD in neurons (Kunkler and Kraig, 1998).
However, this idea has been challenged, because SD has been shown to occur
even when astrocyte Ca2+ waves were abolished (Basarsky et al., 1998; Peters
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et al., 2003). Furthermore, astrocytic Ca2+ waves occur some time before
changes in light transmittance (IOS) associated with SD (Basarsky et al., 1998),
and they spread further than both IOS signals and measurable DC-potential
shifts (Peters et al., 2003). This suggested that astrocytic Ca2+ waves may simply
correlate with SD, but are not causative (Somjen, 2001). Recent studies using
two-photon imaging techniques of neurons and astrocytes during SD have
provided direct evidence showing that astrocytes follow rather than lead SD
(Zhou et al., 2010). SD induced in murine cortical slices by perfusion with 40mM
KCl, resulted in reversible increases in neuronal volume, acidification, and
mitochondrial depolarization, but without observable responses in neighboring
astrocytes (Zhou et al., 2010). These studies further suggest that astrocytes play
a passive role in response to the wave of neuronal depolarization. While ruling
out astrocytes and their Ca2+ waves for SD initiation, these findings did not rule
out other roles for astrocytes in regulating SD propagation.
Indeed, early work with putative astrocyte gap junction inhibitors
completely blocked the propagation of SD in isolated chick retina (Nedergaard et
al., 1995). However, in subsequent studies, low concentrations of the same
inhibitors resulted in an increase in SD velocity, while high concentrations (similar
to those used in the initial studies (Nedergaard et al., 1995)) resulted in an
immediate decline in the velocity and even complete block of SD (MartinsFerreira and Ribeiro, 1995). These observations suggested that at high
concentrations, these inhibitors are unlikely to be acting specifically on astrocytic
gap junctions and could instead be affecting neuronal hemichannels as well
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(Martins-Ferreira and Ribeiro, 1995). A lack of gap junction involvement was also
suggested from additional studies using genetic inactivation of astrocyte-specific
connexin 43. These preparations showed significantly decreased dye-coupling
between astrocytes and 20% acceleration in the velocity of the SD event in the
stratum radiatum (Theis et al., 2003). This acceleration contrasted with the
slowing of SD propagation as would be expected if gap junctional communication
were responsible for SD propagation. It is possible that under these experimental
conditions, astrocyte networks were no longer able to sufficiently spatially buffer
K+, and [K+]e reached threshold (10-12mM) more rapidly during SD stimuli (Theis
et al., 2003). These studies, together with those investigating astrocytic Ca2+
waves, suggest that astrocyte function may help prevent the spread of neuronal
depolarization, but are likely not initiating these events.
A role for astrocyte metabolism in regulating the spread of SD has also
been demonstrated with the use of fluorocitrate (FC). FC is a TCA cycle inhibitor
with specificity for astrocytes due to selective uptake via the MCT1
monocarboxylate-like transporter. In rat cortex, FC-facilitated SD propagation,
suggests that normal astrocyte function is important in the context of these
depolarizations (Largo et al., 1997a). Thus, oxidative astrocyte metabolism and
consequent facilitation of extracellular K+ and glutamate clearance may
significantly affect SD propagation. As discussed above (Section 1.4.1.3),
astrocytes are thought to be primarily glycolytic cells and the primary source of
brain glycogen, but it is currently unknown how glycogen may be involved in SD
initiation and propagation. Furthermore, astrocytes are known to undergo
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significant phenotypic changes following injuries, which are associated with SDlike events, but it is also currently unknown how changes in astrocyte structure
and function may affect SD.

1.4.3 Astrocyte Activation
1.4.3.1

General changes in reactive astrocytes

Astrocyte populations are not static and can take on a reactive phenotype
following many pathological insults. These include ischemia, brain trauma,
infection, and chronic neurodegenerative diseases (Eddleston and Mucke, 1993;
Ridet et al., 1997; Kalman, 2004). Similar phenotypes can also be induced
experimentally, and these will be discussed below (Section 1.4.3.3). Astrocyte
reactivity is characterized by significant hypertrophy of main astrocytic structural
processes (Pekny and Nilsson, 2005). Importantly, this thickening of structural
elements does not translate to a significant alteration in overall cell volume and
each astrocyte maintains its own cellular domain (Wilhelmsson et al., 2006). Glial
fibrillary acidic protein (GFAP) is the prototypic marker for astrocyte activation,
but other intermediate filament proteins, including vimentin and nestin, are also
increased and used to identify reactive astrocytes (Eddleston and Mucke, 1993;
Pekny and Nilsson, 2005; Escartin and Bonvento, 2008). While these primary
morphological alterations within reactive astrocytes appear to be universal
regardless of the inducing stimulus, the range of functional consequences may
be quite different and will be discussed in more detail below (Section 1.4.3.2).
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Regardless of the inducing stimuli, reactive astrocytes appear to generally
increase the expression of cytokines, neuronal growth factors, and calciumbinding protein S100β (Eddleston and Mucke, 1993; Ridet et al., 1997; Escartin
and Bonvento, 2008). Release of other factors including (NO) and inflammatory
molecules may be potentially toxic and induce neuronal damage, while the
release

of

VEGF,

neurotrophic

factors,

and

ATP/adenosine

may

be

neuroprotective (Endoh et al., 1994; Zhang et al., 2000; Hermann et al., 2001;
Zhao and Rempe, 2010). Presumably the expression of these different molecules
has a wide range of effects, and recent reviews have emphasized that a greater
understanding of which molecules are upregulated in reactive astrocytes during
different neurological diseases states could be valuable for determining novel
targets for therapeutic intervention (Escartin and Bonvento, 2008; Hamby and
Sofroniew, 2010). For the remainder of my discussion, I will remain consistent
with a recent review, and use the term “reactive astrocytes” to refer to cells
following endogenous changes induced by any pathology, while reserving the
term “activated astrocytes” to refer to astrocytes modified by exposure to
experimental agents in the absence of brain injury (Escartin and Bonvento,
2008).
1.4.3.2

Neuroprotective versus neurodegenerative in ischemia

In the context of ischemia, phenotypic changes within astrocytes are
rapidly induced following initial injury, but astrocytes have been shown to remain
in this reactive phenotype for more than a month following transient cerebral
ischemia; raising the possibility that astrocytes may be relevant as targets for
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long term therapy after ischemia (Choi et al., 2010). Reactive astrocytosis
following brain injury has long been considered detrimental to neuronal survival
due to its apparent association with neurodegeneration (Kalman, 2004). As
mentioned above, release of pro-inflammatory factors and NO may induce
neuronal damage by causing oxidative stress and disruption of the blood-brain
barrier (Chen and Swanson, 2003). In addition, inhibition of axonal regrowth by
the formation of a glial scar may also retard recovery following injury (McKeon et
al., 1991; Bush et al., 1999).
There is a growing body of work suggesting protective effects of
astrocytes following ischemic injury. For example, GFAP/Vimentin double-KO
mice have been generated to prevent expression of astrocytes activation, at least
as determined by these markers. Following middle cerebral artery occlusion
(MCAO) these mice have final infarct volumes three times larger when compared
with control littermates, suggesting that reactive astrocytes following ischemia
may be neuroprotective (Li et al., 2008). Furthermore, the formation of glial scars
following focal lesions may be protective by isolating an area of injury to prevent
further expansion of the lesion (Ridet et al., 1997). The production of reactive
oxygen species is thought to be one of the underlying causes of ischemic injury,
and the primary antioxidant in the brain, glutathione (GSH), is expressed at a
higher concentration in astrocytes than neurons (Makar et al., 1994; Chan, 1996;
Dringen, 2000). Increased glutathione peroxidase production has been shown in
reactive astrocytes, and suggests an increased capacity to protect neurons from
nitric oxide (NO) and other oxidative stress (Chen et al., 2001; Shih et al., 2003).
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In addition, astrocytes appear to release ATP (through hemichannels) that is then
rapidly degraded to adenosine following injury (Lin et al., 2008). Adenosine is
known to significantly reduce neuronal activity, an effect, which may in turn
preserve energy stores as well as provide neuroprotection from excessive
glutamate release (Dunwiddie and Masino, 2001). In addition, adenosine is also
known to be a potent vasodilator in hypoxic conditions (Gordon et al., 2008), and
increasing local blood flow to increase metabolic substrate delivery may also be
a neuroprotective function of adenosine. Lastly, astrocytes express a range of
growth factors following injury, which may promote neuronal survival and
plasticity as well as angiogenesis (Ridet et al., 1997; Zhang et al., 2000).
It is not yet known whether reactive astrocytes may lead to changes in SD
propagation and/or initiation. This is an exciting possibility in the context of
ischemic injury, since both reactive astrocytes and SD-like events are have been
shown to occur together following the initial injury.
1.4.3.3

Models of astrocyte activation

There are several models currently used to induce astrocyte activation to
investigate the functional properties associated with reactive astrocytes without
the confounds of neuronal injury. These models aim to target astrocytes
specifically while leaving other cell types relatively unaffected. In vitro studies in
primary cortical astrocyte cultures used cytokines (interleukin-1β (IL-1β) and
tumor necrosis factor α (TNFα)) to induce activation, which resulted in enhanced
metabolism and increased GSH release (Gavillet et al., 2008). Additional in vitro
studies have used ciliary neurotrophic factor (CNTF) to induce astrocyte
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activation, and in coculture experiments, resulted in a two-fold increase in
neuronal survival and a significant enhancement in neurite outgrowth (Albrecht et
al., 2002).
Lenti-viral injections with a vector coding for CNTF have been shown to
result in sustained and profound activation of astrocytes in the rat striatum
(Escartin et al., 2006; Escartin et al., 2007). These preparations show large
increases in intermediate filament protein expression within astrocytes including
increased GFAP, vimentin, and nestin, as well as an increase in the astrocyte
specific connexin 43 (Escartin et al., 2006). Importantly, lenti-viral injections with
CNTF did not appear to result in any significant differences in neuronal proteins,
including those involved in glutamatergic transmission. Single cell recordings
also showed no significant differences in spontaneous activity in glutamatergic
neurons when compared with lenti-LacZ controls in rat striatum (Escartin et al.,
2006). When exposed to the excitotoxin quinolinate (QA), increases in
extracellular glutamate concentrations were significantly lower in CNTF animals,
suggesting increased glutamate uptake by astrocytes in CNTF preparations,
which could be neuroprotective following ischemic injury (Escartin et al., 2006).
However, it is currently unknown whether CNTF-astrocyte activation may affect
SD-like events.
Interestingly, very recent work has used high-titer bilateral injections of
adeno-associated virus AAV2/5-Gfa104-eGFP to induce astrocyte activation
(Ortinski et al., 2010). Injections into murine hippocampus led to the
overexpression of enhanced green fluorescent protein (eGFP) selectively within
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astrocytes, which in turn appeared to induce an activated phenotype (Ortinski et
al., 2010). In these mice, activated astrocytes expressed lower levels of
glutamine synthetase (GS), and there was a significant reduction in evoked
inhibitory postsynaptic currents (eIPSCs) and miniature inhibitory postsynaptic
currents (mIPSCs), which could result in neuronal hyperexcitability (Ortinski et
al., 2010). While this model may be useful for studies of SD threshold, it is
unclear whether this model is truly absent of injury, since astrocyte activation was
simply induced by over expression of eGFP, raising the possibility that in this
model, astrocytes are potentially reacting to toxic levels of the fluorescent
protein. Therefore, a model of astrocyte activation in a preparation suitable for
SD studies, but lacking injury is still required to address the possible effects of
reactive astrocytes on the phenomenon of SD.

1.5 Goals of this study
The primary goal in these studies was to test the overall hypothesis that
manipulation of astrocyte metabolic capacity can modify the initiation and
propagation of deleterious spreading depression (SD)-like events in hippocampal
brain slice preparations. If this hypothesis is supported, it would suggest that
strategies that increase the ability of astrocytes to clear extracellular glutamate
and K+ may reduce the incidence of SD and limit neuronal injury in pathologic
conditions where SD-like events still occur.
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1.6 Specific Aims
1.6.1 Specific Aim 1
How does modifying astrocyte metabolism contribute to the initiation and
propagation of spreading depression (SD) and related events in brain slices?
Experiments utilized a hippocampal slice model in which SD was
generated either by using localized microinjections of KCl in normoxic conditions
or by oxygen glucose deprivation (OGD), which mimics aspects of ischemic
insults. Experiments tested the hypothesis that glycogen depletion or
pharmacological inhibition of glycogen availability accelerates the rate of SD in
both normoxic and ischemic conditions; similar to effects of selective inhibition of
astrocyte oxidative metabolism. Furthermore, these experiments tested whether
supplementing glycogen stores in astrocytes can significantly retard SD
progression. These experiments were expected to provide suggestions about
whether targeting astrocyte glycogen stores might be beneficial to limit SD-like
events in pathologic circumstances.

1.6.2 Specific Aim 2
How does astrocyte activation influence SD and related events?
In these studies, I first established and validated a new model of astrocyte
activation within the hippocampus, which exploited a recently-described
approach using injection of CNTF expressing lenti-virus constructs. I then used
this model of long-term astrocyte activation for subsequent electrophysiological
studies testing the hypothesis that astrocyte activation can significantly modify
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SD initiation and propagation when compared to LacZ injected control
preparations.

Information from these studies could provide new insights into

possible neuroprotective effects of astrocyte activation in injured brain.

1.6.3 Specific Aim 3
How does an additional metabolic burden provided by NO exposure modify SD
under normoxic conditions?
Previous work has suggested that exposure to NO may be useful clinically
to increase SD threshold. Studies in this aim tested the hypothesis that addition
of exogenous NO may also inhibit mitochondrial respiration to such an extent that
it provides an additional metabolic burden to tissues during SD. Thus, NO may
convert normally non-deleterious SD events (in the context of normoxia) into
irrecoverable SD-like events that induce neuronal damage. These studies may
provide a caution to the use of NO clinically in the treatment of SD and suggest
approaches, which discriminate the protective effects of NO while eliminating its
deleterious effects on metabolism.
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2.1 Abstract
Spreading

depression

(SD)

is

a

wave

of

coordinated

cellular

depolarization that propagates slowly throughout brain tissue. SD has been
associated with migraine aura and related events have been implicated in the
enlargement of some brain injuries. Selective disruption of astrocyte oxidative
metabolism has previously been shown to increase the propagation rate of SD,
but it is currently unknown whether astrocyte glycogen stores make significant
contributions to the onset or propagation of SD. We examined SD in acutelyprepared murine hippocampal slices using either localized microinjections of KCl
or oxygen and glucose deprivation (OGD) as stimuli. A combination of
glycogenolysis

inhibitors

1,4-dideoxy-1,4-imino-D-arabinitol

(DAB)

and

1-

deoxynojirimycin (DNJ) increased the propagation rates of both high K+-SD and
OGD-SD. Consistent with these observations, exposure to L-methionine-DLsulfoximine (MSO) increased slice glycogen levels and decreased OGD-SD
propagation rates. Conversely, glycogen availability did not appear to influence
the latency to onset of OGD-SD. Effects of glycogen depletion were matched by
selective inhibition of astrocyte TCA cycle activity by fluoroacetate (FA).
Prolonged exposure to reduced extracellular glucose (2 mM) has been
suggested to deplete slice glycogen stores, but significant modification of SD
propagation rate was not observed with this treatment. Furthermore, reduced
extracellular glucose resulted in significantly decreased latency to onset of OGDSD. These results suggest that astrocyte glycogen stores contribute to delaying
the advancing wavefront of SD, including during severe metabolic challenge of
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OGD. Approaches to enhance astrocyte glycogen reserves could be beneficial
for delaying or preventing SD in some pathologic conditions.

2.2 Introduction
SD is characterized as a wave of severe depolarization that can propagate
throughout CNS tissue and result in suppression of electrical activity, disruption
of ion homeostasis, and provide repetitive large metabolic burdens to both
neurons and astrocytes (Leao, 1944; Hansen, 1985; Somjen, 2001). If SD is
generated in otherwise healthy tissue, neuronal ionic gradients and brain function
can be fully restored after SD (Nedergaard and Hansen, 1988), and such
recoverable events are believed to be related to migraine aura (Okada et al.,
1988; Hadjikhani et al., 2001). However, SD triggered in the context of ischemia,
can result in irrecoverable injury if metabolic substrates are not resupplied
immediately following SD onset (Rader and Lanthorn, 1989; Tanaka et al., 1997),
in both animal models (Nedergaard and Astrup, 1986; Hossmann, 1996; Strong
et al., 2000; Hartings et al., 2003) and in human trauma and stroke (Fabricius et
al., 2006; Dohmen et al., 2008). Therefore, inhibition of SD-like events following
ischemia is being considered a potential therapeutic approach to limit injury
progression (Lauritzen et al., 2011), but selective agents are not yet available.
A large body of work has implicated extracellular accumulation of K+
and/or glutamate in SD initiation and propagation (Somjen, 2001). Under normal
conditions, maintenance of both these factors is tightly regulated by astrocyte
uptake (Lajtha et al., 1959; Orkand et al., 1966; Rothstein et al., 1996; Kofuji and
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Newman, 2004). Selective disruption of astrocyte oxidative metabolism with
fluorocitrate (FC) increased the rate of SD propagation (Largo et al., 1997a).
Prolonged inhibition of astrocyte oxidative metabolism alone can also be
sufficient to initiate SD in hippocampal brain slices under some experimental
conditions (Canals et al., 2008); consistent with normal astrocyte function playing
a central role in SD by maintaining ionic gradients below threshold levels
required for feed-forward cellular depolarization.
Although effects of FC imply a dependence on mitochondrial oxidative
metabolism, glycolysis is a major source of ATP production within these cells,
and astrocytes are the primary source of glycogen in the brain (Cataldo and
Broadwell, 1986; Wender et al., 2000; Brown, 2004). Glycogen stores are known
to be depleted following SD events (Selman et al., 2004) and inhibition of
glycolysis or glycogenolysis in culture results in decreased glutamate uptake by
astrocytes (Swanson, 1992; Sickmann et al., 2009), but the possible
contributions of astrocyte glycogen stores in the initiation and/or propagation of
SD are currently unclear. A previous study has suggested that the latency to
single cell anoxic depolarizations in rat hippocampal slices was determined by
depletion of astrocytic glycogen (Allen et al., 2005). However, it is not yet known
1) whether the glucose depletion approach used previously did in fact deplete
glycogen stores, 2) whether the delay in the onset of a single neuron AD also
applies to SD initiation, and 3) whether initiation and/or propagation of
coordinated waves of SD are significantly influenced by astrocyte glycogen
stores.
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In the present study, we have examined these questions by studying SD
in murine hippocampal slices. SD was generated either by OGD or by localized
high K+ stimuli, and astrocyte metabolism was disrupted by using fluoroacetate
(FA), putative inhibitors of glycogen metabolism, or approaches previously
suggested to deplete glucose/glycogen stores prior to SD onset. We conclude
that availability of astrocyte glycogen stores does not significantly influence the
latency to SD onset generated in ischemia-like conditions. However, SD
propagation rates appear to be regulated by astrocyte metabolism, likely by
reducing the rate of extracellular K+ and/or glutamate accumulation within
astrocytes at the advancing wave front of SD generated in both normoxic and
ischemic-like conditions.

2.3 Materials and Methods
2.3.1 Slice preparation
Male mice (FVB\N) were obtained from Harlan Laboratories (Indianapolis,
IN) at 4-6 weeks of age and were housed in standard conditions (12 hr light/dark
cycle) for up to 2 weeks prior to euthanasia. Mice were deeply anesthetized with
a mixture of ketamine and xylazine (85 and 15 mg/ml, respectively, s.c.) and
decapitated. Brains were rapidly removed and placed in ice-cold cutting solution
(see below for composition). Coronal sections (250 μm) were cut on a Vibratome
(Technical Products International, St. Louis, MO) and slices were subsequently
transferred to oxygenated room temperature ACSF (see below). Cutting and
recording solutions were both 300-305 mOsm/l. After warming to 34oC for one
hour, the ACSF was exchanged again and slices were then held at room-
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temperature. Individual slices were then transferred to a recording chamber and
superfused with oxygenated ACSF at 2 ml/min at 35oC.

2.3.2 Electrical recording
Extracellular measurements of slow DC shifts characteristic of SD were
made using borosilicate glass microelectrodes, filled with ACSF (~5 M) and
placed in stratum radiatum ~45 µm below the surface of the slice and
approximately 150μm from the pyramidal cell body layer. In some experiments,
Schaffer collateral inputs to the CA1 region were stimulated using a bipolar
electrode (25 μm tip) placed on the surface of stratum radiatum. Single shocks
(80 μs, 0.1-1.5 mA) were applied using a constant-current stimulus isolation unit
(Isoflex, AMPI, Israel). Stimulus intensity was chosen based on an input/output
curve generated in each slice, to produce responses ~60% of maximal amplitude
(0.4-0.55 mA). Signals were amplified (Neurodata IR-283), digitized (Digidata
1322A, Axon Instruments, Union City, CA), and then acquired using Axoscope
software (v 8.1, Axon Instruments).

2.3.3 Autofluorescence measurements
NAD(P)H autofluorescence was used to assess the inhibition of slice
mitochondrial function during OGD exposures, and also to track the progression
of high K+-SD and OGD-SD. This was performed as previously described
(Shuttleworth et al., 2003) with minor modifications. In most experiments, 360 nm
excitation was delivered via a fiber optic/monochromator system (Polychrome IV;
Till Photonics, Grafelfing, Germany) and reflected onto the slice surface using a
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dichroic mirror (DMLP 400 nm, Chroma Technology, Brattleboro, VT).
Fluorescence emission (>410 nm) was collected with a cooled interline transfer
CCD camera (IMAGO, Till Photonics). Image data were background-subtracted
to account for camera noise, and presented as the changes in fluorescence
intensity/prestimulus fluorescence intensity (∆F/Fo) from stratum radiatum. All
imaging was performed after focusing onto the surface of the slice with a 10X
water immersion objective (NA 0.3, Olympus) and fluorescence collected after 2
x 2 binning of the 640 x 480 line image. Single images or image pairs were
acquired every 2.5 s.

2.3.4 Tissue glycogen levels
Glycogen measurements were performed following previously-described
methods (Cruz and Dienel, 2002). Isolated hippocampal slices were allowed to
recover in nACSF for at least 4 hours following slicing, to allow glycogen levels
recover (Lipton, 1989) prior to different exposure paradigms. Tissues were then
flash-frozen and added to ice-cold 0.3 ml 65% ethanol/phosphate-buffered saline
solution and then homogenized and centrifuged at (9000 g, 10 minutes). The
supernatant was discarded, and the extraction procedure repeated 4-5 more
times, before pellets were freeze dried. Samples were then acidified (0.4 ml 0.03
N HCl), boiled (45 min), and then stored at 4oC. Glycogen levels were
determined indirectly, after hydrolysis to glucose. Samples were acidified (final
concentration of 0.1 M acetate), divided and incubated (2 hours, 37oC) in either
the presence or absence of amylo-α-1,4-α-1,6-glucosidase (30 µg/ml). Samples
were then centrifuged to remove particulate matter and glucose levels were
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analyzed

by

fluorometry

(hexokinase/glucose-6-phosphate

dehydrogenase

procedure, and responses compared with a glucose standard curve. Tissue
levels were within the linear detection range of the assay (Supplementary Figure
2.1), and an approach expected to deplete tissue glycogen (20 min OGD, see
(Lipton, 1989)) abolished glycogen signals in slices (-1.18±0.13 nmol/mg protein,
n=2, p<.0001) when compared with controls (11.59±0.53 nmol/mg protein, n=7).
We used the rough estimate of 150 mg protein per 1 g wet tissue wt to compare
our measurement to published work, and found that, while our values were lower
(~2 µmol/g wet wt vs. 12.5-5.4 µmol/g wet wt (Cruz and Dienel, 2002)), they were
within an order of magnitude of previous work utilizing larger volumes of tissue.

2.3.5 Reagents and Solutions
Except where noted, all drugs and salts were obtained from Sigma
Chemical Co (St Louis, MO). ACSF contained, in mM: 126 NaCl, 2 KCl,
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NaH2PO4, 1 MgSO4, 26 NaHCO3, 2 CaCl2, and 10 glucose, equilibrated with
95%O2 / 5%CO2. Cutting solution contained, in mM: 2 KCl, 1.25 NaH2PO4, 6
MgSO4, 26 NaHCO3, 0.2 CaCl2, 10 glucose, 220 sucrose and 0.43 ketamine. For
OGD studies, ACSF was modified by replacement of glucose with equimolar
sucrose, and equilibration with 95% N2 / 5% CO2, rather than 95% O2 / 5% CO2.
Studies of hypoxia alone, or hypoglycemia alone were performed using ACSF
equilibrated with 95% N2 / 5% CO2 or replacement of 10 mM glucose by 10 mM
sucrose, respectively.
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2.3.6 Statistical analysis
Significant differences between group data were evaluated using unpaired
Student’s t tests or one-way ANOVA. Bonferroni’s multiple-comparison test or
contrast comparisons were used for post hoc analysis in which the effects of
multiple treatments were compared against each other. A value of p<.05 was
considered significant in all cases. Numbers in the study refer to the number of
slices, with a maximum of three slices from an individual animal used for each
experimental protocol.

2.4 Results
2.4.1 Decreasing glycogen availability increased propagation rate
Normoxic SD was generated by localized microinjections of 1 M KCl and
similar events were generated by oxygen-glucose deprivation (OGD) as
previously described (Nedergaard and Hansen, 1988; Dietz et al., 2008). Both
stimuli produced slow negative DC potential shifts characteristic of SD (Figures
2.1A&B) and the propagation of events across the tissue were monitored using
autofluorescence imaging. High K+-SD generated an initial autofluorescence
decrease that was tracked at 2.4±0.1 mm/min across area CA1 (Figure 2.1C). A
sustained

autofluorescence

increase

following

the

transient

decrease

corresponds to increased oxidative metabolism following the event, as described
previously following SD in vivo (Hashimoto et al., 2000). During OGD challenges,
oxygen deprivation generates a high initial autofluorescence level prior to onset
of the SD-like event. OGD-SD propagation was then tracked by prominent
autofluorescence decreases (3.25±0.18 mm/min) that appeared more prolonged
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than in high K+ preparations, due to the absence of the substrate-dependent
overshoot phase.
To determine whether astrocytic glycogen stores contributed to SD
propagation rate, we examined first the effects of pharmacological inhibition of
glycogen breakdown using 1,4-dideoxy-1,4-imino-D-arabinitol (DAB, 10 µM) and
1-deoxynojirimycin hydrochloride (DNJ, 10 µM), which inhibit glycogen
phosphorylase (GP) and glucosidase respectively (Kuriyama et al., 2008; Walls
et al., 2008). As shown in Figure 2.1E-F, pre-exposure to a combination of these
agents (15 min) led to a significant increase in propagation rate of both high K+SD and OGD-SD. To test whether these exposures were maximally effective, an
additional set of studies were conducted with significantly higher exposures to
the same inhibitors (100 µM each inhibitor, 75 min exposure) with OGD-SD.
Prolonged exposures did not produce any additional increase in OGD-SD
propagation rate, (4.1±0.3 vs. 4.2±0.3 mm/min, 100 µM, 75 min vs 10 µM, 15
min,

respectively,

n=6,

p=.83),

suggesting

adequate

penetration

and

effectiveness of the inhibitors.

2.4.2 Increasing glycogen content slows OGD-SD propagation
To assess the impact of increasing the content of glycogen stores on SD
propagation, brain slices were exposed to L-methionine-DL-sulfoximine (MSO, 2
mM; 90-180 minutes), an approach, which has previously been established to
significantly increase astrocyte glycogen content in cell cultures (Swanson et al.,
1989b). In initial studies, the effectiveness of this approach was evaluated on
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glycogen content in isolated hippocampal slices. These MSO exposures
significantly increased glycogen content from 11.59±0.53 nmol/mg protein to
13.23±0.44 nmol/mg protein (n=7/8, p=.034).
For high K+-SD, MSO pre-exposures (90-180 min) did not significantly
influence SD propagation rate, when compared with interleaved controls (Figure
2.1E n=6, p=.46). In contrast, OGD-SD was significantly slowed by MSO (Figure
2.1F). As discussed below, MSO exposures prevented the onset of OGD-SD in
some preparations, but in those where OGD-SD was generated, the effects on
propagation rate appeared dependent on MSO exposure time. Propagation rates
approximately

halved

with

180

minute

pre-incubations,

compared

with

interleaved controls (n=3/6, p=.02). Shorter (90 min) MSO incubations appeared
to reduce SD propagation rate, but these effects were not significant (n=4/6,
p=.16).
When taken together with effects of DAB/DNJ, these data suggest 1) that
basal levels of astrocyte glycogen serve to limit the rate of SD and SD-like
propagation, and 2) that supplementation of these stores above basal levels
selectively decreases the propagation of SD-like events generated by substrate
depletion.

2.4.3 Selective inhibition of astrocyte oxidative metabolism
Previous work has established that selective inhibition of astrocyte TCA
cycle activity accelerated SD propagation (Largo et al., 1997a). Since glycogen
stores are largely (if not entirely) restricted to astrocytes (Cataldo and Broadwell,
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1986; Wender et al., 2000), we next examined whether disruption of astrocyte
mitochondrial metabolism matched the effects of glycogenolysis inhibitors, under
the same experimental conditions. Selective inhibition of astrocyte oxidative
metabolism was achieved using fluoroacetate (FA) (Clarke et al., 1970), and
compared with interleaved control slices as well as slices pre-exposed to sodium
acetate (1 mM), which provided an additional metabolic substrate that could feed
directly into the TCA cycle (Waniewski and Martin, 1998). For high K+ and OGDSD, FA pre-exposure (FA, 1 mM, 25 min) resulted in a significant acceleration of
SD compared to both acetate pre-exposures and control conditions (Figure 2.2AB, n=6, p< .01). This is consistent with prior work inhibiting astrocytic oxidative
metabolism (Largo et al., 1997a) and when taken together with the results above,
suggests that astrocyte ATP derived from different sources can regulate the
spread of SD and related events.

2.4.4 Glucose (rather than glycogen) availability regulates onset of OGD-SD
Based on the significant effects on SD propagation, we next asked
whether glycogen stores affect the initiation of SD-like events. OGD-SD occurs
after a substantial (11.3±0.5 min) delay following the onset of OGD exposure,
and this delay presumably reflects the time taken for depletion of metabolic
substrates and cellular ATP, sufficient to result in loss of Na+/K+-ATPase activity
leading to the induction of a feed-forward SD-like event (Jarvis et al., 2001). High
K+-SD is initiated virtually instantaneously, as the elevation of extracellular K+
concentration is sufficient to generate SD, without localized metabolic depletion.
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Therefore the subsequent studies concentrated on the latency to initiation of SDlike events generated by OGD alone.
Figure 2.3 shows the time course of development and consequences of
OGD-SD

in

a

population

of

slices.

Simultaneous

autofluorescence

measurements and recordings of synaptic potentials were used to assess both
mitochondrial redox potential and neuronal viability. Initial NAD(P)H fluorescence
increases (contributed to by NADH increases as slice oxidative metabolism is
impaired (Chance et al., 1962; Chance, 2004)), reached a plateau at 78.1±2.1%
above basline, (Figure 2.3A). The passage of OGD-SD across the field of view
was visualized as a transient dark band propagating across CA1 at a rate of
2.4±0.4 mm/min (see Fig 2.1B). In individual slices, this observed propagating
wave of NAD(P)H autofluorescence coincided with abolition of postsynaptic
fEPSP potentials. Prior to the initiation of SD, there was a brief period of
electrical hyperexcitability within the slice that was promptly lost at SD onset,
similar to the burst in spontaneous spike firing reported just prior to SD in
previous studies (Herreras and Somjen, 1993). This loss of fEPSPs persisted,
even after reintroduction of nACSF; suggesting that SD triggered by prolonged
metabolic challenge in brain slice results in neuronal damage as previously
described (Obeidat et al., 2000).
Consistent with previous reports of substrate dependence for single cell
anoxic depolarizations (AD), the onset of SD was dependent on the availability of
glucose, rather than oxygen. Slices were pre-exposed to either hypoxia or
hypoglycemia for 10 minutes prior to 20 min OGD exposure (Figure 2.3B). While
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pre-exposure to hypoxia did not significantly reduce the latency to SD when
compared with interleaved controls (n=5/6), hypoglycemia significantly reduced
the time to SD onset (n=6, p=.002).
Interestingly, pre-exposure to glycogen breakdown inhibitors DAB and
DNJ (10 µM, 15 min), did not result in any decrease in the time to SD when
compared to interleaved controls (Figure 2.4, n=6, p=.13). Even prolonged
exposures to DAB/DNJ (100 µM, 75 min) did not significantly decrease SD
latency to SD when compared with interleaved controls (11.7±0.5 min and
11.5±1.0 min respectively, n=6, p=.87), suggesting that depletion of basal
glycogen stores within astrocytes does not contribute to OGD-SD onset.
However, significantly increasing glycogen content with prolonged MSO
exposures had a time-dependent effect on OGD-SD onset (Figure 2.4). Similar to
the time-dependent effects of MSO on propagation rate, preparations subjected
to shorter (90 min) 2 mM MSO pre-exposures did not show a significant
difference in the time of SD onset when compared with interleaved controls
(n=4/6, p=.095), but prolonged pre-exposures (180 min) resulted in a significant
delay in the time to SD (n=3/6, p=.008).

2.4.5 2mM glucose pre-exposures
It has previously been suggested that extended (>60 min) exposures to
reduced extracellular glucose concentrations (2 mM, rather than 10 mM) may
effectively deplete astrocytic glycogen stores in hippocampal slices (Allen et al.,
2005). We evaluated this possibility with glycogen measurements and effects on
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SD initiation and propagation. There was a trend towards a decrease in total
glycogen between samples exposed to 2 mM glucose versus normal ACSF
(9.9±0.64 nmol/mg protein and 11.59±0.53 nmol/mg protein respectively, n=7,
p=.065) and 2 mM glucose pre-exposures induced SD significantly earlier than
the time to SD in interleaved control preparations (Figure 2.5A, n=6, p=.045).
However, 2 mM glucose pre-exposed preparations showed no significant
increase on the rate of SD across the CA1 when compared with interleaved
controls during OGD-SD (Figure 2.5B, n=6, p=.88) or high-K+ SD (Figure 2.5C,
n=4, p=.79). Experiments where slices were pre-exposed to both 2 mM glucose
and 10 µM DAB/DNJ (60 min) showed a decrease in SD latency and an increase
in SD propagation rate that was not significantly different from pre-exposure to 2
mM glucose or DAB/DNJ alone suggesting there are no additive effects when
inhibiting the utilization of glycogen stores prior to OGD (latency: 9.58±0.48 min
and 9.68±0.84 min respectively, n=6, p=.92 and propagation: 4.6±0.5 mm/min
and 4.7±0.4 mm/min respectively, n=6, p=.42). The contrasting effects of 2 mM
glucose pre-exposures with the glycogenolysis inhibitors (see above) suggests
that, although this procedure may somewhat deplete glycogen stores, the effects
on reducing glucose availability may be much more important for regulating the
initiation of SD.

2.5 Discussion
2.5.1 General
This study has addressed the involvement of glycogen stores and
astrocytic metabolic function on both the initiation and propagation of SD and
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related events in brain slices. Depletion of glucose availability (rather than
glycogen stores) appeared more important for determining initial metabolic failure
and the onset of SD-like events in experimental oxygen-glucose deprivation
studies. In contrast, maintenance of astrocyte metabolism by glycogen stores
appeared significant for limiting the rate of SD propagation through tissues in the
ischemia model, and also in normoxic conditions. These findings support the
possibility that targeting astrocyte glycogen stores could be of benefit in limiting
the spread of SD-like events, through peri-infarct tissues in in vivo stroke models.

2.5.2 SD propagation rate
Astrocytic uptake of both glutamate and K+ is likely an important regulator
of the propagation of SD and SD-like events. There is evidence that extracellular
accumulation of both of these mediators can contribute to the progression of SD
(Somjen, 2001), and astrocytic uptake of glutamate (via GLT-1 and GLAST
transporters) and K+ (via

Kir channels and Na+/K+/Cl- cotransport) is well

established (Walz and Hertz, 1984; Rothstein et al., 1996; Kofuji and Newman,
2004). Previous work using the astrocyte selective TCA cycle inhibitor
fluorocitrate (FC) demonstrated the importance of astrocyte oxidative metabolism
in setting the rate of SD propagation in rat cortex (Largo et al., 1997a), implying
that ATP produced by mitochondrial respiration can be utilized to maintain
electrochemical gradients required for transport functions at the advancing SD
wavefront. Our results with fluoroacetate (FA) in hippocampal slices were similar,
as a significant increase in propagation rate was observed with high K+-SD in
normoxic conditions. Pre-exposure to FA also accelerated the rate of OGD-SD.
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Under these ischemia-like conditions, loss of oxygen availability is expected to
inhibit utilization of TCA-derived substrates during OGD-exposures, and preexposures to FA are likely to accelerate depletion of other metabolic reserves
(including astrocyte glycogen) prior to the onset of OGD.
Our results with pharmacological approaches to limit glycogenolysis
(DAB/DNJ), suggest that ATP derived from astrocyte glycogen can also
significantly contribute to limiting the propagation rate of high K+-SD and OGDSD. Inhibitor concentrations utilized for these studies were based on a previous
preliminary report in slice preparations (Sadgrove et al., 2008), and no additional
effects were observed in a secondary set of studies using higher inhibitor
concentrations (100 µM) and more prolonged (75 min) exposures. The
effectiveness of this could be due in part to cooperative effects of the inhibitors,
as previously suggested (Kuriyama et al., 2008), and is consistent with effective
inhibition of glycogenolysis with 10 µM exposures.
In the case of high K+-SD, two observations suggest that adequate
metabolic substrates are available in normoxic conditions to limit SD propagation.
Neither supplementation of glycogen stores with MSO, nor provision of an
additional substrate for oxidative metabolism (acetate) significantly slowed the
propagation of high K+-SD. In contrast, OGD-SD was significantly slowed by
MSO exposures. If depletion of astrocyte metabolic reserves prior to the onset of
SD-like events is sufficient to allow more rapid accumulation of extracellular K+
and/or glutamate, then supplementation of glycogen reserves may be a useful
strategy to limit the spread of these events in ischemic tissues. Glycogen is
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recognized to be particularly useful in times of severe energy depletion, since it
does not require ATP for initiation of glycolysis (Brown, 2004), and there is also
the possibility that astrocytes could provide glycogen-derived glucose to neurons
(Rossi et al., 2007). It has recently become appreciated that SD-like events can
occur repetitively in the ischemic brain in both animal models and humans
(Hartings et al., 2003; Dohmen et al., 2008; Lauritzen et al., 2011). Glycogen
stores are known to be reduced in ischemic tissues prior to SD onset and also
completely depleted by SD-like events in in vivo rat brain (Selman et al., 2004).
Therefore, these stores could be a particularly useful target to limit the
progression and/or metabolic consequences of repetitive depolarizing events.

2.5.3 SD initiation
OGD-SD occurred in all preparations with a delay of ~11 min. We found
that both complete (0 mM) and partial (2 mM) removal of glucose prior to OGD
decreased the latency to OGD-SD, while removal of O2 alone had no effect. This
implies that the dependence on extracellular glucose for initiation of AD in single
cells during similar OGD challenges (Allen et al., 2005), also applies to initiation
of propagating SD events. One possibility is that the delay to SD onset is due to
the time taken to deplete astrocytes of glycogen stores (Allen et al., 2005).
However, the combination of pharmacological and substrate depletion studies
completed here suggest that this may not be the case. On the contrary, it
appears that depletion of tissue glucose availability (rather than glycogen stores)
is responsible for setting the time to OGD-SD onset. It remains to be determined
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whether it is depletion of glucose in all cell types or solely in neurons that is most
relevant.
Interestingly, increasing glycogen stores within slice preparations during
prolonged MSO exposures prior to OGD resulted in a significant increase in the
time to SD onset, and in half of the preparations pre-exposed to MSO, OGD-SD
events were completely prevented. It is noted that despite the lack of a
propagating SD, there were still clear signs of neuronal damage in these
preparations. This is not unexpected in extended OGD exposures, when all
substrate must eventually be consumed. It is likely that, under these conditions
single cell neuronal depolarizations occurred stochastically and astrocytes had
sufficient energy substrate to prevent the accumulation of glutamate and/or K+ to
SD threshold levels. It is possible that the effects observed following prolonged
MSO exposures could be due to the depletion of vesicular glutamate, since it is
known that MSO may also disrupt glutamate-glutamine cycling in hippocampal
slice preparations (Laake et al., 1995; Liang et al., 2006). Significant depletion of
glutamate could inhibit the onset of SD by preventing extracellular glutamate
concentrations from reaching threshold levels. However, if this were underlying
the observed effects of MSO on OGD-SD initiation and propagation, similar
results would be expected under normoxic high K+-SD as well. Since no effects
of MSO were observed on high K+-SD threshold or rate of spread, it is suggested
that the effects of MSO are not likely due to vesicular depletion. Taken together
these results suggest that while basal levels of glycogen may not be able to limit
SD initiation during extreme stress conditions such as OGD, pharmacologically
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increasing glycogen stores may be able to sufficiently fuel astrocyte function to
prevent these depolarizing events in the context of ischemia.
The relevance of these results to in in vivo studies is not yet determined,
but it is possible that the regulation of SD onset by astrocytes may be even more
apparent in vivo, since in those preparations astrocyte-mediated buffering and
transport of K+ to vessels may be an additional contributor to reducing SD
threshold (Newman et al., 1984; Amedee et al., 1997).

2.5.4 Implications for SD in normoxic and ischemic conditions
In regions where glycogen levels are depleted, SD events may be able to
propagate more readily into previously healthy tissue. Prior to each SD event,
astrocytes in penumbral tissues, which will have a range of substrate depletion
(Lipton, 1999), may have less glycogen available to provide additional substrate
required for glutamate and/or K+ clearance from the extracellular space. Thus,
maintenance of glycogen levels within astrocytes may be critical in preventing the
spread of SD events through moderately compromised tissue and the stepwise
expansion of the core following ischemic injury. It is not yet known how changes
in propagation rate may affect the expansion of injury. DC shift duration and SD
frequency are well established to correlate injury progression (Dijkhuizen et al.,
1999; Lauritzen et al., 2011), but could not be assessed in the current study.
Thus, only single SDs could be induced in conditions leading to damage (OGD)
and continuous recordings of evoked field potentials limited the ability to reliably
measure DC shifts. These parameters would be useful to assess in future
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studies. It is noted that even in otherwise healthy tissue, normoxic SD leads to a
prolonged decrease in extracellular glucose concentrations, and repetitive
depolarizations lead to a stepwise depletion of this substrate in vivo (Hashemi et
al., 2008). It is not yet known whether this significantly contributes to or may be
part of a consequence of glycogen depletion.
As noted above, recent clinical recordings have strongly implicated SDlike events in the progression of stroke injury. The current studies emphasize the
importance of astrocyte metabolism in preventing the spread of SD-like events
both under normoxic and ischemic conditions, suggesting that these cells may
provide a novel therapeutic target for the prevention of SD-like events in clinical
settings.
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2.6 Figure Legends
2.6.1 Figure 2.1
Effects of modifying astrocytic glycogen on high K+-SD and OGD-SD.
(A) Characteristic negative voltage shift produced by the initiation of SD (arrow)
by 1M KCl microinjection (B) Similar DC shift potential by OGD exposures. (C-D)
Visualization of high K+-SD and OGD-SD propagation using NAD(P)H
autofluorescence imaging. Advancing wavefront indicated by arrows (see text for
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details). Inset at top left panel is a bright field image of the preparation, followed
by 11 consecutive panels showed at 2.5s intervals (numbers indicate the time
from SD onset). R: recording electrode, S: KCl delivery electrode. Scale bar:
500µm. (E) Rates of high K+-SD after pre-exposure to either DAB/DNJ
combinations (15 min) or MSO (90-180 min). Rates in 10µM DAB/DNJ were
significantly faster than interleaved controls, but no difference was observed
between 2mM MSO and interleaved controls. (F) Rates of OGD-SD were
significantly increased by DAB/DNJ, and greatly reduced by prolonged (180min)
MSO pre-exposures (n=6, **p<.01 and *p<.05).

2.6.2 Figure 2.2
Effects of fluoroacetate (FA) or acetate on high K+-SD and OGD-SD.
(A) Pre-exposures with 1mM FA significantly increased the rate of high K+-SD
when compared with both control and 1mM acetate pre-exposures. (B) FA also
significantly increased OGD-SD propagation rates in preparations pre-exposed to
1mM FA when compared with control and 1mM acetate preparations (n=6,
*p<.05).

2.6.3 Figure 2.3
Effects of substrate removal on OGD-SD initiation. (A) Mean effects of
OGD on NAD(P)H autofluorescence signals and evoked fEPSPs recorded
simultaneously in the same preparations. OGD-SD occurred on average at
11.3±0.5 min and propagated at an average rate of 2.5±0.4 mm/min. Prior to
onset of OGD-SD, NAD(P)H initially increased due to inhibition of mitochondrial
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respiration, stepped down during the progression of OGD-SD, and then
continued to decline to levels below the initial baseline, even after restoration of
oxygen and glucose. (B) Effects of pre-exposures on OGD-SD latency. Slices
were pre-exposed to either 10 min hypoxia alone or 10 min zero glucose alone
prior to subsequent OGD exposures. OGD-SD latency was significantly reduced
by prior glucose reduction, but not pre-exposure to hypoxia (n=6, **p<.01).

2.6.4 Figure 2.4
Effects of modifying astrocyte glycogen on latency to OGD-SD onset.
Pre-exposure with glycogenolysis inhibitors, DAB/DNJ (10µM, black bars) did not
significantly affect the time to OGD-SD compared with interleaved controls. Preexposure with 2mM MSO (striped bars) did not significantly effect the time to SD
onset with 90 min pre-exposures, but did result in significant delays to OGD-SD
latency following 180 min pre-exposures (n=6, *p<.05).

2.6.5 Figure 2.5
Effects of extended exposures to reduced glucose on OGD-SD and
high K+-SD. Slices were pre-exposed to modified ACSF with 2mM glucose
rather than 10mM for >60min prior to subsequent OGD exposures. Reduced
glucose pre-exposure resulted in significant reduction in OGD-SD latency (A),
but had no effect on rates of propagation for either OGD-SD (B) or high K+-SD
(C) (n=6, *p<.05).
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2.6.6 Supplemental Figure 2.1
A glucose standard curve was generated to ensure that all tissue glycogen
measurements fell along the detectible range of the curve. Glucose standards
ranged from 0.01-100µg/ml. Following all exposure paradigms (with the
exception of 20 min OGD which completely depleted glycogen stores) tissue
glycogen fell between 3-10µg/ml on the glucose standard curve. All
measurements were normalized to protein levels to calculate final glycogen
content in nmol glucose/mg protein.
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Figure 2.1
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Figure 2.2
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Figure 2.3
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Figure 2.4
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Figure 2.5
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Supplemental Figure 2.1
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3.1 Abstract
3.1.1 Background
Astrocyte activation is concurrent with many different forms of CNS injury
including ischemia, yet the role these cells in the pathophysiology underlying
these injuries is not well understood. Previous work has shown that localized
activation of astrocytes can be achieved and neuroprotective in vivo by
constitutive expression and release of ciliary neurotrophic factor (CNTF) in rat
striatum using gene transfer. It is not yet known what effects such CNTF
exposures have on excitability and potentially noxious stimuli within other regions
of the brain. In the present study we examined the effects of CNTF astrocyte
activation in murine hippocampal slice preparations.

3.1.2 Methodology / Principal Findings
After injection of a lenti-viral vector encoding CNTF into the hippocampus,
activation of astrocytes was verified by the significant upregulation of glial
fibrillary acidic protein (GFAP) compared to a control vector encoding LacZ. No
significant changes in neuronal density or intrinsic excitability were observed in
CA1 neurons, but excitatory postsynaptic potentials (fEPSPs) were significantly
reduced in CNTF tissues. This effect was not mediated by a reduction of
glutamate release probability or enhanced glutamate clearance by activated
astrocytes. The consequences of reduced excitatory transmission were tested on
the pathophysiological phenomenon of spreading depression (SD). SD was
invariably

generated

following

localized
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K+

microinjections

in

control

preparations, but never obtainable in CNTF preparations with K+ stimuli. CNTFinjected tissues were capable of generating SD by other stimuli, as demonstrated
with the Na+/K+-ATPase inhibitor ouabain; although the latency for SD onset was
significantly longer and the mean propagation rate significantly slower compared
to control.

3.1.3 Conclusions/Significance
These data are consistent with the hypothesis that CNTF lenti-viral
injections can lead to strong sustained activation of astrocytes in hippocampus,
and this activation is associated with a decrease in excitatory synaptic
transmission, which may underlie the increased threshold for SD in these
preparations.

3.2 Introduction
It is well appreciated that astrocytes are not a static population of cells, but
can undergo substantial changes in structure and function due to a wide range of
stimuli. Transformation to an “activated” phenotype has been described following
brain injury, and this involves marked upregulation of the structural proteins glial
fibrillary acidic protein (GFAP), nestin, and vimentin (Kalman, 2004; Pekny and
Nilsson, 2005). Strong increases in astrocyte GFAP labeling have been
described in peri-infarct regions in rats following middle cerebral artery occlusion
(Chen et al., 1993; Li et al., 1995) and in postmortem tissues from human stroke
patients (Zhao et al., 2006), but it is not yet known how activation of astrocytes
influences the spread of ischemic damage in these tissues. Whether activated
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astrocytes contribute to damage or provide neuroprotection has been difficult to
determine; perhaps in part because, while morphological alterations appear to be
fairly universal, there is significant heterogeneity in the functional changes
associated with astrocyte activation depending on the stimulus (Escartin and
Bonvento, 2008).
Recent studies have begun to explore the functional roles of astrocytes
with different models of activation. One study utilized high-titer transduction of
enhanced green fluorescent protein to achieve an activated phenotype within the
hippocampus, resulting in increased excitatory synaptic transmission, attributed
to decreased GABA availability due to reduced glutamate-glutamine cycling in
astrocytes (Ortinski et al., 2010). It is not yet known whether longer-term
(months) activation of astrocytes might also disrupt excitatory transmission, since
glutamate pools have also been shown to be sensitive to changes in glutamateglutamine cycling (Laake et al., 1995; Rae et al., 2003). In vitro stimulation with
CNTF leads to astrocyte activation (Hudgins and Levison, 1998), and in an
alternative approach to achieve longer-term activation of astrocytes, this has
been extended to in vivo studies by exploiting lenti-viral infection of neurons to
constitutively express and release CNTF in the striatum (Escartin et al., 2006;
Escartin et al., 2007). The effects of CNTF astrocyte activation within the
hippocampus are unknown. These studies sought to determine if this model of
astrocyte activation resulted in any changes in neuronal excitability and if any
such changes would impact the susceptibility of cells to the pathophysiological
phenomenon of spreading depression (SD).
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SD is characterized as a wave of severe depolarization that can propagate
throughout CNS tissue and result in suppression of electrical activity, disruption
of ion homeostasis, and increased energy metabolism in both neurons and
astrocytes (Leao, 1944; Hansen, 1985; Somjen, 2001). Previous work has also
shown that repetitive SD events alone (in the absence of ischemia or other
noxious stimuli) can increase GFAP expression in astrocytes (Kraig et al., 1991;
Bonthius and Steward, 1993; Wiggins et al., 2003), but little is currently known of
the functional consequences of this activation. We examine here whether lentiviral infection with CNTF 1) resulted in sustained astrocyte activation, 2)
significantly modified neuronal excitability, and 3) was associated with changes in
SD threshold within hippocampal slice preparations. The results demonstrate
persistent activation of hippocampal astrocytes following lentiviral-mediated gene
delivery of CNTF in vivo for prolonged periods, with a significant decrease in
excitatory neuronal transmission and a coincident large elevation in SD threshold
in hippocampal slice studies. These effects raise the possibility that some forms
of astrocyte activation may strongly influence the spread of SD events in injured
brain tissue that may ultimately lead to neuroprotection.

3.3 Materials and Methods
3.3.1 In vivo CNTF expression
Expression and release of CNTF in the mouse hippocampus was
achieved by adaptation of a lenti-viral approach recently described for rat
striatum (Escartin et al., 2006; Escartin et al., 2007). Self-inactivated lentivirus
encoding the human CNTF gene with the export sequence of Ig, were
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constructed, purified, and titrated as previously described (de Almeida et al.,
2001). Bilateral hippocampal injections (1 µl per hippocampus at 0.1 µl/min) were
made in male C57Bl/6 mice, aged 5-7 weeks using the following stereotactic
coordinates: anteroposterior -2 mm from bregma; lateral +/-2 mm; ventral 1.3
mm. All experimental procedures were performed in strict accordance with the
recommendations of the European Commission (86/609/EEC) concerning the
care and use of laboratory animals and animals were used within 21 weeks of
age. Throughout the study, an equal number of age-matched control animals
were studied. These controls were injected with lentivirus encoding the βgalactosidase gene (LacZ) at the same time as injection of CNTF animals. Equal
numbers of CNTF and LacZ experiments were interleaved throughout the course
of the study.
Immunohistochemical detection of β-galactosidase was used to determine
the distribution of transgene expression in a sample of LacZ control animals (see
Fig 1). Following perfusion fixation (4% paraformaldehyde), brains were postfixed overnight, cryoprotected with 30% sucrose and then sectioned at 30 µm
thickness using a freezing sliding knife microtome. Floating sections were
permeabilized (0.1% Triton X-100), blocked (5% normal donkey serum) and
incubated with mouse anti-β-galactosidase antibody (1:100, University of Iowa
o

Developmental Studies Hybridoma Bank, overnight at 4 C) and antigen then
localized

with

FITC-conjugated

secondary

ImmunoResearch Laboratories, West Grove, PA).
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antibody

(1:250;

Jackson

3.3.2 Brain slice preparation
Brain slice preparation was as previously described (Dietz et al., 2008),
and followed procedures authorized by the University of New Mexico Animal
Care and Use Committee. Briefly, mice were deeply anesthetized with a mixture
of ketamine and xylazine, brains removed and cooled in an ice-cold cutting
solution (containing, in mM: 2 KCl, 1.25 NaH2PO4, 6 MgSO4, 26 NaHCO3, 0.2
CaCl2, 10 glucose, 220 sucrose and 0.43 ketamine), hemisected and then
coronal slices cut at 250 or 350 μm using a Vibratome. After recovery for 1 hour
at 34°C in ACSF (containing, in mM: 126 NaCl, 2 KCl, 1.25 NaH2PO4, 1 MgSO4,
26 NaHCO3, 2 CaCl2, and 10 glucose, equilibrated with 95%O2 / 5%CO2), the
ACSF was changed again and slices were held at room-temperature (~23°C)
until transfer to the recording chamber. Individual slices were then superfused
with oxygenated ACSF at 2 ml/min at 35oC and recordings made from the
hippocampal CA1 region. For in vitro studies, numbers refer to the number of
slices, with a maximum of three slices from an individual animal used for each
experimental condition.
The

degree

of

astrocyte

activation

was

assessed

by

GFAP

immunohistochemistry in the same slices as used for electrophysiological
studies. Slices were not re-sectioned, and extended antibody incubation periods
were required for adequate penetration into the slice, using methods previously
described (Hoskison and Shuttleworth, 2006). Briefly, slices were fixed (4%
paraformaldehyde), blocked (10% normal goat serum) and exposed to mouse
anti-GFAP-Cy3 (1:200; 48 hr at 4oC, Sigma Aldrich). After thorough washing,
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nuclei were labeled with DAPI (300 nM, 10 min, Invitrogen, Carlsbad, CA) and
slices were mounted with Gel Mount and examined using a Zeiss 510 Meta
confocal microscope (Carl Zeiss, Thornwood, NY, USA). Astrocyte counts were
made of GFAP and DAPI positive soma within the region of interest in the CA1
stratum radiatum, from an image stack (300x300 µm, 20 µm depth) centered
above the apex of the upper blade of the dentate gyrus. Identical image
acquisition parameters were used for each preparation. In some studies,
dendritic density was assessed by using microtubule associated protein-2
(MAP2)

immunohistochemistry

as

previously

described

(Hoskison

and

Shuttleworth, 2006). After fixation and washing, thick slices were incubated in
anti-MAP2 antibody (AP-20; 1:500, for 48 hr at 4oC), and primary antibody
localized by using goat anti-FITC (1:200; 24 hours at 4°C).

3.3.3 Postsynaptic potentials and intracellular recordings
Excitatory post synaptic potentials (fEPSPs) were characterized following
stimulation of Schaffer collateral inputs. A bipolar electrode (25 μm tip) was used
to apply single shocks (80 μs pulse, 10 s interpulse interval, 0.0-0.32 mA, using a
constant-current stimulus isolation unit Isoflex, AMPI, Israel) and fEPSPs were
recorded using extracellular glass microelectrodes placed in stratum radiatum,
~150 μm from the pyramidal cell body layer. Recording electrodes were 3-5 M
when filled with ACSF. For tests of drug action, the stimulus intensity for test
pulses was chosen as 50% of maximal amplitude, based on input/output curves
generated in each slice. Paired pulse facilitation was measured at a range of
interpulse intervals (50-300 ms). Slopes were measured from 20-80% of the
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maximal response and then the ratio of the two fields was determined
(fEPSP2/fEPSP1).
Characterization

of

CA1

membrane

properties

were

made

from

intracellular recordings using sharp microelectrodes (~100 MΩ Ohm when filled
with 3M KCl) as previously described (Shuttleworth and Connor, 2001).
Impalements were accepted if neurons required less than 100 pA of negative
current injection to maintain stable resting membrane potentials more negative
than 65 mV, and injection of depolarizing current pulses produced activation
potentials that overshot 0 mV. After stable impalements were achieved, neurons
were allowed to recover at least 10 min before characterization of input
resistance, action potential threshold and characteristics of action potential trains.

3.3.4 Stimulation and recording spreading depression (SD) in hippocampal slice
SD threshold was determined by using localized microinjections of KCl as
described in (Dietz et al., 2008) with minor modifications. A conventional wholecell patch electrode (tip resistance 3-5 MΩ) was placed 50 µm below the slice
surface in stratum radiatum, and microinjections of KCl (1 M) were triggered by
brief (10-200 ms) pressure pulses delivered by a PicoPump (SYS-PV830, World
Precision Instruments). In other studies, SD was produced by inhibition of
Na+/K+/ATPase activity by superfusion of the slice with ouabain (100 µM).
SD was characterized as a sharp drop in DC potential (Somjen, 2001), as
measured with an extracellular recording electrode placed in stratum radiatum
(45 µm below the slice surface, ~300 µm from the KCl ejection electrode).
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Recording electrodes were identical to KCl ejection electrodes, but filled with
ACSF. Signals were amplified (Neurodata IR-283), digitized (Digitata 1322A,
Axon Instruments, Union City, CA) and analyzed using Axoscope software (v 8.1,
Axon Instruments).
The propagation of high K+-SD across slices was monitored by
autofluorescence imaging using excitation at 450 nm (150 ms), emission 535±25
nm using a monochromator-based imaging system (Till Photonics) with a cooled
interline transfer CCD camera (IMAGO, Till Photonics). Imaging at this
wavelength produces a mixed signal during SD. Initial autofluorescence
increases provided a measure of initial depolarization and mitochondrial
activation (flavoprotein associated), and were used to assess the degree of
tissue activation following K+ application. The spread of large, delayed
fluorescence decreases provided a robust measure of swelling associated with
spreading SD events (see supplemental data). Studies of ouabain-SD did not
require assessment of initial mitochondrial redox changes, and required lowerpower observation of both neocortex and hippocampus, and therefore ouabainSD propagation was tracked by using changes in light transmittance (>575 nm)
as previously described (Andrew et al., 1999).

3.3.5 Astrocyte coupling in hippocampal slices
Acute transverse hippocampal slices (300 µm) were prepared as
previously described (Rouach et al., 2005) from 12 weeks old C57BL6 mice
injected with lenti-LacZ (n=3) or lenti-CNTF (n=3) and were maintained at room
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temperature in a storage chamber that was perfused with ACSF containing (in
mM): 119 NaCl, 2.5 KCl, 2.5 CaCl2, 1.3 MgSO4, 1 NaH2PO4, 26.2 NaHCO3 and
11 glucose, saturated with 95 % O2 and 5 % CO2, for at least one hour prior to
recording. Slices were transferred to a submerged recording chamber mounted
on an Olympus BX51WI microscope equipped for infra red-differential
interference (IR-DIC) microscopy and were perfused with ACSF at a rate of 1.5
ml/min at room temperature. Cells in the stratum radiatum were identified as
astrocytes based first on morphologic criteria second on electrophysiologic
properties (Rouach et al., 2008). Somatic whole-cell recordings were obtained
using 5-10 MΩ glass pipettes filled with (in mM): 105 K-gluconate, 30 KCl, 10
HEPES, 10 phosphocreatine, 4 ATP-Mg, 0.3 GTP-Tris, 0.3 EGTA (pH 7.4, 280
mOsm). For intercellular coupling experiments, the internal solution contained
biocytin (2 mg/ml), which diffused passively in astrocytes during 20 min in
current-clamp mode. Immediately after recording, slices were fixed with 4%
paraformaldehyde in PBS for 12 h at 4°C. During biocytin experiments,
membrane potential and resistance were measured from patched astrocytes
(LacZ: -67.5±3.1 mV (n = 4) and CNTF -70.2±2.7 mV (n = 5); LacZ: 8.4±2.2
MOhm and CNTF: 7.1±2 MOhm respectively). Biocytin was localized by
incubating slices in TRITC-conjugated streptavidin (Invitrogen, Carlsbad CA).
After several washes, slices were mounted in Fluoromount (Southern
Biotechnology) and examined with a confocal laser-scanning microscope (Leica
TBCS SP2). Stacks of consecutive confocal images taken at 0.5 µm intervals
were acquired using a helium/neon laser at 543 nm and Z projections were
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reconstructed using Leica Confocal Software. Manual cell counting was
performed with Image J software.

3.3.6 Reagents and Solutions
Except where noted, all drugs and salts were obtained from Sigma
Chemical Co. (St Louis, MO). Phosphate buffered saline (PBS) was from
Invitrogen (Carlsbad, CA, USA). Antibodies were diluted in PBS supplemented
with 2% Triton X-100 (PBST) and including 3% normal goat serum. 8Cyclopentyl-1,3-dipropylxanthine (DPCPX, 200 μM stock) was dissolved in
DMSO and stored at -20oC until use. Ouabain was dissolved in ACSF (100 μM).
Neurobiotin (1%) was dissolved in normal intracellular solution containing the
following, in mM: 135 K-gluconate, 8 NaCl, 1MgCl2, 10 HEPES, 2Mg2+-ATP.

3.4 Results
3.4.1 CNTF activation of hippocampal astrocytes
Figure 3.1A shows that intrahippocampal stereotaxic injection of the VSVG pseudotyped lenti-viral vector encoding LacZ resulted in effective transduction
of hippocampal neurons as observed with -galactosidase immunostaining. High
β-galacotosidase expression was observed in nerve cell bodies in CA1 and CA2
subregions, the dentate granule cells and hilus, but was not observed in brain
regions outside the hippocampus, including the neocortex. A similar distribution
of β-galactosidase labeling was observed throughout the rostro-caudal axis of the
hippocampus in two animals examined (data not shown).

84

Injection of CNTF-expressing lenti-viral vector resulted in strong activation
of hippocampal astrocytes, as demonstrated by increases in GFAP-like
immunoreactivity. Individual astrocytes showed a marked increase in thickness of
the main GFAP-positive immunoreactive processes, when compared with LacZ
injected controls, and naïve (non-injected) animals (Fig 3.1B). This was assessed
in thick brain slices prepared as for electrophysiological analysis (see Methods)
and verified throughout the course of the study in preparations from each animal
used for electrophysiological recording. Figure 3.1C quantifies the mean area
occupied by GFAP fluorescence in 8 CNTF preparations, to demonstrate
significant increases compared with LacZ and non-injected controls (n=8,8,7
respectively). Animals used for quantitative analysis were 8-12 weeks postinjection, and in additional studies it was shown that CNTF preparations at 16
weeks post-injection continued to show elevated GFAP expression. Figure 3.1C
also plots the average density of astrocytes in the three types of preparation, and
shows no significant difference between CNTF, LacZ, and non-injected control
preparations (measured in a 300x300x20 µm volume). Together, these results
suggest that CNTF expression resulted in localized, long-term activation of
astrocytes by transformation of the resident population of astrocytes in the
hippocampus, rather than proliferation of progenitor cells. These findings are
consistent with previous conclusions from CNTF-lentiviral injections in rat
striatum (Escartin et al., 2006; Escartin et al., 2007) and suggest that this
approach is useful for subsequent in vitro slice studies of the consequences of
hippocampal astrocyte activation on spreading depression (SD).
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Astrocyte coupling was compared in LacZ and CNTF preparations since
previous work has shown that disruption of gap junctional networks can both
increase and decrease SD propagation (Nedergaard et al., 1995; Theis et al.,
2003). Dye coupling in astrocyte networks was determined by injection of biocytin
into a single astrocyte and counting the number of coupled cells based on
diffusion of the tracer, but no significant difference in the degree of coupling was
observed between the two types of tissues (27.9±4.4 vs. 26.0±3.5 coupled cells
n=8 for LacZ and n=9 for CNTF).

3.4.2 Effects on neuronal structure and excitability
Previous reports of astrocyte activation resulted in decreased GABAergic
transmission within the hippocampus (Ortinski et al., 2010), we examined
whether glutamate-mediated synaptic transmission was modified in CNTF
tissues. Excitatory postsynaptic potential (fEPSPs) recorded in area CA1 were
significantly decreased in CNTF preparations, throughout the range of stimulus
intensities tested (Figure 3.2A, LacZ n=7, CNTF n=6). Normalization of fEPSPs
to maximal responses in each preparation showed that the stimulus intensity
required for half-maximal responses was not significantly different (LacZ: 146±6
µA and CNTF: 149±4 µA), implying a significant difference in efficacy, rather than
sensitivity. Single cell recordings from CA1 pyramidal neurons also showed a
significant difference in fEPSCs in CNTF preparations when compared with LacZ
controls (Figure 3.2B).
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It was possible that CNTF lenti-viral injections could be significantly
altering neurons in some way that could account for the decrease in excitatory
transmission, so we next examined the arrangement of CA1 pyramidal neurons
and found that CNTF expression did not lead to readily demonstrable changes in
the packing density or structure of CA1 neurons. Estimates of CA1 pyramidal cell
number were made from DAPI counts of nuclei in stratum pyramidale of confocal
stacks (10 µm thickness) and showed no significant difference between CNTF
and LacZ controls (Figure 3.3A, 9160±331 cells/mm2 and 8920±838 cells/mm2
respectively, n=5, p=.797). The density of apical dendritic projections (as
calculated from MAP-2 immunoreactive processes in 20x150x10 µm confocal
stacks centered 200 µm from stratum pyramidale) also showed no significant
differences between CNTF and LacZ preparations (Figure 3.3B, 11905±2926
dendrites/mm3 and 10068±923 dendrites/mm3 respectively, n=5, p=.566).
Intrinsic membrane properties of CA1 neurons (assessed from intracellular
recordings) were also not significantly different between the CNTF and LacZ
groups. When tested at a resting membrane potential of -65 mV, input
resistances were almost identical (87.5±10.8 and 92.7±10.84 MΩ for LacZ and
CNTF, respectively; n=10 and 12, p=0.74) and depolarizing current pulses (100500 pA) produced very similar trains of action potentials (no significant difference
in number of events, p=0.24) and degrees of spike frequency adaptation during
long stimuli (Figure 3.3C).
There are several possible mechanisms, which may underlie the decrease
in fEPSP observed. We first addressed the possibility that CNTF preparations
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had reduced presynaptic glutamate release. In order to test this hypothesis,
paired-pulse facilitation (PPF) was performed at a range of interpulse intervals
(Figure 3.4A, 50-300 ms, n=6). We found no significant differences between
LacZ and CNTF preparations suggesting that differences in initial presynaptic
glutamate release probability are unlikely to underlie differences in the amplitude
of evoked synaptic potentials. Another possible mechanism underlying the
decrease in fEPSPs could be an increase in activated astrocytes ability to clear
glutamate from the synaptic cleft. To test this hypothesis, single cell recordings
were made from astrocytes in both CNTF and LacZ preparations. No significant
differences were observed in GLT-1 currents when normalized to the fEPSC
amplitude (Figure 3.4B) suggesting astrocytes in CNTF preparations are not able
to remove glutamate more effectively from the synapse and decreasing
availability to the post synaptic cells. We next tested whether the reduced fEPSP
slope could be due to increased presynaptic adenosine A1 receptors activation in
CNTF tissues. Astrocytes are likely a primary source for extracellular adenosine
accumulation (Halassa et al., 2009) and presynaptic A1 receptor activation
effectively inhibits glutamate release and may contribute to neuroprotection (e.g.
Dunwiddie and Masino, 2001; Martin et al., 2007; Canals et al., 2008). However
the difference in synaptic efficacy between CNTF and LacZ tissues was not
resolved by blocking adenosine A1 receptor activation using the selective A1
receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, 200 nM).
DPCPX increased fEPSP slopes in both CNTF and LacZ preparations at the halfmaximal stimulus intensity (Figure 3.4C, (86±7% and 106±2% increase in CNTF
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and LacZ preparations respectively, n=5 for both). However, fEPSPs were still
significantly smaller in CNTF preparations when DPCPX was present when
compared with control LacZ preparations. These results imply that differences in
adenosine accumulation are not sufficient to explain the change in synaptic
efficacy in CNTF preparations and are consistent with the conclusion of PPF
studies that initial glutamate release probability is not reduced in CNTF tissues.
Changes in synaptic transmission could be a result of decreased glutamateglutamine recycling or changes in postsynaptic receptors.

3.4.3 Increased SD threshold in CNTF preparations
The decrease in synaptic transmission could have many downstream
mechanisms. We chose to investigate the possible effects on the pathological
phenomenon of SD since glutamate receptor activation can contribute to the
spread of SD (Somjen, 2001). SD was reliably triggered by localized
microinjections of KCl in all LacZ preparations. Localized KCl pulses of
progressively increasing duration were used to estimate the threshold for onset
of these all-or-none events, and they revealed a threshold from 30-100 ms in
LacZ preparations (n=18). SDs were recorded as a sharp negative shift in
extracellular DC potential at a recording site ~300 µm from the KCl injection site
(Figure 3.5A). The propagation of SD in LacZ preparations was readily monitored
by large autofluorescence decreases that propagated across the CA1 region
(Figure 3.5B). In the LacZ preparations these signals spread at least as far as the
edge of the field of view (~1300 µm in 7/11 preparations) with average
propagation rate in LacZ preparations was 3.85±0.21 mm/min (n=18). In the case
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of LacZ preparations, SDs generated by KCl microinjection were fully
recoverable, and could be evoked repetitively at 10 minute intervals in these
slices.
In contrast, K+ injections never induced SD in slice preparations from
CNTF-injected mice. No DC shift was recorded (Figure 3.5C, Fig 3.6A) over the
range of stimuli that were effective in LacZ tissues, and even when the K+
stimulus was increased by using much longer pulses (500 ms Fig 3.6B), no
propagating event was observed optically (Fig 3.5D) or recorded with
extracellular electrodes. Previous reports have shown that modest [K+]e (8 mM)
increases can significantly reduce the threshold for SD in tissue resistant to the
propagating wave by increasing neuronal excitability (Funke et al., 2009).
However, when extracellular K+ levels were raised to 8 mM (from 2 mM) SD still
could not be induced in CNTF preparations (data not shown, n=2). The lack of
spreading events in all CNTF preparations was confirmed by analysis of the
spread of delayed autofluorescence decreases that occurred after K+ ejection.
These relatively sustained autofluorescence decreases are a consequence of
tissue swelling that accompanies tissue depolarization. After they became
established within 10 s of the K+ stimulus, there was no further spread of the
signals. The fluorescence decreases are therefore likely to represent the
consequences of passive spread of K+ from the stimulating electrode.
Comparison of initial components of autofluorescence transients also
suggested that the lack of high K+-SD in CNTF preparations was not due to
differences in effective depolarization of the tissue surrounding the stimulating
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electrode. Initial autofluorescence (Ex 450 nm) increases following KCl ejection
are matched by NAD(P)H autofluorescence (Ex 360 nm) decreases, and
therefore provide an indication of mitochondrial redox potential changes in
stimulated tissue (Shuttleworth et al., 2003). Consistent with similar initial
activation, we found no significant difference in initial autofluorescence transients
between LacZ and CNTF preparations (7.2±0.6% and 7.9±1.1% respectively at
100 ms K+ pulse, p=.49).

3.4.4 Increased threshold, rather than inability to generate SD
To determine whether CNTF-activation of astrocytes resulted in a
generalized inability to generate SD in slice preparations or alternatively whether
there was a more selective increase in high K+-SD threshold, we examined
responses to extended exposures of slices to ouabain (100 µM). Ouabain inhibits
Na+/K+-ATPase activity and is known to be an effective stimulus of SD in
hippocampal slices (Basarsky et al., 1998; Dietz et al., 2008). In LacZ
preparations, SDs were induced in all preparations 3.9±0.3 min after ouabain
reached the bath and propagated at a rate of 4.08±0.96 mm/min (Figure 3.7A,
n=5). SD was also generated in all CNTF preparations, although the latency to
SD onset was significantly longer (5.42±0.32 min) and the mean propagation rate
was significantly slower (Figure 3.7B, 2.28±1.26 mm/min, n=6, p=.002). As an
internal control, we simultaneously measured SD in the adjacent neocortex
(using intrinsic optical imaging for these low power imaging studies, see
Methods). Ouabain-SD propagation rates in neocortex were not significantly
different between CNTF and LacZ slices (3.62±0.60 mm/min and 3.78±0.69
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mm/min respectively, n=6,5, p=0.69), consistent with the hypothesis that
differences in ouabain SD were selectively related to CNTF-activated astrocytes
in hippocampus.

3.5 Discussion
The main conclusions from this study are 1) that a CNTF expression
model can be used to successfully produce strong sustained activation of
astrocytes in the hippocampus, suitable for subsequent slice electrophysiological
studies, 2) excitatory transmission within CNTF preparations is significantly
decreased and may be due to reduced glutamate-glutamine cycling and 3) SD
threshold is substantially elevated in tissues with activated astrocytes. These
findings are consistent with the hypothesis that astrocyte activation may
contribute to neuroprotection in some neurological or neurodegenerative
disorders where SD is known to contribute to the expansion of injury.

3.5.1 CNTF model for astrocyte activation
In mature astrocytes, CNTF triggers a cascade of intracellular events
involving the JAK-STAT pathway that leads to the generation of an activated
phenotype (Bonni et al., 1997; Hudgins and Levison, 1998). CNTF is normally
expressed by astrocytes in the mature brain, with little (if any) neuronal
expression. Our experimental model involves transduction of neurons with a
CNTF expression system, so that the factor is now expressed in these cells.
Because the CNTF construct includes an immunoglobulin export sequence, it
does not accumulate within neurons, but is released in the extracellular space
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(up to 1ng/mg protein, see (de Almeida et al., 2001). All cell types within the CNS
express the CNTFRα, making it possible that some of the effects observed in this
model may not be astrocyte specific. Studies both in vitro and in vivo tested the
effect of CNTF on hippocampal neurons during both excitotoxic and ischemic
injury respectively, and showed that the neurotrophic factor provided significant
neuroprotection during both types of injury (Wen et al., 1995; Semkova et al.,
1999). However, these studies were unable to determine whether these
neuroprotective effects were mediated by specific changes within neurons and/or
astrocytes. CNTF may also act as a pro-survival factor by restricting apoptotic
cell death in oligodendrocytes, which suggests a possible protective role for
CNTF in inflammatory demylinating diseases such as multiple sclerosis (Louis et
al., 1993; Cagnon and Braissant, 2009). Our results demonstrate robust and
sustained activation of murine hippocampal astrocytes by CNTF, as has been
described previously following injection of the same lenti-viral construct into rat
striatum (Escartin et al., 2006; Escartin et al., 2007; Beurrier et al., 2010).
Because hippocampal slices are so widely used for electrophysiological studies,
this model could be useful to assess functional consequences of astrocyte
activation on many aspects of neuronal-glial interactions. This model may also be
particularly relevant when discussing ischemic injury since previous work has
shown an increase in both CNTF and CNTFRα expression following transient
occlusion (Lin et al., 1998). More generally, these studies provide a model for
modifying gene expression in vivo that may then be translated to a commonly
used in vitro model. In vivo lenti-viral injections into the hippocampus allow for

93

constitutive, long term expression of a gene of choice, which could then be used
for in vitro hippocampal slice studies.

3.5.2 Consequences of CNTF exposure on astrocyte and synaptic function
Increased GFAP immunolabeling is a well-established anatomical
hallmark of astrocyte activation following a range of stimuli (Kalman, 2004; Pekny
and Nilsson, 2005), yet the associated functional changes are not well
characterized and are likely to be different depending on the inducing stimulus.
There is an ongoing debate about the contribution of astrocyte activation to
neuronal survival or to cell death following CNS injury. On the one hand,
astrocytes may exacerbate injury by secreting pro-inflammatory factors and
forming a glial scar, which can prevent regrowth of neuronal processes
(Swanson et al., 2004). However, there is also increasing evidence supporting
the hypothesis that astrocytes promote neuronal survival following injury
(Sendtner et al., 1994; Li et al., 2007), and experiments where activation is
inhibited in mice subjected to MCAO resulted in infarct sizes three times larger
than in littermate controls (Li et al., 2008). Importantly, astrocytes have been
shown to remain in this activated phenotype more than a month following
transient cerebral ischemia (5 min); making these cells a useful target for
therapeutics following ischemic injury (Choi et al., 2010).
We found a significant decrease in synaptic efficacy in studies of
stimulation of glutamatergic inputs from Shaffer collateral fibers to CA1 pyramidal
neurons. Paired pulse facilitation studies suggested that this effect was not due
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to a decrease in the initial probability of transmitter release. The possibility of
decreased vesicular release was further tested using the A1 receptor antagonist,
DPCPX. One of the many ways in which astrocytes modulate synaptic activity is
by the release of adenosine at the synapse to decrease presynaptic release of
glutamate (Dunwiddie and Masino, 2001; Pascual et al., 2005). However,
addition of DPCPX did not restore CNTF fEPSPs to similar levels as LacZ
preparations, which provides additional support to the PPF data suggesting that
decreased synaptic efficacy was not a result of decreased probability of vesicular
release. Recent work has evaluated a range of functional consequences linked to
astrocytes activation by CNTF in the striatum. CNTF over-expression produced a
redistribution of astrocytic glutamate transporters, GLAST and GLT-1, into raft
functional membrane microdomains, which are believed to be important for
efficient glutamate uptake (Escartin et al., 2006). However, our single cell
recordings from astrocytes suggest that enhanced glutamate uptake is likely not
to contribute significantly to the decreased excitatory transmission or resistance
to SD of CNTF-exposed tissues.
We hypothesize that the changes observed in synaptic transmission are
due to decreased glutamate-glutamine cycling within astrocytes resulting in
decreased glutamate within presynaptic neurons. Previous work in hippocampal
slice culture has shown significant decreases in glutamate in pre-synaptic
terminals when glutamate-glutamine cycling is inhibited within astrocytes (Laake
et al., 1995). As mentioned above, a recent study showed decreased GABAergic
transmission in preparations where activated astrocytes had reduced glutamate-
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glutamine cycling (Ortinski et al., 2010). Inhibitory transmission was restored
following brief bath application of exogenous glutamine at a high concentration
(10 mM). However, it has been shown that at physiological levels (0.5 mM),
prolonged glutamine exposures showed no significant effects on synaptic
transmission and at higher concentrations (2-5 mM) prolonged exposures
resulted in an attenuation of synaptic transmission and the induction of SD in
some preparations at 34°C (An et al., 2008). In other experiments conducted at
room temperature, SD was not induced after prolonged glutamine exposures at 4
mM (Kam and Nicoll, 2007). Due to the wide variability in conclusions made from
exogenous glutamine exposures, the apparent importance of glutamine may
depend on the specific experimental method since metabolic demands,
anatomical relationship, and other factors may determine the degree of a
neuronal populations’ dependence on the glutamate-glutamine cycle (Kam and
Nicoll, 2007; An et al., 2008). It does appear that GABA neurotransmitter pools
depend on astrocyte-derived glutamine for GABA synthesis to a greater extent
than glutamatergic synapses, which could depend more on direct reuptake
and/or have a greater cytoplasmic reserve pool (Fricke et al., 2007; Ortinski et
al., 2010).
In the context of ischemia, differences between sensitivities of
glutamatergic and GABAergic transmission to glutamine may have a profound
effect on the progression of post-stroke injury. This initial phase of excitotoxicity
and hyperexcitability (due to GABA depletion), may precede a delayed decrease
in excitatory transmission in the days following the initial infarct. Importantly, such
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a decrease in excitatory transmission may underlie the resistance to SD we
observe in CNTF slice preparations (see below).

3.5.3 Changes in SD threshold
SD threshold is determined by progressively increasing the intensity of
electrical or K+ stimulation to the brain surface or brain slice. In our studies, we
characterized the threshold for SD using graded, localized KCl microinjections,
delivered by pressure pulses of increasing duration from a conventional patch
electrode. Rapid and localized extracellular K+ elevations are expected to
depolarize a population of cells, and subsequent glutamate and/or K+ release
from these cells is thought to underlie the feed-forward propagation of the SD
event (Kager et al., 2000; Somjen, 2001). Once initiated, SD then progressed
slowly (~3-5 mm/min) from the injection site, and if generated in otherwise
healthy tissue, the depolarizing event is fully recoverable (Nedergaard and
Hansen, 1988). While SD threshold could be readily determined in each LacZ
control slice (generally between 30-100 ms pulse duration), SD could never be
induced with KCl in CNTF preparations, even with very prolonged K+ stimuli and
elevations in extracellular K+ concentrations (8 mM). This striking difference was
not due to differences in the K+ microinjection, since the same delivery electrodes
were utilized for paired CNTF and LacZ studies on individual recording days, and
autofluorescence studies of mitochondrial activation indicated similar degrees of
slice activation at the K+ ejection site (Supplemental data). These observations
suggested instead that there was a greatly increased threshold for SD initiation
with the K+ stimulus, or possibly a complete inability of CNTF preparations to
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allow propagation of SD waves. Previous studies have shown an increase in
connexin 43 expression with CNTF infection in rat striatum (Escartin et al., 2006)
which could increase astrocyte gap junctional coupling. However, we found no
significant differences in astrocyte coupling in the present studies suggesting that
differences in K+ buffering within the astrocytic network, or other consequences
of changes in coupling between astrocyte are not major contributors to effects of
CNTF. It is possible that increased connexin 43 expression could result in an
increase in hemichannels on astrocytic membranes, which could potentially
increase the ability of a single astrocyte to clear local K+ even if there is not an
enhancement in the ability to siphon it to neighboring astrocytes. This could be
important under in vivo conditions where astrocytes can connect with the local
vasculature and clear K+ into the bloodstream, but this would not explain the
effects on SD threshold in slice preparations shown here.
Subsequent experiments with bath application of ouabain revealed that
CNTF tissues do retain the ability to generate SD, albeit with a significantly
longer latency to onset and significantly slower propagation rate than was
observed in LacZ controls. By confirming that CNTF tissues retain appropriate
structural and functional properties required for SD, this observation provides a
useful control for the high K+ studies. In addition, the fact that ouabain triggers
SD by a very different mechanism (inhibition of Na+/K+-ATPase) provides insight
into possible mechanisms by which CNTF limits SD. The concentration of
ouabain used here is expected to inhibit the major Na+/K+-ATPase isoforms
found in both neurons and astrocytes (α3 and α2, respectively) (Watts et al.,
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1991), and has previously been shown to reliably generate SD in hippocampal
slices (Haglund and Schwartzkroin, 1990; Basarsky et al., 1998; Balestrino et al.,
1999; Dietz et al., 2008). Inhibition of Na+/K+-ATPase in neurons will lead to rapid
depolarization and extracellular K+ and glutamate elevations. The main difference
between ouabain and high K+ stimuli is that ouabain will also lead to a significant
impairment in Na+-dependent glutamate uptake by astrocytes as a consequence
of Na+/K+-ATPase inhibition. However, a decrease in the overall glutamate pool
(as suggested by our fEPSP results) in CNTF tissues could be sufficient to
prevent the propagation of high K+-SD and would explain the increased latency
and slower propagation of ouabain-SD.

3.5.4 Activation of astrocytes by SD and ischemia
A number of studies have described astrocyte activation following SD, as
demonstrated by strong increases in GFAP immunolabeling in the affected tissue
(Kraig et al., 1991; Wiggins et al., 2003). This association between SD and
astrocyte activation has been demonstrated most clearly in studies of repetitive
application of K+ in otherwise healthy brains. Activation occurred within 6 hours of
induced SD events and persisted for at least one week post-SD (Kraig et al.,
1991; Bonthius and Steward, 1993; Wiggins et al., 2003). There have been few
studies of the consequences of astrocyte activation following SD, but it is
noteworthy that a recent preliminary report describes a progressive increase in
SD threshold when rats are repetitively challenged by SD (Sukhotinksky et al.,
2008) as well as studies where preconditioning with SD showed a correlation
between reduced cortical infarct volume following MCAO and increase in GFAP
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expression (Matsushima et al., 1998). Our results raise the possibility that
astrocyte activation itself could underlie SD threshold increases, when animals
are subjected to repetitive SD in vivo.
Recent work has provided increasing support for the hypothesis that
repetitive SD events are common following animal and human stroke (Hartings et
al., 2003; Dohmen et al., 2008), and that the metabolic consequences of SD
contribute to the enlargement of stroke injuries (Iijima et al., 1992; Busch et al.,
1996). It is not yet known whether SD events associated with ischemia contribute
to the well-described activation of astrocytes in peri-infarct regions in animal
models of stroke (Chen et al., 1993; Li et al., 1995) or in postmortem tissues from
human stroke patients (Zhao et al., 2006). However our observations of greatly
elevated SD threshold in tissues with CNTF-activated astrocytes suggest that
periinfarct activated astrocytes could serve to limit the spread of SD into healthy
brain tissue following stroke. As noted above, decreases in glutamate-glutamine
cycling may contribute to elevated SD thresholds, and it will be of interest to
examine these and other mechanisms in future studies, in particular, using in
vivo ischemia models. The present results in slice do provide evidence consistent
with an important supportive role for astrocytes, and suggests that maintaining
normal astrocytic function in compromised tissue may be valuable for preventing
repetitive depolarizing events, which contribute to the expansion of neuronal
injury.
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3.6 Figure Legends
3.6.1 Figure 3.1
Astrocyte activation within murine hippocampus. A. Representative
distribution

of

β-galactosidase

immunohistochemistry

demonstrates

that

intrahippocampal lentivirus injections lead to infection localized within the
hippocampus, and high power confocal images of the CA1 and dentate gyrus
showing localization to neuronal cell bodies (30 μm cryostat section, scale bar:
1mm and 100 µm respectively). B. GFAP immunohistochemistry: Low power
confocal projections (20 µm thick) were used to quantify changes in either total
astrocyte number or simply increases in GFAP expression within resident
astroscytes in hippocampal slice preparations (250 µm sections) from mice
injected with lenti-CNTF versus lenti-LacZ as well as none injected controls (top
panel, n=8/8/7). Representative high power confocal images (20 µm thick) show
increased GFAP within single astrocytes from CNTF hippocampal slices versus
LacZ and controls (bottom panel). (GFAP: red, DAPI: blue, Scale bars: top panel
100 µm, bottom panel 50 µm). C. Quantification of area expressing GFAP and
total astrocyte density. There was a significant increase in GFAP expression in
CNTF preparations when compared with both LacZ and non-injected controls
(F(2,22)=5.049, *p=.017, One-way ANOVA with Tukey’s post-hoc test), but no
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significant difference in total number of astrocytes (F(2,22)=.968, p=.40, One-way
ANOVA with Tukey’s post-hoc test). D. Representative low-power images from
slice preparations where single astrocytes were loaded with biocytin to assess
astrocytic coupling (scale bar: 150 µm). When the number of coupled cells were
counted, there were no significant differences in astrocyte coupling between
LacZ and CNTF preparations (t(15)=.335, p=.74, independent t-test).

3.6.2 Figure 3.2
CNTF astrocytes activation results in reduced synaptic efficacy. A.
Input-output curves were generated from the slope of fEPSP at increasing
currents (0.0-0.3 mA, 0.02 mA interval) (left) and representative fEPSPs at half
maximal amplitude are shown (right). There was a significant decrease in the
slope of the fEPSPs in CNTF hippocampal slices when compared to LacZs (n=6
and n=7 respectively, F(2,10)=4.32, *p<.05). B. Single cell recordings were made
from pyramidal neurons within the CA1 cell layer. CNTF preparations showed a
significant decrease in fEPSCs when normalized to the pre-synaptic fiber volley.

3.6.3 Figure 3.3
Effects of CNTF lentiviral injections on pyramidal neurons within the
hippocampus. A-B. Confocal stacks (10 µm thick) processed for MAP-2 (green)
to determine dendritic density within the sr and the nuclear stain DAPI (blue) to
determine neuronal density within the CA1 pyramidal cell layer. Representative
images from the sp show similar neuronal density between LacZ and CNTF
preparations (scale bar: 20 µm) and low-power images of the entire CA1 region
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show no demonstrable changes in dendritic density (region centered 200um from
stratum pyramidale, scale bar: 50 µm). C. Intrinsic membrane properties of
neurons were also not significantly different between CNTF and LacZ controls.

3.6.4 Figure 3.4
Reduced fEPSPs not due to decreased probability of presynaptic
glutamate release or increased glutamate clearance by astrocytes. A.
Paired pulse facilitation (PPF) was measured at a range of interpulse intervals
(50-300 ms), and no significant differences were observed between CNTF and
LacZ preparations suggesting that the decrease in fEPSP slope was not a result
of decreased presynaptic vesicular glutamate release (F(4,40)=.289, p=.884,
repeated measures ANOVA, n=6). B. Single cell recordings from astrocytes
determined that there was no significant difference in glutamate current through
the GLT-1 transporter in LacZ and CNTF preparations. C-D. Input-output curves
were generated in preparations both pre- and post- exposures to the A1 receptor
antagonist (DPCPX, 200 nM) to determine if the decrease in synaptic efficacy in
CNTF preparations was adenosine dependent (C) and representative fEPSPs at
half maximal amplitude are shown both pre- and post-DPCPX (D). Bath
application of DPCPX significantly increased fEPSPs in both CNTF and LacZ
preparations (at half maximal stimulus intensity (0.14 mA), F(1,8) = 5.94, p=.04,
repeated measures ANOVA, n=5), but CNTF fEPSPs were still significantly
smaller that LacZ preparations (F(1,8)= 6.42, *p<.05, repeated measures
ANOVA, n=5).
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3.6.5 Figure 3.5
Inhibition of SD in slices with CNTF-activated astrocytes. A.
Representative DC recordings from LacZ preparations during 50 ms, 100 ms,
and 200 ms KCl microinjections with 10 min intervals between stimuli.
Recordings (R) were taken ~300 µm from the KCl injection site (S) as shown in
bright field images in top corner of montages (B). B. Representative montage of
450 nm autofluorescence during the 100 ms KCl microinjection (shown
electrically in A) from the LacZ preparation which resulted in the propagation of
SD across the preparation beyond the field of view (~1300 µm). C.
Representative

DC

recording

from

a

CNTF

preparation

where

KCl

microinjections up to 200 ms in duration did not result in SD. D. Representative
450 nm autofluorscence recording during the 100 ms KCl microinjection from the
CNTF preparation where the initial passive depolarization due to the exogenous
KCl application occurred, but no propagating SD event.

3.6.6 Figure 3.6
A. SD threshold determined with high K+ microinjections (1M KCl). In LacZ
slices SDs were induced in all preparations by the longest K+ microinjection (200
ms) (n=18/18). The same stimuli did not generate an SD in any CNTF
preparations (n=0/18). B. Distance of the final tissue depolarization in CNTF
preparations versus the initial passive depolarization due to the spread of
exogenous K+. CNTF preparations showed no significant differences between
the passive K+ depolarization (white triangles) and the final response (white
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boxes), providing further support for the lack of SD in CNTF preparations (n=12,
dashed line represents the average distance of the view frame).

3.6.7 Figure 3.7
During 100 µM ouabain exposures, both electrical recordings and intrinsic
optical signals were used to measure SD in the sr of the CA1. A. Although SD
could be induced in all CNTF preparations (n=6), the latency to SD was
significantly longer when compared to LacZ controls (n=5) (t(14)=4.19, p=.001,
independent t-test). B. The rate of propagation was also significantly slower in
CNTF preparations when compared to LacZ slices (t(14)=-3.89, p=.002,
independent t-test).

3.6.8 Supplemental Figure 3.1
NAD(P)H autofluorescence has been widely used to visualize the spread
of SD and similar events in vivo and in brain slice (Strong et al., 2000;
Shuttleworth et al., 2003; Takano et al., 2007). We chose to near-simultaneously
optically measure both NAD(P)H and AF450 in order to better understand the
biphasic NAD(P)H response which results in an initial rapid oxidizing event
followed by a slower “overshoot” that is confounded by swelling. A.
Representative NAD(P)H and AF450 kinetics from a LacZ preparation where SD
occurred. The initial rapid oxidizing event (AF450) could not be used to measure
the propagation of SD since it was no longer visible in most preparations by 300
μm away from the stimulating electrode (black trace (stimulating electrode)
versus green trace (300 µm)). Additionally, changes in the NAD(P)H “overshoot”
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phase were difficult to distinguish over baseline due to swelling (blue and red
traces). However, the slower AF450 response was amplified by the optical artifact
of swelling (black and green traces). B. Population data from LacZ preparations
(n=7) determined that, as suggested by the representative traces in A, the initial
AF450 oxidizing response decreased in intensity rapidly and was overcome by the
swelling response in almost all preparations (black bars), while the slower
response showed a stable intensity across the entire slice (white bars), and is
easy to visualize due to the additive effects of the swelling response.

3.6.9 Supplemental Figure 3.2
K+ spread versus SD in a LacZ preparation. A. DC electrical recording 50
µM from stimulating electrode of both a sub-threshold depolarizing event and an
SD event. At 50ms there was a negative voltage shift, but it lacked the
characteristic saddle shape indicative of SD which was observed with the 100 ms
K+ microinjection. B. AF450 at 50 ms showed the local passive depolarization due
to the K+ microinjection while when SD was induced with the 100 ms
microinjection, the AF450 decrease propagates across the slice.
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4.1 Abstract
Previous reports have suggested that nitric oxide (NO) may provide
protection following some forms of ischemic brain injury by limiting the number of
spreading depression (SD) events that occur. Levels of NO are known to
increase following SD and may increase SD threshold. However, NO is also
known to inhibit respiration, suggesting that excessive NO exposure may induce
an additional metabolic burden to compromised tissues. The present study
evaluates the effects of NO on SD progression and consequences in acutely
prepared murine hippocampal slices. Selective inhibition of nitric oxide synthase
(NOS) resulted in a significant increase in rates of SD induced by localized KCl
microinjections. Addition of an NO donor 2-(N, N-Diethylamino)-diazenolate 2oxide (DEA/NO, 100-300 M) also resulted in a significant increase in SD
propagation rates. NAD(P)H and flavoprotein autofluorescence measurements
during DEA/NO exposures demonstrated inhibition of mitochondrial respiration
similar to that produced by sodium cyanide. NO-dependent metabolic inhibition
appeared to be cGMP-independent and presumably due to direct inhibition of
cytochrome oxidase. Exogenous NO resulted in a loss of synaptic transmission
which occurred coincident with metabolic inhibition and was attenuated by A1
receptor antagonists. Under normal conditions, SD was recoverable and synaptic
transmission returned to baseline levels after SD. However, in the presence of
DEA/NO, SD led to irrecoverable suppression of synaptic potentials, likely due to
the inability of neurons to restore ionic homeostasis. These results suggest that
while basal NO levels may be protective, excessive NO exposures can provide
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an additional metabolic burden, sufficient to transform a benign response into a
deleterious one.

4.1.1 Research highlights
1. Inhibition of NO production increased SD propagation rate in murine
hippocampal slices. 2. Addition of exogenous NO increased SD propagation rate,
and transformed normoxic SD into a non-recoverable event. 3. Deleterious
effects of exogenous NO are likely due to inhibition of mitochondrial respiration.

4.1.2 Keywords
Hippocampal slice, spreading depression, nitric oxide

4.1.3 Abbreviations
nACSF: normal artificial cerebral spinal fluid, SD: spreading depression,
NO: nitric oxide, DEA/NO: 2-(N, N-Diethylamino)-diazenolate 2-oxide,NAD(P)H:
Nicotinamide adenine dinucleotide, L-NNA: Nω-Nitro-L-arginine, fEPSP: postsynaptic field potential.

4.2 Introduction
Spreading depression (SD) is characterized as the rapid depolarization of
both neurons and glia in an “all-or-none” fashion (Somjen, 2001). SD-like events,
known as peri-infarct depolarizations (PIDs), are known to occur following a wide
range of ischemic insults and contribute to the subsequent expansion of infarct
volume (Mies et al., 1993; Busch et al., 1996). It has been shown in animal
studies that these events occur for many hours following initial ischemic injuries
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(Hartings et al., 2003), and recent work has shown that PIDs occur in humans
following traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), and
stroke (Dreier et al., 2006; Fabricius et al., 2006; Dohmen et al., 2008; Dreier et
al., 2009). For these reasons, there is a significant interest in finding new ways to
target and minimize the number of these depolarizing events and improve patient
outcome (Lauritzen et al., 2011).
Previous studies have shown that spreading depression events lead to
increased expression of inducible nitric oxide synthase (iNOS) and synthesis of
its product nitric oxide (NO) (Read et al., 1997; Petzold et al., 2008; Viggiano et
al., 2008). NO production can regulate SD and inhibition of basal NO synthesis
results in decreased SD threshold and delayed recovery of the negative DC shift
(Wang et al., 2003; Petzold et al., 2008). These prior studies suggested that
increasing NO availability following ischemic injuries may be useful clinically to
prevent SD during a period of delayed ischemic neurologic deficits following SAH
(Petzold et al., 2008). For this strategy to be effective the concentration of NO
available will likely be important, since the role of NO in neuronal cell death and
survival is complex.
It is well established that NO can inhibit cytochrome oxidase activity (by
competing with oxygen for binding) and can significantly reduce neuronal ATP
production (Brown and Cooper, 1994; Brookes et al., 1999). Astrocytes, which
are considered primarily glycolytic cells, are relatively resistant to the toxic effects
of NO on mitochondrial function, unless glucose is removed from the media
(Almeida et al., 2001).
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The main question addressed in this study was whether basal
endogenous or exogenous NO applications could limit the propagation and
influence the consequences of SD. The effects of both removal and addition of
NO were examined in hippocampal slice preparations, and SD was induced by
localized 1M KCl microinjections. We conclude that while basal levels of NO may
limit SD events, exposures to excessive exogenous NO concentrations
significantly accelerate SD and worsen outcomes in brain tissue. These effects
may limit NO exposures that can be used clinically to modulate SD threshold.

4.3 Materials and Methods
4.3.1 Slice preparation
Male mice (C57Bl/6) were obtained from Jackson Laboratories (Bar
Harbor, ME) or Harlan (Indianapolis, IN) at 4-6 weeks of age and were housed in
standard conditions (12hr/12hr light/dark cycle) for up to two weeks before
euthanasia. All experiments were performed in accordance with approved
protocols from the University of New Mexico Laboratory Animal Care and Use
Committee. Numbers in the study refer to numbers of slices, with a maximum of
two slices obtained from an individual experimental animal used for each
protocol. Mice were deeply anesthetized with a mixture of ketamine and xylazine
(85 mg/ml and 15 mg/ml, respectively; 150 ml s.c.) and then decapitated. Brains
were removed and placed in ice cold cutting solution (see below for composition).
350 μm coronal sections were cut using a Vibratome (Technical Products
International, St Louis MO) and slices were transferred into room-temperature
ACSF (see below). Cutting and recording solutions were both 300-305 mOsmol/l.
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After warming to 34oC and holding for 1 hour, ACSF was changed again, and
slices were held at room temperature until used for recording. Individual slices
were transferred to the recording chamber, and were perfused with warmed
(34oC), oxygenated ACSF at 2 ml/min.

4.3.2 Autofluorescence imaging
NAD(P)H

autofluorescence

was

imaged

as

previously

described

(Shuttleworth et al., 2003). Briefly, UV excitation (360 nm) was delivered via a
fiber optic - monochrometer system (Polychrome IV; Till Photonics) and reflected
onto the slice surface using a dichroic mirror (Chroma, DMLP 400 nm).
Fluorescence emission (>410 nm) was collected using a cooled, interline-transfer
CCD camera (IMAGO, Till Photonics, Germany). Changes in flavoprotein (FP)
autofluorescence were monitored using excitation at 450 nm, and emission
detected using a 535 (50 BW) interference filter. In some experiments, nearsimultaneous NAD(P)H / FAD imaging was performed by switching filter cubes at
0.4 Hz. In both cases, imaging was performed after focusing onto the surface of
slices, using either 10X or 40X water immersion objectives (Olympus, NA 0.3 and
0.8 respectively), and collected after 2x2 binning of the 640x480 line image. After
binning, individual pixels corresponded to areas of 2.6 μm2 and 0.64 μm2 for 10X
and 40X objectives, respectively. For analysis, image data were filtered using
3x3

pixel

averaging

and

presented

as

the

intensity/prestimulus fluorescence intensity (∆F/Fo).
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change

in

fluorescence

4.3.3 Recording of Postsynaptic Potentials
Schaffer collateral inputs to the CA1 region were stimulated using a
concentric bipolar electrode (25 μm tip) placed on the surface of stratum
radiatum. Single shocks (80 μs, 0.1-1.5 mA) were applied using a constantcurrent stimulus isolation unit (Isoflex, AMPI, Isreal). Extracellular field recordings
of excitatory postsynaptic potentials (fEPSPs) were made using glass
microelectrodes (4-8 M) filled with ACSF. Electrodes were placed in stratum
radiatum of CA1, approximately 150 μm from the pyramidal cell body layer.
Stimulus intensity was chosen based on an input/output curve generated in each
slice, to produce responses >60% of maximal amplitude (0.6-1.0 mA). Signals
were amplified (Neurodata IR-283), digitized (Digidata 1322A, Axon Instruments,
Union City, CA), and then acquired using Clampex software (v 9.2, Axon
Instruments).

4.3.4 Stimulation of spreading depression events
Spreading depression (SD) was induced using localized microinjections of
KCl as described in (Dietz et al., 2008) with minor modifications. A conventional
whole-cell patch electrode (tip resistance 4-8 MΩ) was placed ~50 µm below the
slice surface in stratum radiatum, and miroinjections triggered by brief (10-200
ms) pressure pulses delivered by a PicoPump (SYS-PV830, World Precision
Instruments). SD resulted in the loss of fEPSPs and the propagation of SD
across the tissue was monitored using autofluorescence imaging (see methods
above).
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4.3.5 Reagents and Solutions
Except where noted, all drugs and salts were obtained from Sigma
Chemical Co (St Louis, MO). ACSF contained, in mM: 126 NaCl, 2 KCl, 1.25
NaH2PO4, 1 MgSO4, 26 NaHCO3, 2 CaCl2, and 10 glucose, equilibrated with
95%O2 / 5%CO2. Cutting solution contained, in mM: 3 KCl, 1.25 NaH2PO4, 6
MgSO4, 26 NaHCO3, 0.2 CaCl2, 10 glucose, 220 sucrose and 0.43 ketamine.
NaCN stock was made fresh daily at 1 M concentration based on previous work
(Gerich et al., 2006). DEA/NO was prepared as reported previously (Bon and
Garthwaite, 2001). Briefly, 100 mM DEA-NO was dissolved in 10 mM NaOH and
stored frozen for <24 h before use. DEA/NO was then dissolved in ACSF to its
final concentration (100 µM) immediately before use.

4.3.6 Statistical analysis
Significant differences between group data were evaluated using unpaired
Student’s t tests or one-way ANOVA. Bonferroni’s multiple-comparison test or
contrasts were used for post hoc analysis in which the effects of multiple
treatments were compared with each other. A value of p<.05 was considered
significant in all cases.

4.4 Results
4.4.1 Effects of modifying NO availability on SD
Initial experiments set out to determine whether there were changes in SD
threshold with the manipulation of endogenous NO as previously reported in rat
cortical slices (Petzold et al., 2008). To block NO synthesis, slices were pre-
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exposed to the NOS inhibitor Nω-Nitro-L-arginine (L-NNA, 1 mM, 15 min) prior to
KCl challenges, and these responses were compared to control responses with
preparations exposed to an excess of endogenous NOS substrate L-arginine (0.5
mM). SD threshold is usually determined by progressively increasing the intensity
of electrical stimulation or K+ concentration applied to the brain surface or brain
slice (Ayata et al., 2000; van den Maagdenberg et al., 2004; Ayata et al., 2006).
For the current studies, we characterized SD threshold using graded localized
KCl microinjections, delivered by increasing durations of pressure ejection from a
conventional patch electrode (10-200 ms). NOS inhibition did not obviously
change SD threshold, with 100 ms duration stimuli initiated SD in all slices (data
not shown). Inhibition of NO synthesis did significantly increase SD propagation
rate (Figure 4.1A); consistent with previous observations in rat slices (Petzold et
al., 2008).
To test the hypothesis that the addition of exogenous NO may provide
neuroprotection and decrease SD propagation, slices were pre-exposed to an
NO donor for 10 minutes prior to SD induction with KCl microinjection. Excitatory
postsynaptic potentials were monitored throughout these experiments, to assess
the impact on neuronal viability. We chose to utilize 2-(N, N-Diethylamino)diazenolate 2-oxide (DEA/NO) since its release of authentic NO has been well
characterized, including in hippocampal slices (Keefer et al., 1996; Feelisch,
1998; Bon and Garthwaite, 2001, 2003; Hopper et al., 2004). Figure 4.1B shows
representative recordings of evoked excitatory synaptic potentials in L-arginine
controls (open circles) and DEA/NO pre-exposed preparations (filled circles),
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before and after the onset of high K+-SD (arrow). As discussed in detail below
(Figure 4.4), DEA/NO itself led to a robust suppression of fEPSP slope, but it did
not prevent the initiation or propagation of SD. In fact, SD propagation rate was
increased in DEA/NO (Figure 4.1C). Importantly, under control conditions, SD
resulted in only a transient depression of evoked synaptic activity, which
generally recovered within ~10 min as neurons restored ionic homeostasis. Thus,
in control preparations, fEPSPs recovered to 81.01±19.75% baseline levels
(Figure 4.1C, n=5). In contrast, in preparations pre-exposed to DEA/NO, SD
never recovered and the loss of synaptic activity at SD onset persisted
suggesting neuronal damage (-1.97±2.03% recovery, n=5). Therefore, while
basal levels of NO may be important for setting SD threshold and propagation
rate, excessive NO may be detrimental to tissue subjected to SD.

4.4.2 Effects of exogenous NO on neuronal function
It is well established that NO can inhibit oxidative metabolism by
competing with oxygen at cytochrome oxidase within the electron transport chain
(Brown and Cooper, 1994; Cleeter et al., 1994; Giulivi, 1998). Near simultaneous
NAD(P)H and flavoprotein autofluorescence were used to monitor the effects of
100 µM DEA/NO on oxidative metabolism. DEA/NO exposures resulted in
sustained increase in NAD(P)H autofluorescence, which was mirrored by
flavoprotein autofluorescence decrease (Figure 4.2A, n=6). These effects were
mimicked by the respiratory chain inhibitor sodium cyanide (NaCN, 100 µM),
which inhibits oxidative metabolism in a concentration-dependent manner (Figure
4.2B-C). Direct effects of NO on mitochondrial respiration are cGMP
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independent. In these preparations, inhibition of cGMP synthesis with 1H[1,2,4]oxadiazolo-[4,3-α]quinoxalin-1-one (ODQ, 100 M) are consistent with this
conclusion, since small cGMP increases in NAD(P)H autofluorescence were not
matched by flavoprotein autofluorescence decreases (Figure 4.3), implying a
cytosolic origin.
It is possible that endogenous NO production may provide a significant
contribution to autofluorescence measurements. Thus, the NO binding of
cytochrome oxidase might be close to saturated, making the effects of
exogenous NO smaller. However, neither L-NNA (1mM) nor L-arginine (0.5 mM)
resulted in significant changes in NAD(P)H autofluorescence (data not shown),
consistent with there being little contribution of endogenous NO to resting
NAD(P)H autofluorescence.
As noted above, DEA/NO exposures resulted in reversible reduction of
fEPSPs (Figure 4.4A-B). It has been described previously in rat hippocampus
that NO triggers adenosine accumulation and inhibition of synaptic potentials,
and that selective A1 receptor antagonists can prevent the loss of fEPSPs
induced by application of the NO donor S-nitroso-acetylpenicillamine (SNAP)
(Broome et al., 1994; Saransaari and Oja, 2004). The adenosine dependence of
the loss of fEPSPs in our studies was confirmed by pre-exposing preparations to
the A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, 200 nM)
prior to 10 minute DEA/NO. Under these conditions, fEPSPs were not
significantly decreased due to DEA/NO (Figure 4.4C).
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4.5 Discussion
These studies have shown that, consistent with previous work, loss of
endogenous NO alters SD events. Our studies were unable to delineate a
difference in SD threshold, but there was a significant increase in the rate of SD
propagation across the tissue with the inhibition of NO production. Interestingly,
we found that the addition of exogenous NO also resulted in an increase in the
spread of SD across the tissue and led to neuronal damage measured by fEPSP
recovery. Our data are consistent with the possibility that these effects are likely
due to the inhibitory effects of NO on mitochondrial respiration. Therefore, while
NO may be neuroprotective against SD-like events following some ischemic
injuries (discussed in (Petzold et al., 2008)), effectiveness may be quite
concentration dependent, and these additional deleterious effects should be
taken into consideration when discussing the therapeutic potential of NO.
As mentioned above, previous studies have found a significant decrease
in SD threshold both in vivo and in vitro slice preparations with the inhibition of
NO production (Wang et al., 2003; Petzold et al., 2008). The lack of effects on
threshold in the current studies is likely due to a difference in the methods of
elevating extracellular potassium in the preparation. In the current studies,
extracellular potassium was increased within a small localized region of the slice
preparations by micro-injection of 1 M KCl; making the overall change in [K+]e
dependent on the duration of the micro-injection. Previous studies have
evaluated SD-threshold by increasing [K+]e in the superfusing solution (Petzold et
al., 2008; Zhou et al., 2010). The later method likely allows for changes in
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extracellular potassium over a wider range of concentrations while the method
employed in these studies may not provide the gradual increases required to
determine subtle changes in SD threshold.
We did observe a significant increase in the rate of SD propagation across
the tissue with NOS inhibitor exposures; suggesting that endogenous NO can
provide protection against the spread of SD. The mechanisms underlying these
protective effects have been examined both in vivo and in vitro. Vascular effects
of NO are well established (Moncada and Higgs, 1993). Within the context of SD,
NO production is known to increase following depolarization and may be critical
for the preservation of a cerebral blood flow (CBF) response to hypercapnia that
follows (Fabricius et al., 1995; Scheckenbach et al., 2006; Petzold et al., 2008).
However, NO can act on neurons as well, and the effects of NO on SD threshold
in previous studies, were not solely due to modifications of CBF, but believed to
be predominantly direct effects of NO on neuronal P/Q-type voltage gated
calcium channels and NMDA receptors to reduce neuronal excitability (Petzold et
al., 2008). Therefore, changes in NO concentrations will modify both vascular
and neuronal factors, each of which will likely affect the initiation, propagation,
and consequences of SD-like events.

The addition of exogenous NO together

with NOS inhibitors results in a recovery of SD threshold to levels not significantly
different from control conditions; leading to the suggestion that the addition of
exogenous NO or inhibition of NO-lowering mechanisms could provide a possible
therapeutic treatment for delayed ischemic neurological deficits (Petzold et al.,
2008). However, the addition of exogenous L-arginine, which leads to an
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increase in NO synthesis, facilitated the propagation of SD in previous studies
(Maia et al., 2009). In our studies, the addition of exogenous NO alone, without
the inhibition of endogenous NO synthesis, also resulted in an increased rate of
SD propagation across the tissue and appeared to be neurodegenerative; likely
due to the fact that NO can compete with oxygen at cytochrome oxidase and
inhibit mitochondrial respiration (Brown and Cooper, 1994; Cleeter et al., 1994). It
is estimated that 100-300 M DEA/NO should produce local NO concentrations
in the 100 nM range in brain slices, which should be enough to partially inhibit
mitochondrial respiration and higher DEA/NO should not give a proportional rise
in NO concentration, because of loss of NO by reaction with O2 (Bon and
Garthwaite, 2001). DEA/NO dissociates rapidly with a half life of ~6 minutes at
30oC to release the NO radical from DEA (Bon and Garthwaite, 2001). The
effects of the liberated DEA were not explicitly tested in these studies. However,
the effects observed with DEA/NO exposures were consistent with previously
observed effects of NO. Thus, inhibition of mitochondrial respiration was
confirmed in our preparations with autofluorescence imaging showing similar
inhibition to that of 100 µM CN. The NO donor also resulted in the reversible loss
of fEPSPs which was confirmed to be adenosine dependent by the addition of
the A1 receptor antagonist DPCPX. In preparations pre-exposed to DEA/NO
prior to SD, there was the adenosine-dependent loss of fEPSPs prior to SD
events that did not recover even after a twenty minute wash-out period of
DEA/NO. In control conditions, SD events resulted in a loss of fEPSPs that
recovered back to baseline over time. The lack of recovery in DEA/NO slices
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even after wash-out of the drug suggests that under these conditions, SD results
in neuronal damage.

4.5.1 Conclusions
These results show that basal concentrations of NO are likely to provide
protection against SD events, and that either a decrease or increase from basal
levels may facilitate the spread of these depolarizing waves through tissue.
Increasing NO significantly above basal concentrations may prove to be
especially detrimental, since our results suggest that it can transform normallyrecoverable SD events into terminal depolarizations. Strategies, which target NO
as a potential therapeutic target against SD, will require tight regulation to ensure
exogenous NO concentrations stay within basal ranges, or alternative agents that
reduce P/Q-type calcium channel and NMDA receptor activity without inhibition of
mitochondrial respiration must be utilized.

4.6 Figure Legends
4.6.1 Figure 4.1
Effects of changing NO availability on SD progression and
consequences. A. Inhibition of NOS production with L-NNA (100 µM, 20 min)
prior to induction of SD significantly increased SD propagation rate (n=6,
p=.0082). B. Representative examples of field potential recordings before and
after generation of SD (arrow) by localized KCl microinjections. In control tissues
(open circles), SD resulted in only transient loss of synaptic activity that
recovered over the course of ~15 minutes to baseline levels (n=4, p=.406).
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Interleaved slices were exposed to DEA/NO for 10 min prior to SD onset (black
bar, filled circles). Under these conditions, fEPSPs were suppressed by DEA/NO
alone. If SD were not induced, fEPSPs would recover following DEA/NO washout
(see Figure 4.4). However, SD in the presence of DEA/NO led to irrecoverable
loss of fEPSPs (n=6). C. Addition of the NO donor DEA/NO 10 minutes prior to
SD induction did not inhibit SD onset, and significantly increased in SD
propagation rate (n=6, p=.0095).

4.6.2 Figure 4.2
Effects of exogenous NO on mitochondrial function measured by
changes in NAD(P)H and flavoprotein autofluorescence. A. DEA/NO resulted
in a significant increases in NAD(P)H autofluorescence that were matched by
flavoprotein decreases, consistent with inhibition of oxidative metabolism (n=6).
B-C. The effects of DEA/NO on NAD(P)H and flavoprotein were mimicked by the
complex IV inhibitor NaCN in a concentration dependent manner (n=6).

4.6.3 Figure 4.3
Effects of a selective cGMP inhibitor. Inhibition of soluble guanylate cyclase
with ODQ (100 µM) resulted in an increase in NAD(P)H autofluorescence which
was not matched by flavoprotein decreases, due to cytosolic rather than
mitochondrial consequences. This is consisted with the conclusion that NO
effects on mitochondrial respiration are likely cGMP independent and due to
direct inhibition of cytochrome oxidase.
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4.6.4 Figure 4.4
DEA/NO results in a transient, fully-reversible loss in fEPSPs that is
adenosine dependent. A. Representative traces during baseline, 10 minutes
DEA/NO, and washout (n=6). B. Population data for 10 minute DEA/NO
exposures. C. Slices were pre-exposed for 20 minutes with the A1 receptor
antagonist, DPCPX (200 nM), prior to wash in of DEA/NO. DPCPX completely
prevented the loss of fEPSPs when compared with preparations exposed to
DEA/NO alone (n=4).
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Figure 4.1
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Figure 4.2
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Figure 4.3
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Figure 4.4
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5. General Discussion
5.1 Introduction
Studies in this dissertation examined basic mechanisms contributing to
regulation of spreading depression (SD) in brain slices. In recent years, a
combination of animal and clinical recordings has raised the exciting possibility
that SD and related events can contribute to the expansion of brain injury.
Understanding better the basic mechanisms involved using reduced brain slice
preparations should be helpful to the development of novel specific therapeutic
interventions targeting SD-like events.
Previous work has evaluated roles of astrocytes in SD initiation, but
concluded that depolarization of these cells follows the progression of SD rather
than lead it. However, astrocytes are well-positioned to regulate the spread of SD
by uptake of both extracellular K+ and glutamate. Indeed, it has been shown
previously that selective inhibition of astrocyte metabolic function (with
fluorocitrate), leads to more rapid SD propagation. However, I found that
providing additional oxidative substrate for astrocytes did not significantly slow
the rate in either normoxic or ischemic conditions, implying that targeting
astrocyte oxidative metabolism may not be a useful therapeutic strategy. My
studies have gone on to show that manipulation of astrocyte glycogen stores
does significantly modify SD propagation. In preparations where astrocytic
glycogen stores were significantly enhanced, SD propagation across the tissue
significantly slowed or inhibited all together in ischemic condition. This work
suggests that targeting astrocyte glycolytic substrates, particularly glycogen, may
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be useful for reducing the incidence of SD-like events in the context of brain
injury.
Previous work has studied the roles of reactive astrocytes in brain injury
and historically, these studies have emphasized deleterious roles underlying
these phenotypic changes within astrocytes. However, an emerging view is that
reactive astrocytes could be neuroprotective and contribute to limiting spread of
injury and promote recovery. In my studies I have developed a new model of
astrocytes activation to test the effects of this phenotypic change on SD initiation
and propagation. My studies provide exciting evidence consistent with the
possibility that activation of these cells could be protective by limiting the onset of
SD and related events in the context of ischemia.
Previous work has studied the possible protective effects of nitric oxide
(NO) in the context of delayed neurological deficits associated with subarachnoid
hemorrhage (SAH). Those studies suggested that NO may act directly on NMDA
receptors and P/Q-type voltage gated Ca2+ channels to reduce neuronal
excitability and increase SD threshold. My studies emphasize the possible
deleterious effects of NO due to inhibition of mitochondrial respiration, and
suggest that other therapeutic agents which may target the protective effects of
NO without inhibition of oxidative metabolism are required.

138

5.2 Propagation of SD
5.2.1 SD Propagation
Extensive work has previously established that the propagation of
spreading depression relies on feed-forward accumulation of glutamate and/or K+
in the extracellular space (see Section 1.1.3). As discussed above (Section
1.4.1), the clearance of both these mediators is regulated by astrocytes and
consumes ATP. It is generally accepted that SD and related depolarizing events
progress across tissues in the general range of 3-6 mm/min (Somjen, 2001).
Previous studies using rat hippocampal slice preparations compared propagation
rates between normoxic SD (induced with microinjections of KCl) and hypoxic SD
(induced by replacing 95% O2 with 95% N2) (Aitken et al., 1998). Based on the
duration and amplitudes of IOS and electrical signals between the two stimuli,
they concluded that there was no significant difference in the SD propagation
rate between the conditions, although hypoxic SD trended towards a faster
propagation (Aitken et al., 1998).
My studies utilizing high K+ and OGD-SD showed a clear difference in
propagation rates, with OGD exposures in slice preparations resulting in
significantly more rapid SD propagation rates than high K+-SD. During OGD,
removal of metabolic substrates from the entire preparation results in slow
depolarization of all neurons as extracellular K+ levels rise toward SD threshold
levels (Vyskocil et al., 1972; Hansen and Zeuthen, 1981). Thus, it is possible that
the faster propagation rate during OGD is a result of the fact that neurons ahead
of the advancing SD wavefront are moderately depolarized by K+. Ischemic
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glutamate accumulation could also contribute. Under ischemic conditions large
increases in extracellular glutamate, attributed mainly to the reversal of neuronal
glutamate transporters, likely contribute to initial anoxic depolarizations
(Szatkowski et al., 1990; Rossi et al., 2000). Increased extracellular K+ can
stimulate the reversal of glutamate uptake (Szatkowski et al., 1990), and since
increases in extracellular K+ occur during OGD conditions, it is possible that
reversal of glutamate transporters could contribute to the increased rate of OGDSD compared with normoxic responses. However, the relative importance of
reversed glutamate transport to OGD-SD propagation is not yet known.
Another intriguing possibility is that, during OGD, astrocytes lose
metabolic capacity to limit glutamate and/or K+ clearance ahead of the advancing
wavefront. During high K+-SD, threshold levels of extracellular K+ (10-12 mM)
and glutamate (~34-40 µM) are required at the front of the depolarization
(Hansen and Zeuthen, 1981; Fabricius et al., 1993; Scheller, 1993; Iijima et al.,
1998; Muller and Somjen, 2000). Normally-functioning astrocytes are expected to
retard both extracellular K+ and glutamate accumulation (see Section 1.4.1). In
contrast, in the context of OGD, astrocyte ATP levels may be severely depleted,
and accumulation of K+ and glutamate to threshold levels may thus be more
rapid at the front edge of the depolarization, which could lead to a more rapid
spread of SD across tissues. This idea is supported by the effects of selective
astrocyte metabolism discussed below (Sections 5.2.2 and 5.2.3).
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5.2.2 Astrocyte glycogen stores and SD propagation
5.2.2.1

Astrocyte metabolism

As discussed above (Section 1.4.1.3), astrocytes appear to utilize both
mitochondria and glycolysis for ATP production. However, astrocytes are often
considered to be primarily glycolytic cells, and indeed, previous work has shown
that even in the complete absence of oxygen, glycolysis can produce sufficient
ATP to maintain normal astrocyte glutamate uptake (Swanson, 1992; Swanson
et al., 1994). This implies a strong Pasteur Effect, as the rates of glycolysis must
be dramatically increased during anoxia (Krebs, 1972).
Glycolysis can be fueled during severe energetic demands by glycogen.
Brain glycogen stores are found almost exclusively in astrocytes (Cataldo and
Broadwell, 1986; Wender et al., 2000; Brown, 2004), and are thought to be
rapidly metabolized when cellular energy demands increase (Brown et al., 2003).
Glycogen mobilization is regulated by phosphorylation and allosteric binding of
AMP to glycogen phosphorylase, which results in hydrolysis to glucose-6phosphate (Brown, 2004). Metabolism of glycogen is energy efficient since
glucose-6-phosphate

enters

glycolysis

after

the

initial

ATP-dependent

phosphorylation required for glucose metabolism (Brown, 2004). From these
considerations it is not surprising that previous work has shown depletion of
glycogen stores by SD (Selman et al., 2004). Consistent with this, in my studies,
20 minute OGD exposures (which always generated OGD-SD) resulted in
complete depletion of glycogen from brain slices.
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As will be discussed below, my studies also suggest a significant role for
glycogen stores in the regulation of SD propagation; a finding that may be useful
for future approaches to limit SD in pathological conditions.
5.2.2.2

Preventing glycogenolysis and SD propagation

In my in vitro studies, inhibition of glycogenolysis was obtained by brief (15
minute) pre-exposures to a combination of inhibitors (DAB and DNJ). Inhibiting
the metabolism of glycogen in astrocytes resulted in a significant increase in the
propagation rate of both high K+ and OGD-SD. These results suggest that the
ability of astrocytes to clear glutamate and/or K+ from the extracellular space was
compromised by inhibition of glycogenolysis. Furthermore, utilization of rapidly
metabolized glycogen stores likely contributes to limiting the rate of SD
propagation in both normoxic and ischemic conditions.
An important consideration for these studies was whether glycogenolysis
inhibitors reached effective concentrations in astrocytes in situ. It was not
possible to test the inhibition of glycogen breakdown in brain slices directly using
the glycogen assay described above (Section 2.3.4). In this assay, endogenous
glucose was initially removed from the samples before hydrolysis of tissue
glycogen by amyloglucosidase (Cruz and Dienel, 2002). The presence of
glycogenolysis

inhibitors

would

prevent

the

activity

of

exogenous

amyloglucosidase, which was essential for the assay. The choice of both the
duration and the dosage of these inhibitors was thus based on previous
hippocampal slice studies showing effects on field EPSPs (Sadgrove et al.,
2008). It is noted that previous studies in rat optic nerve have shown that longer
142

exposures (60 min) to higher DAB concentrations (300-1000 µM) were required
for complete inhibition of glycogen phosphorylase (GP) (Walls et al., 2008).
However, optic nerves are tightly wrapped in myelin and penetration of DAB is
likely better in hippocampal slices used in the present studies. In addition, the coincubation of DAB with DNJ likely greatly potentiated its effects. This assumption
is based on previous studies in rat hepatocyte cultures, which have shown that
the inhibitory effects of DAB were significantly enhanced by the addition of 100
µM DNJ (Kuriyama et al., 2008). However, due to concerns that my initial choice
of drug concentrations may not have been sufficient for complete inhibition of
glycogenolysis, I conducted a secondary set of studies where slice preparations
were exposed to a combination of DAB and DNJ at relatively higher
concentrations (100 M) for more extended periods of time (75 min). There was
no additional effect of the glycogenolysis inhibitors when compared to my initial
studies with shorter exposures at lower concentrations (Section 2.4). These
findings support the assumption that glycogen metabolism was effectively
impaired with my initial exposure paradigm.
5.2.2.3

Increasing glycogen content

To increase glycogen concentrations within astrocytes, I utilized Lmethionine-DL-sulfoximine (MSO, 2 mM). MSO was first identified as the
convulsant formed in bleached wheat flour (Bentley et al., 1950), and it has since
been shown to increase brain glycogen, although the mechanisms underlying
this effect are not well understood (Folbergrova, 1973; Swanson et al., 1989b;
Swanson et al., 1990). Other methods have previously been employed to
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increase astrocyte glycogen stores, including increased glucose, insulin, and
insulin-like growth factor (IGF) (Dringen and Hamprecht, 1992). However, MSO
was chosen for these experiments based on previous work in primary astrocyte
cultures where 24 hour exposures to MSO (1 mM) resulted in a 300% increase in
astrocyte glycogen (Swanson et al., 1989b). It is known that MSO is not taken up
as readily in slice preparations (Folbergrova, 1973), so confirming an increase in
glycogen

was

important

for

the

design

and

interpretation

of

my

electrophysiological studies. I found prolonged 2 mM MSO exposures resulted in
a significant increase in slice glycogen stores. The magnitude of increased
glycogen was much smaller the previously reported in astrocyte cell cultures
studies (Swanson et al., 1989b), which may be due to a number of significant
differences in experimental methods. Firstly, utilizing astrocyte cultures permitted
24 hour drug exposures, and such extended treatments are not possible with
acutely-prepared brain slices, which were viable for only approximately 8-10
hours. Therefore, my pre-exposure paradigm required balancing the time
required to have a significant effect of MSO on glycogen stores, with the
diminishing health of slice preparations throughout a given experimental day. It is
also possible that astrocytes derived from neonatal tissues and maintained in
confluent cultures may have a greater capacity to increase glycogen stores than
mature astrocytes that are integrated into functioning hippocampal networks.
In my studies, three hour MSO (2 mM) exposures were required for a
significant increase in slice glycogen content, and this was accompanied by a
decrease in OGD-SD propagation rate, but had no effect on high K+-SD. The
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significant slowing of OGD-SD is likely a result of a strong Pasteur Effect, which
could lead to a significant increase in the rate of glycolysis to increase ATP
availability and support the clearance of both extracellular glutamate and K+ by
astrocytes. The lack of effect of MSO on high K+-SD may be a result of the fact
that under normoxic conditions, there are sufficient metabolic substrates
(including glycogen) available to astrocytes and provision of excess substrates
may not provide an additional benefit. This general conclusion is also supported
by the lack of effect of additional substrate for oxidative metabolism on high K+SD propagation rate (discussed Section 5.2.3).
The chemical structure of MSO strongly resembles glutamate and this
compound is a known convulsant (see above); likely because it mimics the
neurotransmitter at the synaptic cleft. MSO is also known to inhibit glutamine
synthetase (GS) activity within astrocytes (Cloix and Hevor, 2009) which could
reduce glutamate recycling. Indeed, hippocampal slice culture studies have
shown that MSO exposures lead to significant decreases in glutamate in nerve
terminals while increasing both glutamate and glutamine in astrocytes (Laake et
al., 1995). MSO also has significant effects on inhibitory transmission; leading to
a decrease in evoked inhibitory postsynaptic currents (eIPSC) (Liang et al.,
2006). Thus, seizure activity resulting from MSO exposures may be due not only
to diminished capacity for astrocytes to clear extracellular glutamate, but
decreased inhibitory GABA tone as well. Increases in glycogen stores within
astrocytes are known to precede the convulsive period induced by MSO
exposures suggesting that this increase in metabolic substrate is not a response
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to the seizure activity, but may actually serve to delay seizure onset (Cloix and
Hevor, 2009). It is possible the the decreased SD propagation rate observed
during OGD could be the result of diminished synaptic glutamate. However, the
same effects were not observed under normoxic conditions during high K+-SD
suggesting that there is a metabolic component mediating the observed effects
rather than a change in synaptic glutamate concentrations.
Overall, these studies with both inhibitors and a potentiator of glycogen
utilization suggest that astrocytic glycogen stores slow the rate of SD in both
normoxic and ischemic conditions. This raises the interesting possibility that
targeting astrocyte glycogen could be a useful strategy when trying to limit the
spread of these depolarizing events in clinical conditions.

5.2.3 Astrocyte oxidative metabolism and SD propagation
5.2.3.1

Selective inhibition of astrocyte oxidative metabolism

The effect of selective inhibition of astrocyte oxidative metabolism (with
1mM fluorocitrate) on SD propagation rate has been shown previously in in vivo
rat cortex (Largo et al., 1997a). Selective metabolic inhibition with either
fluorocitrate (FC) or fluoroacetate (FA) is a result of by preferential uptake by the
monocarboxylate-like transporters isoform on astrocytes, MCT1 (Waniewski and
Martin, 1998), and subsequent block of the TCA enzyme aconitase. In my
studies, I confirmed the facilitatory effects of FA on SD propagation in
hippocampal slices. Interestingly, inhibition of astrocyte oxidative metabolism
with FA had a comparable effect on increases in SD propagation rate for both
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high K+ and OGD-SD when compared with effects of glycogenolysis inhibition.
The effect on SD propagation in these FA studies were larger than those
described in vivo by Largo (Largo et al., 1997a). It is possible that by utilizing in
vitro slice preparations, I was able to more effectively deliver FA uniformly from
above and below a thin tissue slice, while in in vivo preparations, where FC was
delivered by microdialysis, a homogeneous distribution of the drug over the
whole SD field was likely very difficult.
In the present studies, I was also interested in the possible effects of FA
pre-exposures on glycogen levels within hippocampal slices. I expected that
inhibition of oxidative metabolism may result in a decrease in glycogen within
astrocytes due to increased glucose consumption as a result of the Pasteur
Effect (Krebs, 1972). However, I found that FA exposures did not significantly
deplete glycogen concentrations. It is possible that glycogen stores within slice
preparations are already low, which is supported by the lower levels of total
glycogen measured in my preparations when compared with that measured from
whole brain homogenate and cell culture (Swanson et al., 1989a; Swanson and
Choi, 1993; Cruz and Dienel, 2002). In addition, previous studies have reported
that slice glycogen falls dramatically immediately after cutting during the hour
incubation period at 36oC, and recovers over the next 3 hours (Lipton, 1989). I
was careful to allow my preparations sufficient time to recover after cutting, to
ensure that glycogen levels had returned to baseline levels. Given these
considerations, it seems possible that anaerobic glucose consumption through
glycolysis can be sufficient to fuel ATP production within astrocytes. Therefore, it
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is possible that in the presence of 10 mM glucose, FA-induced inhibition of
astrocyte oxidative metabolism may increase the glycolytic rate of these cells,
leading to increased glucose uptake that may flux through glycogen stores.
Previous work provides evidence that brain glycogen is not static and glucose
that enters astrocytes may go through glycolysis or glycogenolysis depending on
neuronal activity (Shulman et al., 2001). Therefore, although selective inhibition
of astrocyte TCA cycle activity in the presence of 10 mM glucose does not
appear to deplete glycogen stores, increased glucose may flux first through
glycogen stores prior to glycolysis.
5.2.3.2

Non-selective inhibition of oxidative metabolism and SD

propagation
In contrast to FA, non-selective inhibition of oxidative metabolism in both
neurons and astrocytes can be achieved by agents such as sodium cyanide,
which easily enters all cells and results in effective inhibition of mitochondrial
respiration by inhibition of cyctochrome oxidase (complex IV). This was
demonstrated in my studies with inverted signals generated by near
simultaneous NAD(P)H and flavoprotein (FP) imaging (Figure 4.1). However,
cyanide is an irreversible toxin, and not of clinical utility for therapeutic
intervention for SD. In this dissertation, I instead chose to examine the effects of
nitric oxide (NO) as another non-selective inhibitor of cytochrome oxidase, since
this agent has been suggested to be useful in adjunct therapy for SAH in relation
to SD (see below). I chose to utilize the nitric oxide (NO) donor 2-(N,NDiethylamino)-diazenolate 2-oxide (DEA/NO) to inhibit oxidative metabolism. NO
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can inhibit cytochrome oxidase activity by competing with oxygen for binding,
resulting in reduced ATP in brain mitochondria and an increase in anaerobic
glycolysis (Brown and Cooper, 1994; Brookes et al., 1999). My studies show
effective inhibition of mitochondrial respiration by DEA/NO in brain slices (Figure
4.1), again as assessed by near simultaneous autofluorescence imaging of
NAD(P)H and FP (discussed below). The effects of DEA/NO were concentrationdependent, and comparable with the well-established inhibitor cyanide.
SD leads to increases in inducible nitric oxide synthase (iNOS) and its
product NO (Read et al., 1997; Petzold et al., 2008; Viggiano et al., 2008). In my
studies, addition of DEA/NO resulted in a significant increase in the rate of high
K+-SD propagation. It was possible that the inhibition of either neuronal or
astrocyte oxidative metabolism by NO could underlie these effects. NO
exposures could result in moderate neuronal depolarization at the advancing
wavefront. In addition, as discussed above, exogenous NO may inhibit astrocyte
oxidative metabolism prior to high K+-SD onset, and thus result in decreased
astrocyte clearance of extracellular K+ and glutamate. This latter mechanism is
consistent with the results observed with selective inhibition of astrocyte
metabolism with FA discussed above (Section 5.2.3.2).
The effect of exogenous NO on SD in my studies is different from what
had been described previously with rat brain slices (Petzold et al., 2008). In those
studies, inhibition of nitric oxide synthase (NOS), decreased SD threshold, and
subsequent addition of exogenous NO, returned SD threshold to normal levels.
NO is believed to be neuroprotective by interacting with presynaptic P/Q voltage
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gated calcium channels (VGCCs) to decrease glutamate release as well as
inhibiting postsynaptic NMDA receptors to reduce postsynaptic action (Read et
al., 1997; Petzold et al., 2008); both of which would be expected to be
neuroprotective by decreasing excitatory transmission. It is likely that in my
DEA/NO studies exogenous NO reached higher concentrations than in those
previous studies, where exogenous NO was co-applied with a NOS inhibitor.
Therefore, to determine if the protective effects of NO observed previously
(Petzold et al., 2008) could potentially be exploited to limit SD events, future
studies using an NO donor such as S-Nitrosoglutathione (GSNO), which should
not inhibit cyctochrome oxidase activity, are required.
5.2.3.3

Selective increases in astrocyte oxidative metabolic substrate

To test the hypothesis that increasing astrocyte oxidative metabolism
would decrease the rate of SD propagation, slices were pre-exposed to acetate.
Like FA, acetate is selectively transported into astrocytes due to the preferential
uptake by the astrocytic monocarboxylate-like transporters isoform, MCT1
(Waniewski and Martin, 1998). Previous in vivo studies using radiolabeled
acetate found a significant increase in astrocyte metabolism and acetate
utilization in penumbral tissue during reperfusion following 120 min MCAO
(Haberg et al., 2006) suggesting that astrocytes can readily take up acetate and
utilize it as an oxidative substrate. In my studies, acetate pre-exposures had no
significant effect on SD propagation rates under normoxic (high K+) conditions.
This implies that hippocampal slice preparations have adequate metabolic
substrates during normoxic (high K+) SD, which is consistent with my 2mM MSO
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results with this stimulus (see above). The fact that OGD-SD was not slowed by
acetate was not unexpected. Acetate cannot be metabolized under anoxic
conditions, since removal of oxygen will inhibit electron transport chain activity
and prevent the production of ATP from mitochondrial respiration. Taken
together, these studies suggest that under both normal and ischemic conditions,
providing astrocytes with additional glycolytic (rather than oxidative) substrates
may be useful to limit the spread of SD, especially in ischemic conditions.

5.2.4 Effects of astrocyte activation
5.2.4.1

Long-term astrocyte activation in hippocampus

As discussed in the introduction (Section 1.4.3), astrocyte activation may
lead to a range of phenotypic changes, including changes in metabolism, which
can significantly modify astrocyte function. I set out to develop a model of
astrocyte activation within the hippocampus, which could be utilized for in vitro
slice studies of SD. Astrocyte activation was assessed using the classical marker
of activation, glial fibrillary acidic protein (GFAP) (Pekny and Nilsson, 2005). For
these studies, I required a method, which resulted in sustained activation, but
without the confounding factors of brain injury. Therefore, I chose to use an
approach previously established in studies of rat striatum where astrocyte
activation was induced by lenti-viral injections with a vector that encodes ciliary
neurotrophic factor (CNTF) (Escartin et al., 2006; Escartin et al., 2007). As
discussed earlier (Section 3.5), an export sequence was included to allow
release from neurons and stimulation of astrocyte CNTF receptors. There was a
significant increase in immunohistochemical staining of GFAP in CNTF-infected
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preparations when compared with LacZ controls, and this activated phenotype
persisted and was observed in mice up to 10 months of age. Importantly, this
significant increase in GFAP was due to increased expression within the resident
population of astrocytes and not due to progenitor cell proliferation (Section 3.4).
There were no observable differences in the overall health of the animals
infected with CNTF compared with LacZ control animals. Immunohistochemistry
was preformed to assess both dendritic structure and neuronal density within the
CA1 pyramidal cell layer in CNTF preparations compared with LacZ controls.
MAP2 immunostaining showed no significant differences in dendritic structure
within the CA1 stratum radiatum as a result of astrocytes activation. Nuclear
DAPI staining for neuronal density also showed no significant difference between
CNTF and LacZ preparations. Therefore, CNTF-lenti-viral injections resulted in
profound activation of astrocytes with no significant changes to pyramidal neuron
morphology, suggesting that this model of astrocyte activation within the
hippocampus may be useful when studying a variety of neurodegenerative
diseases where astrocyte activation occurs.
In initial studies, I set out to use each animal as their own control, and
CNTF lenti-viral vectors were initially injected into the hippocampus in a single
hemisphere, and β-galactosidase (LacZ) lenti-viral control vectors were injected
in to the contralateral hemisphere. These unilateral injections of CNTF vectors
resulted in profound, long-term activation of astrocytes within the hippocampus.
However, in these preparations, I found significant astrocyte activation in both
hemispheres. This spread of activation appeared to be the result of diffusion of
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CNTF across the corpus callosum, rather than the spread of the lentivirus
infection itself. I came to this conclusion based on β-galactosidase staining in
LacZ controls, which showed localized immunofluorescence within the injected
hippocampus that did not spread into other regions of the brain (Figure 3.1).
Therefore, for subsequent studies I utilized bilateral hippocampal injections of
lenti-viral vectors containing either CNTF or LacZ. While this experimental design
required more animals to include a full LacZ control set, I was careful to ensure
animals were age-matched and interleaved between experimental days. Thus,
LacZ and CNTF animals were injected, shipped, housed, fed, and handled in an
identical manner to make sure that any variability observed between groups
during electrophysiological studies was likely due to changes induced by CNTF
expression alone.
5.2.4.2

Effects of astrocyte activation on fEPSPs

Once I had a working model of sustained astrocyte activation,
hippocampal slice preparations from CNTF-infected animals were utilized for
electrophysiological studies. I observed a significant decrease in excitatory
postsynaptic field potentials (fEPSPs) in CNTF preparations when compared with
LacZ controls (Figure 3.2). As discussed in detail above, these observed
changes in synaptic efficacy were not a result of decreased probability of
presynaptic glutamate release (see Section 3.5) based on the results from both
my PPF and adenosine A1 antagonist studies.
The decreases in excitatory evoked potentials seen in CNTF animals were
quite unlike those observed in a different model of astrocyte activation within the
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hippocampus. In those recently-published studies, astrocyte activation was
induced by over-expression of eGFP (described above Section 1.4.3.3), and
resulted in a significant reduction in both evoked and spontaneous inhibitory
postsynaptic currents (IPSCs) with no change in excitatory transmission (Ortinski
et al., 2010). Those prior results suggest that decreased inhibitory control may
result in neuronal hyperexcitability, which is the opposite of what I observed in
my CNTF preparations. The decreases in inhibitory transmission in the eGFP
model were attributed to reduced glutamine synthesis in astrocytes, which in turn
is required for the production GABA. However, glutamine recycling between
astrocytes and neurons is also required to maintain glutamate for excitatory
transmission (Bacci et al., 2002). Therefore, it is possible that in our CNTF
preparations, astrocyte activation leads to decreased glutamine availability,
sufficient to reduce fEPSPs by decreasing vesicular glutamate stores. The
reduced glutamine synthesis in the eGFP model of astrocyte activation was
attributed to downregulation of glutamine synthase (GS) expression (Ortinski et
al., 2010). However, in CNTF preparations, glutamate cleared from the
extracellular space by these astrocytes may be metabolized to α-ketoglutarate
and enter the TCA cycle, which would also decrease glutamine recycling and
contribute to smaller fEPSPs. This hypothesis is supported by previous work in
rat striatum with the CNTF model of activation, which has shown these activated
astrocytes to have a significant metabolic shift towards a more oxidative
phenotype (Escartin et al., 2007).
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In mouse models, where astrocyte reactivity was prevented by the double
knock out of intermediate filament proteins GFAP and vimentin, there was a
significant increase in final infarct volumes following MCAO compared with wild
type controls (described above Section 1.4.3.2). It is possible that following
ischemic injury, reactive astrocytes reduce glutamate-glutamine recycling, which
could be protective by preventing neuronal hyperexcitability and excitotoxicity.
However, as observed below (Section 5.3.3), a profound effect of CNTFastrocyte activation on SD initiation may also be of significant benefit following
acute ischemic injuries.
CNTF activation of astrocytes is currently being used in clinical trials for
patients with Huntington’s disease (HD) (Bloch et al., 2004). HD leads to the
degeneration of GABA-ergic striatal neurons, which induces motor disorders and
eventually leads to loss of higher brain function resulting in psychiatric
disturbances (Peschanski et al., 1995). Current clinical trials are based on
previous work showing long-term expression of CNTF by lenti-viral infection
protected striatal neurons in an excitotoxic rat model of HD (de Almeida et al.,
2001). Therefore, in the context of HD, a reduction in excitatory transmission may
be one of the protective effects underlying CNTF astrocyte activation. However,
my results raise some concern, since long term effects of fEPSP suppression are
not known. It seems important that future behavioral studies be conducted in vivo
to determine the possible long-term impact of constitutive CNTF expression and
astrocyte activation on basic neurological functions, including learning and
memory. In the context of chronic diseases such as HD, prolonged expression of
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CNTF is likely desirable, but following ischemic injury, where expression of
CNTF-activated astrocytes is only required for days to weeks, other methods of
inducing activation will likely be more useful than infection with CNTF-expressing
vectors.
5.2.4.3

Astrocyte activation and SD propagation rate

As discussed below (Section 5.3.3), exposure to a Na+/K+-ATPase
inhibitor (ouabain) was needed to reliably initiate SD in preparations containing
CNTF-activated astrocytes. With the ouabain stimulus, the rate of SD in CNTF
preparations was significantly decreased compared with LacZ controls. At the
concentrations used for my studies, inhibition of Na+/K+-ATPase activity by
ouabain is not astrocyte specific (Basarsky et al., 1998), and likely affects
neurons and astrocytes equally. Previous studies utilizing the CNTF model of
astrocyte activation in rat striatum showed indirect evidence of increased
glutamate clearance by these astrocytes (Escartin et al., 2006), which could
account for both the decreased rate of SD propagation and the reduction in
excitatory transmission observed in CNTF tissues. However, no significant
increase in glutamate clearance was observed CNTF preparations suggesting
that enhanced glutamate uptake is not the mechanism underlying my observed
effects. This is not unexpected, since in the context of ouabain-SD, inhibition of
pump activity will reduce the maintenance of the Na+ gradient required to drive
glutamate uptake. Another possible mechanism could be decreased glutamine
recycling, which would reduce glutamate concentrations available for synaptic
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vesicular release and could also underlie the increased resistance to SD
propagation.

Figure 5.1
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5.3 Initiation of SD
5.3.1 SD initiation
5.3.1.1

High K+-SD

For the studies in this dissertation, SD was induced using either KCl
microinjections, oxygen glucose deprivation (OGD), or the Na+/K+-ATPase
inhibitor, ouabain. KCl microinjections trigger SD by focally raising extracellular
K+ concentrations above threshold levels (Aitken et al., 1998; Bahar et al., 2000;
Dietz et al., 2008) resulting in the synchronous depolarization of a group of
neurons, which initiate the feed-forward spreading depolarization. Based on my
studies, I estimate that the synchronous depolarization of ~20 neurons is
required for an SD event to initiate and propagate across a hippocampal slice.
SD threshold could be most effectively evaluated using the high K+-SD
stimulus, and could be finely graded by modifying the duration of the application
pressure pulse. With this procedure, I could apply stepwise increases in K+
volumes to single preparations until the SD threshold was reached. Similar
approaches have been used in vivo and in vitro slice preparations using either
graded K+ applications or electrical stimulation (Ayata et al., 2000; van den
Maagdenberg et al., 2004; Ayata et al., 2006; Petzold et al., 2008). One potential
drawback of my method is possible variability in the tip size of glass
microelectrodes and volumes of K+ delivered. In all SD threshold experiments,
control preparations were interleaved between experimental slices, and the same
delivery electrode was used throughout the day. Furthermore, I verified that tip
resistance was maintained within a range of 5-8 MΩ. While the exact volume of 1
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M KCl injected is not known, microinjection of KCl onto the surface of the slice
led to a localized depolarization that was surrounded by normally polarized
tissue. From visualization of ejection volumes, I estimated that a 100 ms delivery
pulse led to the release of ~3 nL of KCl into the 2 mL bath, implying that these
KCl microinjections (usually 30-200 ms) should lead to negligible changes in
overall bath K+ concentrations. This is much different than is seen in threshold
studies where SD is induced by bath application of elevated KCl (generally ~2540mM) (Petzold et al., 2008; Zhou et al., 2010). Under such conditions, SD
initiates at a random site, similar to OGD and ouabain-SD, and will likely then
propagate through partially depolarized tissue. The focal application method
used in my studies had the advantage of known initiation sites, which facilitated
threshold tests and examination of both SD initiation and propagation.
5.3.1.2

OGD-SD

SD induced by OGD is a result of metabolic substrate depletion and
energy failure, leading to depolarization of neurons that are unable to maintain
ionic homeostasis. To generate a spreading depression-like event, a coordinated
loss of ionic homeostasis of a population of cells must occur with high spatial and
temporal correlation to result in profound depolarization of a tissue volume within
a slice. Previous work has shown that during OGD in slice preparations, there is
a slow depolarization of CA1 neurons, and reducing the bath temperature
resulted in a prolonged delay to the onset of the OGD-induced anoxic
depolarization in single cells (Lipski et al., 2006). This effect of decreased
temperatures is likely due to reduced metabolic demand in these neurons, which
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in turns leads to a longer period of slow depolarization prior to AD threshold. It is
assumed that a similar depolarization occurs for the initiation of OGD-SD.
Neurons are usually assumed to be quite homogeneous, with uniform
resting potentials and responses to substrate deprivation. However, experiments
with OGD show that this may not be the case, since the site of OGD-SD initiation
can be at semi-random locations, presumed to be due to sites of relative
metabolic compromise (Jarvis et al., 2001). My data is consistent with this view,
since OGD-SD showed no consistency in the site of initiation; sometimes
propagating through CA1 towards CA3, and sometimes in the opposite direction.
This would be expected to underlie some of the variability observed in
measurements of the latency to SD onset taken at a single point in mid-CA1, as
responses may initiate at a range of distances from the site of the recording
electrode.
5.3.1.3

Ouabain-SD

Bath application of ouabain generates SD in a way that is similar to OGD
exposures as this agent depolarizes cells, but due to direct Na+/K+-ATPase
inhibition rather than ATP depletion. Thus, the site of initiation may not be as
random as OGD-SD, since depolarization may not be as dependent on regional
heterogeneity of metabolic status. Indeed, Basarsky and coworkers argued that
ouabain-SD originated at CA1 and propagated towards CA3, because neurons in
the initiation site had lower ATPase pump expression levels (Haglund et al.,
1985; Basarsky et al., 1998). In my studies, using low power imaging, ouabainSD events generally initiated in the dentate gyrus (DG) and then moved to the
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pyramidal cell layer; spreading from either the CA1 or CA3 (data not shown).
Although ouabain is not expected to deplete ATP, it is possible that some of the
variability in initiation site could arise because of more rapid ouabain-induce
depolarization of already compromised tissue.
I chose to use 100 µM ouabain for my experiments since this
concentration was expected to inhibit the major Na+/K+-ATPase isoforms found in
both neurons and astrocytes (α3 and α2, respectively) (Walz and Hertz, 1982;
Watts et al., 1991), and has previously been shown to reliably generate SD in
hippocampal slices (Haglund and Schwartzkroin, 1990; Basarsky et al., 1998;
Balestrino et al., 1999; Dietz et al., 2008). In primary neuronal and astrocyte
culture, 100 µM ouabain resulted in almost complete inhibition of K+ uptake (Walz
and Hertz, 1982). This suggests that neurons will begin to slowly depolarize due
to the accumulation of extracellular K+ that cannot be effectively cleared by
astrocytes. Astrocyte membrane potential would be expected to depolarize as
well, since astrocyte Vm closely follows K+ equilibrium potential (Orkand et al.,
1966; Amedee et al., 1997). Like OGD-SD, ouabain-SD was exploited for studies
of SD latency.

5.3.2 Substrate manipulation on OGD-SD initiation
Previous work has established that depletion of glucose availability (rather
than O2 depletion) is an important determinant for the onset of single-cell
depolarizations in in vitro ischemia models. This prior work utilized whole cell
recordings from pyramidal neurons (Rossi et al., 2000; Hamann et al., 2002;
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Allen et al., 2005), and thus, did not evaluate whether these responses were part
of propagating SD waves or were instead stochastic anoxic depolarizations that
occurred as individual neurons succumbed to substrate deprivation. My initial
studies showed that a very similar glucose dependency was also associated with
spreading depolarizing events. Removal of glucose from the recording buffer
prior to OGD challenge significantly reduced the time to OGD-SD onset, but
similar pre-treatments with anoxia were without effect.
Previous studies suggested that depletion of glycogen stores were
responsible for the decreased latency in single cell work (Allen et al., 2005). This
conclusion was based on the assumption and mathematical modeling that
reducing bath glucose concentrations to 2 mM (from 10 mM) would result in
glycogen depletion in slice (Allen et al., 2005). I tested this assumption, and
found a similar reduction in the latency of SD. However, glycogen levels were not
significantly decreased in preparations pre-exposed to 2 mM glucose compared
to 10 mM controls. In addition, inhibition of glycogenolysis with DAB/DNJ prior to
OGD did not have a significant effect on the latency of SD; suggesting that
depletion of glycogen stores within astrocytes does not determine the onset of
OGD-SD. There was a trend towards a decrease in slice glycogen content with 2
mM glucose exposures, but there was not complete loss of glycogen as was
observed after 20 minute OGD exposures. This suggests that the assumptions
made by Allen and colleagues may be partially correct, but it is likely that
astrocyte glycogen is more resistant to glucose deprivation than is accounted for
by their mathematical model (Allen et al., 2005). In conditions of reduced
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glucose, slices were perfused with 95% O2, and while astrocytes are considered
to be primarily glycolytic cells (Wender et al., 2000; Brown, 2004), it is possible
that they may shift to an oxidative phenotype to produce ATP more efficiently.
This is not unreasonable to consider, since astrocytes have significant numbers
of mitochondria and possess all the enzymes required for mitochondrial
respiration (Lovatt et al., 2007). Therefore, to significantly deplete glycogen within
a slice, either the use of lower glucose concentrations or other challenges will
likely be required.
The fact that glucose depletion but not inhibition of glycogenolysis or
astrocyte oxidative metabolism affected OGD-SD latency raised the possibility
that the availability of glucose within neurons is most relevant. Neurons are
known to be more sensitive to metabolic inhibition than astrocytes (Silver et al.,
1997), and my studies provide support for the hypothesis that SD is initiated
under ischemic conditions when glucose is no longer available to neurons to
provide adequate ATP to maintain ionic homeostasis.
In half of the preparations pre-exposed to MSO prior to OGD, SD events
were not generated, but signs of neuronal damage were still evident after 20 min
OGD exposures. It is possible that single cell depolarizations may have been
initiated, but because of enhanced glycogen content, astrocytes had sufficient
energy substrates to prevent the accumulation of glutamate and/or K+ within the
extracellular space required for SD initiation. In addition to enhancing glycogen
accumulation, MSO is also known to inhibit glutamine-glutamate cycling between
astrocytes and neurons (Laake et al., 1995). Therefore, resistance to OGD-SD
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onset in MSO could also be due to decreased vesicular glutamate content rather
than changes in glycogen concentrations. However, if decreased vesicular
glutamate were underlying the effects of MSO, a decrease in the propagation
rate during high K+-SD would be expected as well. Therefore, the significant
delay in OGD-SD initiation is likely to be due to the effects of MSO on glycogen
concentrations within astrocytes.

5.3.3 Effects of astrocyte activation on SD initiation
For studies on effects of astrocyte activation, SD threshold was
determined using graded, localized KCl microinjections, delivered by pressure
pulses of increasing duration from a conventional patch electrode. I found that
SD could readily be induced in LacZ preparations with 30-100 ms KCl
microinjections, but SD could not be induced with KCl in CNTF preparations,
even with very prolonged K+ stimuli (800 ms). Furthermore, elevated bath K+
concentrations (from 2 mM to 8 mM) did not allow SD generation, as had been
described for other relatively SD-resistant tissues (brainstem) (Funke et al.,
2009). CNTF and LacZ preparations were interleaved on individual recording
days using the same KCl microelectrode and autofluorescence imaging indicated
similar degrees of slice activation at the K+ ejection site. These observations
suggested a greatly increased threshold for SD initiation with the K+ stimulus, or
possibly a complete inability of CNTF preparations to allow propagation of SD
waves (Section 3.4). This is the first demonstration of changes in SD threshold in
conjunction with manipulation of astrocyte phenotype.
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Experiments with bath application of ouabain revealed that CNTF tissues
do retain the ability to generate SD, albeit with a significantly longer latency to
onset than observed in LacZ controls. This confirms that CNTF CA1 pyramidal
neurons do retain the appropriate structural and functional properties required for
SD. This is an important observation in light of the significant reduction in
excitatory transmission (discussed Section 5.2.4), which could be a result of
decreased neuronal viability thereby making it difficult to induce SD. As
discussed above, ouabain triggers SD by a very different mechanism than does
localized K+ applications, and it leads to a significant impairment in Na+dependent glutamate uptake by astrocytes as a consequence of Na+/K+-ATPase
inhibition (Rose et al., 2009). The increased latency observed in CNTF tissues,
may be a result of decreases in the overall glutamate pool, as suggested by the
observed reduction of fEPSP in CNTF tissues (discussed in Section 3.5).
The significant resistance to SD, particularly under normoxic conditions, in
CNTF tissues may explain some of the neuroprotective effects observed in
striatum against excitotoxins (Escartin et al., 2006). It will be of great interest to
determine whether these effects on SD threshold are observed in in vivo studies
as well. For such experiments, CNTF-containing lentivirus would need to be
injected into the cortex instead of the hippocampus. Once cortical astrocyte
activation was confirmed, SD threshold could be evaluated with high K+
application to the cortical surface or the measurement of spontaneous SD-like
events following focal ischemic injury (Nedergaard and Hansen, 1993; Ayata et
al., 2000). Future studies using such models could provide useful additional
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insights as to how activation of astrocytes could be targeted during ischemia and
migraine. If SDs were significantly limited or even abolished in vivo, it would be of
particular interest to determine whether ischemic infarct volumes were also
reduced.
Figure 5.2

5.4 Consequences of SD in slice
5.4.1 General consequences of normoxic and ischemic SD
While the mechanisms underlying the initiation of SD during both normoxic
conditions (high K+-SD) and conditions that mimic ischemia (OGD-SD) are
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inherently different (discussed above Section 5.2.1), the depolarizing event itself
has striking similarities under both conditions (Aitken et al., 1998). Following SD
events in vivo, energy demands to produce ATP required for the restoration of
ionic gradients increase dramatically. This in turn results in significant increases
in both blood flow and oxygen consumption (Gido et al., 1994; Piilgaard and
Lauritzen, 2009). Normoxic SD is usually considered to be innocuous, as long as
it is initiated in healthy tissue and not in metabolically compromised preparations
(Nedergaard and Hansen, 1988; Gido et al., 1994). However, in the context of
ischemia, SD can lead to neuronal damage, if neurons lack the metabolic
capacity to regain ionic homeostasis (Mies et al., 1993; Nedergaard and Hansen,
1993; Hossmann, 1996; Strong et al., 1996). My studies utilizing fEPSPs and
MAP2 immunohistochemistry to assess neuronal viability are consistent with
these general assumptions. Thus, in preparations where SD was induced with
local microinjections of 1 M KCl, these events resulted in no neuronal damage,
while SD induced by OGD invariably led to persistent neuronal injury.

5.4.2 NAD(P)H Autofluorescence imaging
5.4.2.1

Combined NAD(P)H and fEPSPs measurements to asses neuronal

injury following OGD-SD
Evoked synaptic potentials are a well established method to assess
neuronal viability within slice preparations (Rudolphi et al., 1987; Rudolphi et al.,
1992; Masino and Dunwiddie, 1999). Previous studies have shown that following
OGD there is irreversible damage and persistent loss of fEPSPs (Rudolphi et al.,
1992). In my studies, there was an initial loss of fEPSPs, which appeared due to
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adenosine activating presynaptic A1 receptors (Figure 2.3), that was completely
prevented by addition of an A1 receptor antagonist (DPCPX) (Figure A.1). During
continued OGD, following the initial loss of fEPSPs, there was a brief period of
hyperexcitability prior to SD onset (see Section 2.5). All synaptic potentials were
then permanently abolished at the onset of SD in the context of substrate
depletion. On the basis of fEPSPs alone, it is difficult to distinguish between the
initial reversible and the secondary irreversible loss of fEPSPs due to neuronal
injury (see also (Attwell and Laughlin, 2001). However, imaging NAD(P)H
autofluorescence simultaneously with fEPSP recordings allowed such a
discrimination.
As described in Section 2.4, there are significant changes in NAD(P)H
autofluorescence signals during OGD exposures. NAD(P)H autofluorescence
initially increases ~80% above baseline levels due to hypoxia, where it plateaus
until the onset of SD. The spread of SD was well tracked by NAD(P)H
autofluorescence and the time point at which decreases in NAD(P)H crossed the
recording electrode matched very closely the loss of both pre- and post- synaptic
components of the fEPSP. NAD(P)H levels then continued to decline below
baseline levels, even with the reintroduction of nACSF, which was a hallmark of
irrecoverable neuronal damage. This optical decrease is due to swelling (see
below) as well as dendritic beading (Obeidat et al., 2000) that accompanies
injury.
Neuronal

damage

was

confirmed

following

OGD-SD

using

immunohistochemical techniques. Based on previous studies, slices were fixed,
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and stained for microtubule associated protein 2 (MAP2) without resectioning to
assess neuronal damage (Hoskison and Shuttleworth, 2006; Hoskison et al.,
2007). In slices pre-exposed to hypoxia alone, which does not induce SD in our
preparations, there was a transient increase in NAD(P)H autofluorescence
coincident with a decrease in fEPSPs, both of which returned to baseline levels
following reintroduction of nACSF. MAP2 immunohistochemistry was performed
on these preparations, where little to no neuronal damage should have been
induced, for comparison with OGD-SD preparations (Figure A.2). Consistent with
previous work (Hoskison et al., 2007), in healthy slice preparations, neurons
expressed MAP2 almost exclusively in dendrites while in preparations where
OGD induced SD, there was dendritic beading and significant loss of MAP2
within the dendritic process and an accumulation within the cell soma.
Therefore, when NAD(P)H autofluorescence was above baseline levels
and there was a loss of fEPSPs, I could conclude these changes were
adenosine-mediated synaptic depression, but when NAD(P)H autofluorescence
was below baseline levels and there was a loss of fEPSPs, this was invariably
associated with neuronal damage.
5.4.2.2

Metabolic contributions of NAD(P)H signal

NAD(P)H autofluorescence provides a useful method not only to visualize
the propagation of SD across the tissue, but it also provides a measure of
mitochondrial redox potential during these events. Consistent with previous work
(Hashimoto et al., 2000), high K+-SD induced biphasic NAD(P)H transients in my
studies. As noted above, during OGD, NAD(P)H autofluorescence levels are
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already elevated prior to OGD onset, and the propagating event is marked by
NAD(P)H decreases (Figure 2.3). It has been assumed that autofluorescence
excited at 360nm is due primarily to mitochondrial NADH dynamics (Lipton and
Whittingham, 1979; Hansen, 1985; Tian and Baker, 2002), and can therefore be
used to indirectly assess regional oxygen consumption during SD (Jarvis et al.,
2001; Joshi and Andrew, 2001). The rapid decrease in NAD(P)H at the onset of
normoxic SD has been attributed to rapid oxygen consumption (Takano et al.,
2007; Galeffi et al., 2010), but it is likely that other optical effects contribute to the
drop particularly during OGD-SD.
It is well established that NAD(P)H measurements in vivo during SD are
significantly complicated by blood flow changes (Mayevsky et al., 1974). In slice
preparations, blood flow is not a confounding factor, but it remains possible that
autofluorescence signals due to redox changes in NADH concentrations can be
contaminated by intrinsic signals from the preparation itself (Lipton, 1973).
Severe cell swelling is a consequence of SD and provides the bases for intrinsic
optical signal (IOS) imaging of SD described above (Section 1.1.2) (Andrew et
al., 1999). Therefore, it is possible that changes in cellular volume may
significantly contaminate the NAD(P)H autofluorescence signals in the slice. One
of my aims was therefore to determine whether 360 nm autofluorescence signals
were indeed attributable to mitochondrial dynamics alone. In order to determine
which parts of the NAD(P)H signal were in fact due to mitochondrial respiration,
near-simultaneous recordings of NAD(P)H and flavoprotein (FP) were performed
during both high K+ and OGD-SD. Changes due to mitochondrial respiration
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should result in NAD(P)H increases and matched, but inverted FP fluorescence.
Interestingly, I found that the sharp decrease in NAD(P)H was actually matched
by a sharp decrease in FP autofluorescence. This strongly suggests that initial
NAD(P)H decreases are largely an optical artifact, likely attributable to neuronal
swelling, and not a result of rapid oxygen consumption for both high K+ and
OGD-SD (Figure A.3). My results also suggest that the swelling response
enhances the prolonged FP decease while masking part of the prolonged
NAD(P)H increases following high K+-SD. In the context of OGD, following SD
NAD(P)H levels decline and are matched by FP increases for a time following
reperfusion with nACSF. However, NAD(P)H eventually drops below baseline
levels and FP starts to decrease as well, suggesting neuronal damage.
In conclusion, my results reemphasize the importance of accounting for
cellular swelling when using NAD(P)H optical imaging techniques to assess
mitochondrial redox changes. It has been acknowledged previously that this
NAD(P)H imaging method does not provide quantitative measurements of
NAD/NADH redox changes in ischemia SD studies (Strong et al., 2000).
Therefore, rigorous correction for swelling due to SD when interpreting imaging
results is required, and studies, which have not accounted for the profound
contamination of 360 nm autofluorescence signals following SD may misinterpret
changes due to swelling as changes is mitochondrial redox potential (Mayevsky
and Rogatsky, 2007).
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5.4.2.3

Contribution of different cell types to autofluorescence signals

My work also sheds some light on the possible contributions of different
cell

types

to

the

autofluorescence

signals

observed

during

OGD.

Autofluorescence measurements were taken from the stratum pyramidale (sp),
and therefore are likely to arise from a combination of CA1 dendrites, astrocytes,
and interneurons. Following all pre-exposure conditions, which selectively
targeted astrocyte metabolism, there were no significant differences in NAD(P)H
autofluorescence increases during OGD prior to SD onset. If astrocyte
metabolism contributes greatly to the NADH increases due to OGD, then
selective inhibition with FA may be expected to reduce increases in
autofluorescence, since FA inhibits TCA cycle activity prior to NADH-producing
steps. Inhibition of glycogenolysis also did not significantly affect NAD(P)H
autofluorescence changes, a finding, which again could be consistent with a
primarily mitochondrial basis for these signals (see above) .
Taken

together,

these

studies

demonstrate

the

importance

of

simultaneous optical and field potential recordings to allow studies of SD
mechanism as well as effective tracking of SD propagation. In addition, effects
observed that are likely due to metabolic changes appear to be mitochondrial
and likely originate predominantly from neurons.

5.5 Implications for migraine
While there are many moderately effective treatments for relieving
migraine headaches, the mechanisms underlying many of these drugs are not
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well understood (see Section 1.2.2). It is becoming more widely appreciated that
SD events may trigger migraine headache, and it is exciting that some of the
more effective treatments available have recently been shown to reduce SD
events in a dose-dependent manner (Moskowitz, 2008; Ayata, 2010). This
strongly suggests that targeting SD may be a promising strategy to prevent the
onset of migraine itself. My work raises the possibility that targeting astrocyte
metabolism may be useful to inhibit the progression of SD events related to
migraine symptoms.
As discussed above, targeting either glycolytic or oxidative metabolism
could be useful approaches to retard SD propagation. It is unclear from my
studies whether increasing glycogen stores within astrocytes may be protective
against SD in the context of migraine. Prolonged 2 mM MSO pre-exposures prior
to high K+-SD slowed the rate of SD propagation, but did not inhibit the event
completely. As discussed above (Section 5.2.1), under normoxic conditions,
astrocytes appear to have sufficient substrate to clear extracellular K+ and
glutamate at optimal levels. One could speculate however, that in chronic
migraine patients, particularly those with FHM, many cellular processes, perhaps
including some related to astrocyte metabolism and function, may potentially not
be functioning normally. Therefore, it may be of interest to examine effects of
astrocyte manipulation in future studies using animal models of FHM. For
example, in one form of FHM, increased susceptibility is due to genetic mutations
and dysfunction of Na+/K+-ATPase (Vanmolkot et al., 2006). It is unclear which
cell type(s) these mutations will target and result in disruption of pump activity.
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However, in astrocytes, decreased ATPase activity will significantly reduce the
driving force for both glutamate and K+ clearance from the extracellular space,
and may contribute to increased excitability. This could be one mechanism
underlying the susceptibility of these patients to SD-induced migraine
headaches, and perhaps also seizures (Moskowitz et al., 2004).
NO synthesis is known to increase following SD (Read et al., 1997;
Petzold et al., 2008), and it is therefore possible that SD could contribute to
migraine headache by inducing the production of NO. NO has been proposed as
a potential initiator of migraine attacks, likely due to its vasodilatory properties,
and inhibition of nitric oxide synthase (NOS) can inhibit migraine headache
(Olesen et al., 1995; Lassen et al., 1997). In my work, SD was facilitated by high
levels of NO, and it is not yet known whether such actions may contribute to the
beneficial effects of NOS inhibition of migraine patients.
Gabapentin is a Cav2.1 channel antagonist that reduces presynaptic
glutamate release, and previous work has shown that this agent produced a
significant increase in SD threshold (Hoffmann et al., 2010). In our CNTF studies,
activation of astrocytes also led to significant increases in SD threshold in
normoxic models of SD, to an extent that propagating events could not be
induced even at a stimulus intensity 10X that required for SD induction in control
preparations. These results raise the possibility of targeting astrocytes for
migraine treatments. It is exciting to consider that therapeutic strategies that
mimic these effects induced by CNTF-activation without lenti-viral injections may
be protective against SD and prevent migraine onset. It is acknowledged that
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repetitive SD leads to astrocyte activation in animal models (Kraig et al., 1991),
and it is possible that astrocytes in patients who suffer from recurrent headaches
with aura may already be significantly activated. Thus future work to understand
the phenotypic changes in astrocytes following migraine will be of great interest.

5.6 Implications for ischemic injury
5.6.1 Ischemic stroke
5.6.1.1

SD events and the expansion of ischemic injury

As described in the Introduction, focal ischemic infarcts can act as a focus
for the initiation of depolarizing events, which spread outward through penumbral
tissue (see Section 1.3.3). In recent years, exciting evidence has accumulated
that these SD-like events very likely contribute to the expansion of ischemic
injury volume, and may be important targets for treatment of acute strokes.
Within penumbral regions, tissue perfusion can be maintained by collateral flow,
but usually at levels below 40% of normal, leading to ATP reductions of about 5070% of normal levels (Lipton, 1999). Although collateral flow appears to be
sufficient for neuronal survival in penumbral tissues in the absence of other
metabolic challenges, repetitive SD-like events present a substantial additional
metabolic burden due to ionic fluxes which is likely to lead to neuronal damage
(Hossmann, 1996). In addition, other factors released by SD may further
compound the metabolic burden of ionic disruption. One such factor is NO, and
in my work, high levels of NO are sufficient to transform recoverable SD into an
event that results in irreversible neuronal damage even in normoxic tissues.
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It is important to emphasize that SD-like events are not restricted to the
initial formation of the ischemic core, but have been shown to occur repetitively
with high frequency after stroke onset in animal models (Hartings et al., 2003),
and indeed have been measured electrically many hours after the onset of injury
in human patients. Recordings of SD associated with enlargement of infarcts has
been made even 5 days following the initial stroke (Dohmen et al., 2008;
Lauritzen et al., 2011), suggesting a dramatically larger window of opportunity for
therapeutic intervention than is currently possible with tPA (see Section 1.3.2).
Under normoxic conditions, repetitive SD leads to a stepwise depletion of
glucose and accumulation of lactate over time (Krivanek, 1961; Hashemi et al.,
2008), albeit without inducing obvious neuronal damage. In the context of
ischemia, depletion of substrates would be expected to be much more severe
with each SD-like event. The extent of depletion would be dependent on 1)
distance from the ischemic core and 2) number of depolarizing events that occur.
This is a consequence of the fact that across the penumbra, a gradient of energy
substrates from the infarct core to outer lying healthy tissue is expected (Lipton,
1999). Once glucose concentrations fall below levels required to recover ionic
homeostasis in a region, neuronal death is expected to follow.
Paradoxically, it is well established that hyperglycemia exacerbates
ischemic injury in clinical settings (Capes et al., 2001). Insulin has been
suggested for use to manage blood glucose in patients, but the efficacy of this
approach is unclear and hypoglycemia can become considerable risk factor in
this setting (Kansagara et al., 2008). Several mechanisms are thought to underlie
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the deleterious effects of hyperglycemia in stroke recovery. Hyperglycemia in the
context of brain ischemia can lead to the accumulation of lactate and result in
intracellular acidosis (Levine et al., 1988). Furthermore, hyperglycemia increases
reactive oxygen species (ROS) and leads to increased oxidative stress by either
lipid peroxidation (Siesjo et al., 1985) or other mechanisms, including increasing
activity of NADPH oxidase (Suh et al., 2008). It is possible that provision of
alternative approaches to sustain metabolic reserves during repetitive SDs may
be more effective and lack the deleterious effects of high glucose exposures.
In slice preparation studies, there are few methods, which provide good
models for penumbral conditions. Bath application of oxygen and glucose-free
solutions are a useful model of ischemia, which can be used to reliably induce
SD. However, this only mimics some of the conditions in the ischemic core, and
does not include gradients of reduced substrate availability. A recent study has
reported an in vitro brain slice model of focal ischemia where OGD solution is
focally applied to a small region of a cortical slice, while continuing to perfuse
most of the preparation in nACSF, in an effort to produce a gradient of substrates
(Richard et al., 2010). Future studies utilizing this model may provide additional
insights into generation of SD-like events in penumbra, including the potential
roles of astrocytes.
It is important to mention that previous clinical studies on the effects of SD
following a wide range of insults have focused on the frequency of SD events
and the duration of the associated DC shift rather than the rate of the
propagating wave across the tissue. There is a large body of work from the
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COSBID study group providing evidence that prolonged DC shifts are associated
with limited electrocortiographic (ECoG) recovery and poor patient outcome
(Dreier et al., 2006; Fabricius et al., 2006; Oliveira-Ferreira et al., 2010). It has
yet to be tested whether the rate of propagation contributes to the expansion of
injury in a similar manner. One could speculate that accelerating the spread of
SD events may lead to an increase in SD frequency and longer DC durations.
Thus, serving as an indirect measure of tissue health since, based on studies
from this dissertation, improving metabolic status within the tissue slows the
depolarization propagation. It will also be of interest in future studies to determine
if more rapid propagation rates allow for SD events to invade into tissue they
would not normally reach.
5.6.1.2

Targeting astrocyte metabolism post-ischemia

As described in the Introduction, astrocytes are generally less susceptible
to ischemic injury than neurons, and may be important and viable targets for
stroke therapy. My work suggests, for the first time, that supplementing glycogen
stores to fuel astrocyte function may be useful to limit the progression of SD-like
events through ischemic tissues. It is suggested that astrocyte glycogen stores
could be important in limiting the spread of these events, as well as providing
substrate for astrocytes to clear glutamate and K+ after the depolarization has
passed through the tissue. It is not yet known how bolstering glycogen stores in
human stroke brains could be best accomplished. In animal models, insulin and
insulin-like growth factor (IGF) cause an increase in brain glycogen, but these
agents may have complex and even deleterious effects on human subjects (e.g.

178

severe hypoglycemia with insulin, see above). MSO or similar agents could
potentially be considered, but the effects of MSO on glutamate-glutamine
recycling between astrocytes and neurons suggest that it may have profound
effects on glutamate and maybe even GABA concentrations which may alter
normal synaptic activity.
Another possible therapeutic approach may be targeting astrocyte
activation and changes in metabolic substrate dependence that accompanies
activation of these cells. Previous studies have shown that ischemic
preconditioning with SD increased astrocyte GFAP expression and this was
correlated with reduced cortical infarct volume following MCAO (Matsushima et
al., 1998). A number of other studies have also described astrocyte activation
following SD, as demonstrated by strong increases in GFAP immunolabeling in
affected tissues (Kraig et al., 1991; Wiggins et al., 2003). In studies of repetitive
application of K+ in otherwise healthy brain, astrocyte activation occurred within 6
hours of SD-events and persisted for at least one week post-SD (Kraig et al.,
1991; Bonthius and Steward, 1993; Wiggins et al., 2003). There have been few
studies of the consequences of astrocyte activation following SD, but it is
noteworthy that a recent preliminary report describes a progressive increase in
SD threshold when rats are repetitively challenged by SD (Sukhotinksky et al.,
2008). My results with CNTF-activated astrocytes suggest that the SD threshold
increase observed following preconditioning with repetitive SD could be a result
of astrocyte activation seen in those experiments.
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Previous work has shown that astrocytes undergo a profound metabolic
shift following activation with CNTF. This leads to reduced glycolysis and
increased capacity for ketolysis and β-oxidation (Escartin et al., 2007). Therefore,
if ischemia-induced astrocyte activation also induces this metabolic switch,
glucose may not be an appropriate metabolic fuel for activated astrocytes in situ.
One possible treatment strategy could therefore be placing ischemia patients on
a ketogenic diet, as this has been shown to be particularly effective for patients
suffering from intractable epilepsies (Freeman et al., 2007; Noh et al., 2008), and
these fuels may be readily oxidized by reactive astrocytes surrounding ischemic
infarcts.
As discussed above, astrocyte activation is not uniform and the
phenotypic changes that are associated with reactive astrocytes following brain
injury may be significantly different that those induced with CNTF-activation. In
the context of ischemia, the actual phenotypic changes that occur in astrocytes
when they become reactive are not described well enough to know if the effects I
see with my model of astrocyte activation will be directly applicable. In addition,
inhibition of SD under all conditions may not be protective. It seems reasonable
to consider that SD may provide protection to neurons following injury, by
inhibiting neuronal activity for a period of time after the depolarization. However,
in the context of ischemia, where metabolic substrates are not available to allow
neurons

to

repolarize,

it

is

likely

that

SD-like

events

are

primarily

neurodegenerative (Lauritzen et al., 2011), and finding targets to block these
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events may provide possible new therapeutic treatments that are sorely needed
for the majority of ischemic stroke patients.

5.6.2 SD events and subarachnoid hemorrhage (SAH)
As mentioned above (Section 1.3.5.2), NO has been suggested as a
potential therapeutic target for SAH therapy. NO is known to increase following
SD (Read et al., 1997; Petzold et al., 2008), and may have a wide range of
effects due to the ability of NO to diffuse easily throughout the tissue and
influence blood vessels, neurons, and astrocytes. As discussed (Section 5.2.3.2),
previous work has established that nitric oxide (NO) at basal levels may be
protective against SD due to its interactions with both presynaptic P/Q voltage
gated Ca2+ channels and postsynaptic NMDA receptors to reduce neuronal
excitability. However, my work emphasizes that exogenous NO also can lead to
inhibition of oxidative metabolism, which, in turn, promotes the spread of SD
across the slice preparation, similar to the effects of FA. Increasing NO results in
decreased oxygen consumption and ATP production within neurons, which is
likely a result of cytochrome oxidase inhibition (Almeida et al., 2001; Almeida et
al., 2005). Therefore, considering the concentration of NO delivered in the
context of therapeutic intervention is likely to be critical and difficult to manage in
SAH patients. This implies that NO itself may not be useful, and alternative
agents that maintain the beneficial effects of NO without deleterious effects of
cytochrome oxidase inhibition may be more useful. As discussed above (Section
5.2.3.2), the NO donor S-nitrosoglutathione (GSNO) may be a good candidate,
and previous studies have shown that early treatment with GSNO following SAH
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in rat preserved cerebral microvasculature structural anatomy, inhibited
vasoconstriction, and prevented loss of the blood brain barrier (BBB) (Sehba et
al., 2007). Effects on SD of this agent are currently unknown.

5.7 Limitations of research
5.7.1 Animal models
The use of animal models, including mouse models for neurodegenerative
studies, has come under great scrutiny, in large part due to the fact that relatively
few therapeutic treatments that are effective in mice have proven to be clinically
useful in subsequent human trials (Lee et al., 1999). This concern has historically
been extended into SD studies. One important difference, relevant for SD, is the
fact that mice have lissencephalic brains while humans are glyrencephalic.
Indeed, there was a great deal of speculation as to whether SD events were
even capable of spreading across human brain tissue. As discussed in the
Introduction, it is now well established that SD-like events occur in humans
patients following many different forms of injury (Dreier et al., 2006; Fabricius et
al., 2006; Dohmen et al., 2008; Dreier et al., 2009), and that the characteristics of
these depolarizations are strikingly similar to those observed in mice. Therefore,
for studying the phenomenon of SD, using mouse models should provide a great
deal of information on the mechanisms underlying these events that should be
relevant in human clinical settings.
As mentioned in the Introduction, the ratio of glial cells to neurons in the
human brain is at least 10 to 1 (Kimelberg and Nedergaard, 2010), while smaller
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mammals not only have fewer cells within the brain, but the ratio of astrocytes to
neurons also decreases (Nedergaard et al., 2003). This suggests that the
significant effects of astrocyte manipulations observed in my studies conducted
in mice (with smaller glial/neuron ratios) may be underestimated when translated
to humans. It will be of interest in future work to extend studies of astrocyte
activation and also manipulation of astrocyte metabolic substrate availability to
slices of human tissue. This may be considered with specimens removed from
temporal lobe seizure surgeries.

5.7.2 Acute slice preparations
Spreading depression requires tightly packed neuronal networks to initiate
and propagate. Therefore, this phenomenon cannot be studied in cell culture and
the mechanisms underlying these events are studied either in vivo or in vitro slice
preparations. Hippocampal slice preparations were useful since they possess the
neuronal density required for these propagating events (see (Somjen, 2001)) and
maintain basic cellular connections which are not possible in culture. Slices are
also useful to test the main hypotheses for my studies because manipulation of
experimental conditions (including temperature, substrate concentration, and
perfusion rate) is accomplished much more easily in slice preparations than in in
vivo whole brain preparations. However, the most obvious limitation to the in vitro
slice preparations is their lack of blood perfusion, which may limit the
interpretation of some results in the context of human pathological conditions.
This may be very important for stroke and migraine, where blood flow is an
additional significant contributor. It will be interesting in future studies, to examine
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the effects of modifying either astrocyte metabolism or astrocyte phenotype in in
vivo preparations to determine if the significant effects on SD that were observed
in in vitro slice preparations are observed in whole brain.

5.7.3 Lenti-viral injections and immunohistochemistry
Lenti-viral injections are useful for inducing long-term expression of a gene
of interest. Indeed, in my CNTF studies, activation of astrocytes induced by lentiviral infection with CNTF remained persistent for at least 10 months. While this
was useful for mechanistic studies, this long term infection may also be a
potential drawback of this particular method, since gene expression can never be
turned off. This makes the use of these viruses likely not ideal for transient
neurological disorders such as stroke or SAH where increased gene expression
will only be desired for days to weeks, but may be more relevant for chronic
pathological conditions such as Huntington’s Disease or Parkinson’s Disease
where the constitutive expression of CNTF may be neuroprotective and required
for many years.
I utilized immunohistochemical staining of GFAP to assess significant
astrocyte activation in my CNTF slice preparations, and compared activation with
both LacZ and non-injected naïve controls. For these studies, I analyzed areas
expressing GFAP within a given region of interest for all groups. CNTF
preparations had significantly larger areas expressing GFAP than both LacZ and
naïve control preparations. These methods do no provide the best quantitative
measure, and protein levels of GFAP within the three different conditions may
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have provided a more accurate method for quantitative measurement of changes
in GFAP expression levels. However, the changes in GFAP were so robust, that
we felt quantifying immunohistochemical labeling was sufficient to verify strong
astrocyte activation. In addition, cell counts were taken within each region of
interest to ensure that the increased area expressing GFAP was a result of
increased expression within the resident population of astrocytes rather than
progenitor cell proliferation. However, if more quantitative information is required
in future studies to assess the degree of astrocyte activation throughout the time
course of a neurological disorder, PCR or western blot analysis may be
preferable.

5.8 Conclusion
These studies provide support for the hypothesis that astrocytes are
important regulators of depolarizing events, which may spread across tissues.
My findings with the CNTF-model of astrocyte activation suggest that reactive
phenotypes generally induced under many pathological conditions may, in fact,
be neuroprotective by preventing SD-like events which are known to contribute to
the expansion of injury. Therefore, further studies to investigate the direct
mechanism by which astrocytes may stop the spread of these depolarizing
events may be of great clinical relevance to a wide range of disorders including
migraine and stroke.
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Figure 5.3
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Appendix A: Supplemental Data
Figure A.1
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Figure A.1
Effects of A1 receptor antagonist (DPCPX) on OGD-SD. A. Slices were preexposed to DPCPX (200nM) for 10 minutes prior to OGD onset. Continued
application with OGD showed that although there was some reduction in fEPSPs,
it was much smaller than the loss observed in control OGD preparations (see
Figure 2.3). fEPSPs were abolished post-SD despite the presence of DPCPX.
B. DPCPX pre-exposures had no effect on mean latency to onset of OGD-SD
(n=6).
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Figure A.2
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Figure A.2
A. Principles underlying inverted NAD(P)H (Ex360) and flavoprotein (Ex450)
autofluorescence signals of mitochondrial origin. In this figure, red species
are fluorescent, whereas non-fluorescent species are indicated in black.
B. Near simultaneous autofluorescence imaging of Ex360 and Ex450 during
high K+-SD. SD was initiated at the arrow and slices were ultimately excited at
360nm for 300ms and then 450nm for 150ms. SD resulted in a transient
decrease in Ex360 signal followed by a prolonged overshoot. This is typically
interpreted as transient NADH oxidation followed by excessive reduction due to
inhibition of respiration and/or enhanced TCA cycle activity. However, Ex450
measurements are informative because they imply a prominent optical artifact
during the initial phase. This is because no initial Ex450 increase is observed with
this time resolution and Ex360 measurements are not inverted with respect to
Ex450 signals until late in the response.
C. Near simultaneous autofluorescence imaging of Ex360 and Ex450 during
OGD-SD. The same methods used for high K+-SD were employed during OGD
exposures. As described in Section 5.4.2, Ex360 increases prior to SD are likely
due to inhibition of mitochondrial respiration due to hypoxia because they are
well matched by decreases in Ex450 signals. Like the high K+-SD responses,
initial autofluorescence decreases after OGD-SD onset (asterisk) are largely
contaminated by tissue swelling. It is important to note that this does not prevent
effective tracking of the SD event with these methods. It does, however, limit the
ability to assess mitochondrial function right after SD with these methods.
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Figure A.3
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Figure A.3
A. Simultaneous recordings of NAD(P)H and fEPSPs during OGD. Averaged
effects of OGD on NAD(P)H autofluorescence and fEPSPs (n=6). As discussed
in Section 5.4.2, NAD(P)H increases prior to OGD were a result of mitochondrial
inhibition by hypoxia. Coincident with NAD(P)H increases, fEPSPs were
suppressed in an A1 receptor-dependent manner. A brief period of
hyperexcitability was observed just prior to SD onset, and following OGD-SD,
there was a permanent loss of fEPSPs and NADH levels fell significantly below
baseline levels (n=6).
B. Simultaneous recordings of NADH and fEPSPs during hypoxia. Similar to
OGD exposures, NADH levels increased coincident with a loss of fEPSPs shortly
after the onset of hypoxia. However, SD was never generated during 20 minute
exposures to hypoxia (95% O2 replaced with 95% N2), and following the
reintroduction of nACSF, fEPSPs and NADH returned to levels not significantly
different from baseline (n=6).
C. Representative examples of MAP2 Immunohistochemistry following
hypoxia and OGD exposures. Slices were fixed following electrophysiology
experiments and processed for MAP2 immunohistochemistry to assess dendritic
damage. No dendritic injury was evident from MAP2 immunohistochemistry in
slices exposed to hypoxia when compared with naïve control and MAP2 was
localized to the dendrites alone. However, significant damage was observed
following OGD-SD, all preparations had severe dendritic beading and
accumulation of MAP2 in somata, consistent with substantial rapid injury
following SD. (scale bar: 50µms, blue: DAPI nuclear stain, green: MAP2).
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Abbreviations Used
ACSF

artificial cerebral spinal fluid

AD

anoxic depolarization

AMPA

α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid

ATP

adenosine triphosphate

CA1

cornu ammonis 1

CNTF

ciliary neurotrophic factor

DAB

1,4-dideoxy-1,4-imino-D-arabinitol

DAPI

4',6-diamidino-2-phenylindole

DNJ

1-deoxynojirimycin

DPCPX

8-cyclopentyl-1-1,3-dipropylxanthine

EPSP

excitatory post-synaptic potential

FA

fluoroacetate

FAD

flavin adenine dinucleotide

FP

flavoprotein

FHM

familial hemiplegic migraine

GLT-1

glutamate transporter 1

GLAST

glutamate-aspartate transporter

IOS

intrinsic optical signals

LacZ

β-galactosidase

MAP2

microtubule associated protein 2

MCAO

middle cerebral artery occlusion

MSO

L-methionine-DL-sulfoximine

NADH

nicotinamide adenine dinucleotide

NADPH

nicotinamide adenine dinucleotide phosphate
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NMDA

N-methyl-D-aspartic acid

NO

nitric oxide

OGD

oxygen glucose deprivation

PID

peri-infarct depolarization

SAH

subarachnoid hemorrhage

SEM

standard error of the mean

SD

spreading depression

sp

stratum pyramidale

sr

stratum radiatum

TCA

tricarboxylic acid
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